netFormulary
 Report : A-Z of formulary items 18/09/2019 02:31:53
[Back]
 
Section Name Details
A5.02.08   Consider first line dressings appropriate to wound bed type and exudate level
A5.05.02   Consider standard interactive dressings first
A5.06.01   Consider standard interactive dressings first. Dressings advised by TVN
A5.10   Consider standard dressings first
02.02.01 Bendroflumethiazide 

2.5mg dose (higher doses are not indicated in hypertension)

02.05.01 Minoxidil tablets Loniten®
13.14.06 Salicylic acid 5% w/w in emulsifying ointment  
10.02.01 3,4,diaminopyridine  Hospital only
A5.15 3M Cavilon Durable Barrier Cream   Skin protectant
Type of wound product is suitable for
Intact skin
As a barrier against bodily fluids, prevention of skin damage associated with incontinence
Can be used alongside containment products
Can be used to prevent friction to vulnerable areas of skin
Frequency of use
Reapply sparingly twice daily
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Do not use on infected skin
Not be used as an emollient
Not to be used around the peri wound
Can increase adherence of some dressing products and therefore care should be taken when adhesive products are being used in conjunction with the cream on people with fragile skin
Rationale for inclusion in formulary
The only barrier cream that can be used in conjunction with containment products without blocking the absorption of the pad
Cost effective, does not require reapplication at every episode of hygiene
A5.15 3M Cavilon No Sting Barrier Film Pump Spray and applicators  Protective transparent barrier film
Type of wound product is suitable for
Superficial broken skin and abrasions
As a barrier against bodily fluids, prevention of skin damage associated with incontinence
Can be used alongside containment products
Can be used to prevent friction to vulnerable areas of skin
Can be used on superficial abrasions caused by incontinence
Can be used to protect peri wound from exudate
Can be used to protect against aggressive adhesive products
Can be used to protect the skin surrounding stoma sites
Frequency of use
Every 72 hours
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Do not use on infected skin
Allow product to dry before applying the containment products, dressings or clothing (30 seconds)
Too many layers can make the area of skin feel stiff
Can affect electrode readings in the treated area
Rationale for inclusion in formulary
Available in a foam applicator and spray to aid application
Non sticky after use
Can be used on broken areas of skin
Cost effective, does not require reapplication at every episode of hygiene
05.03.01 Abacavir Ziagen®
05.03.01 Abacavir and Lamivudine Kivexa®
10.01.03 Abatacept Orencia® Hospital only

Available via Home Care
08.01.05 Abemaciclib Verzenios®

In line with NICE

08.03.04.02 Abiraterone Zytiga®
04.10.01 Acamprosate Campral EC®
02.08.02 Acenocoumarol Sinthrome®
02.02.07 Acetazolamide  Itracranial hypertension
11.06 Acetazolamide 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Acetazolamide  Hospital Only
    11.06 Acetazolamide M/R  
  • Specialist Ophthalmologist Recommendation
  • 12.01.01 Acetic Acid 2% Earcalm ®
    20 Acetic Acid Solution 3% 
    • Restricted for use by endoscopy only 
    03.07 Acetylcysteine   Hospital Only
  • Tablets
  • Sachets- available as 200mg powder for oral solution- licensed product.
  • 11.08.01 Acetylcysteine 10% eye drops  
    11.08.01 Acetylcysteine 5% with Hypromellose 0.35% Ilube®
    05.03.02.01 Aciclovir oral
  • Tablets
  • Dispersible tablets £
  • Suspension ££
  • 05.03.02.01 Aciclovir injection
    11.03.03 Aciclovir 3% eye ointment 
    13.10.03 Aciclovir 5% cream 
    13.05.02 Acitretin 
    03.01.02 Aclidinium Eklira Genuair®
      • For COPD only

    03.01.04 Aclidinium / formoterol inhaler Duaklir Genuair®

    A5.08.07 Actico®  Cohesive inelastic high compression bandage. Short stretch bandage

    Type of wound product is suitable for
    Venous leg ulceration
    Lymphoedema
    Management of chronic oedema

    Duration dressing remains on wound before changing
    Daily to 7 days

    Frequency of dressing change
    Dependant on exudate levels if wound present or oedema management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not recommended on those patients with an ABPI lower than 0.8. Caution in diabetic patients
    Caution when cardiac overload or renal failure present or suspected.

    Rationale for inclusion in formulary
    Only cohesive short stretch bandage. Nurses competent in its usage.
    A5.02.01 ActiForm Cool  Hydrogel Sheet
    Type of wound product is suitable for
    Necrotic or sloughy wounds that require hydration and cooling pain relief
    Can be used on dry wounds with the backing left in place
    Cut to shape of the wound
    Requires a secondary dressing
    Duration dressing remains on wound before changing
    1-3 days if dressings become discoloured or opaque or at first signs of exudate strike
    through
    Frequency of dressing change
    If dressing becomes discoloured or opaque or at first signs of exudate strike through. Do not allow to dry out
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Should not be used as a covering for deep narrow cavities or sinuses. Do not use on infected wounds.
    Not suitable for heavily exuding wounds Known product or component sensitivity Not for application on ischaemic wounds
    Rationale for inclusion in formulary
    Dry necrotic, sloughy or painful wounds
    For ease of application - sheet gel rather than liquid
    Primary dressing
    Can be used prior to larval therapy to maintain moisture levels
    A5.03.01 Actilite (Honey Dressing)  Non-adherent viscose net dressing 99% Manuka honey and 1% Manuka oil.

    Type of wound product is suitable for
    A primary dressing for low to moderate shallow exuding wound with light slough. Granulating or
    epithelialising wounds with clinical signs of infection. Requires a secondary dressing.

    Max Duration dressing remains on wound before changing
    3-7 Days

    Frequency of dressing change
    3 to 7 days depending on exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known allergy to Bee Venom and Honey products
    Blood sugars should be monitored in patients with diabetes
    Stinging sensation may be experienced. If unacceptable for patient then discontinue.

    Rationale for inclusion in formulary
    For antimicrobial and de-sloughing properties
    Ease of application
    Can be cut to size
    Easy removal in one piece
    Availability of different sizes
    Not found to be harmful to peri-wound skin
    Malodour
    Cost effective
    A5.02.05 ActivHeal Foam  Two layer dressing consisting of a polyurethane bacterial barrier membrane with a centrally located hydrophilic pad +/- acrylic adhesive border.

    Type of wound product is suitable for
    Moderately exuding wounds with signs of granulation, epithelialisation or slough. Can be used as primary or secondary

    Duration dressing remains on wound before changing
    1-7 days

    Frequency of dressing change
    Up to 7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Full thickness burns
    Surgical implantations

    Rationale for inclusion in formulary
    Cost effective
    Simple to use on the foot and digits
    Can be cut to shape
    A5.02.05 ActivHeal Foam (Tracheostomy)   Tracheostomy foam dressing

    Type of wound product is suitable for
    ActivHeal Foam Tracheostomy dressing has a fenestration, which allows the dressing to fit neatly around a tracheostomy tube. The dressing can also be used around intubation and cannula insertion procedures, external bone fixators and appropriately-sized wound drainage tubes.

    Duration dressing remains on wound before changing
    Dependant on clinical need and soiling

    Frequency of dressing change
    Up to 7 days, dependant on clinical need and soiling

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use if reaction to any of its components

    Rationale for inclusion in formulary
    Specific dressing shaped and able to cut for tracheostomies.
    Cost effective
    A5.03.01 Activon ®Tube  100% medical grade Manuka Honey.

    Type of wound product is suitable for
    Use as topical treatment for infected sloughy shallow or cavity wounds. Primary or addition to other Activon products. Requires secondary dressing.

    Max Duration dressing remains on wound before changing
    Up to 4 days

    Frequency of dressing change
    Daily in acute infection
    Up to 4 days in chronic infection dependant on exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Wounds with active blood loss
    Known allergies to bee Venom and Honey products
    Blood sugars should be monitored in diabetic patients
    Stinging sensation may be experienced – discontinue if not tolerant.

    Rationale for inclusion in formulary
    Anti-microbial and de-sloughing properties
    Control of odours
    Benefit of adding to other action products and increasing honey
    Suitable for use in cavities
    Cost effective
    A5.03.01 Activon Tulle (Honey Dressing)   Knitted viscose mesh impregnated with 100% Manuka Honey.

    Type of wound product is suitable for
    Creates a moist healing environment effectively eliminates odour. Provides anti-microbial action.
    Debrides and de-sloughs shallow wounds where the exudate level has started to decrease. Requires secondary dressing

    Max Duration dressing remains on wound before changing
    Up to 4 days

    Frequency of dressing change
    Daily in acute infection
    Up to 4 days for chronic infection depending on exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Wounds with active blood loss
    Known allergies to bee Venom and Honey products
    Blood sugars should be monitored in diabetic patients
    Stinging sensation may be experienced – discontinue if not tolerant.

    Rationale for inclusion in formulary
    Anti-microbial and de-sloughing properties for wounds with reduced levels of exudate.
    Control of odours
    Ease of application and removal in one piece
    Can be cut to size
    Available to various size
    Cost effective
    01.05.03 Adalimumab Humira® Injection
    For specialist use only in line with NICE guidance below
    10.01.03 Adalimumab 
    • Hospital only
    • Biosimilar brands available:
      • Amgevita®
      • Hulio®
      • Imraldi®
      • Hyrimoz®
    11.99.99.99 Adalimumab Humira® In line with NICE
    13.05.03 Adalimumab 
    13.06.01 Adapalene  Avoid in pregnancy
    13.06.01 Adapalene with benzoyl peroxide Epiduo®
  • May be used in preference to antimicrobial-containing agents.
  • 05.03.03 Adefovir Dipivoxil Hepsera®
    02.03.02 Adenosine injection 
    08.02.02 AdoPORT® Tacrolimus
    03.04.03 Adrenaline / Epinephrine Jext®
    03.04.03 Adrenaline / epinephrine EpiPen®

    There are currently supply issues with adrenaline autoinjectors (October 2018) - See SPS for updates

    03.04.03 Adrenaline/Epinephrine (Emerade ®) 
    08.01.05 Afatinib Giotrif®
  • In line with NICE
  • 11.08.02 Aflibercept Eylea®
  • Use in line with NICE
  • 04.03.04 Agomelatine Valdoxan®
    05.05.08 Albendazole 
  • UNLICENSED
  • 08.01.05 Alectinib 

    In line with NICE

    08.02.03 Alemtuzumab Lemtrada® In line with NICE
    06.06.02 Alendronic Acid  Binosto®
    • £££
    • Third line option in individuals who have not tolerated first line alendronate tablets and second line risedronate tablets and in whom a bone-sparing agent is still considered clinically necessary.
    • The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
    06.06.02 Alendronic Acid tablets 
    • The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
    09.06.04 Alfacalcidol injection 
  • Hospital only
  • 09.06.04 Alfacalcidol oral preparations 
    07.04.01 Alfuzosin Hydrochloride 
  • tablets
  • M/R tablets
  • A5.03.01 Algivon (Honey Dressing)  Alginate dressing impregnated with 100% Manuka Honey.

    Type of wound product is suitable for
    Primary dressing for infected, shallow cavity wounds, particularly if necrotic or malodorous with
    moderate exudate. Requires secondary dressing.

    Max Duration dressing remains on wound before changing
    Up to 4 days for chronic infection

    Frequency of dressing change
    Daily for acute infection
    Up to 4 days for chronic infection/depending upon exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Wounds with active blood loss
    Known allergy to be venom and honey products
    Blood sugars should be monitored in diabetic patients
    Stinging sensation may be experienced – discontinue if not tolerated

    Rationale for inclusion in formulary
    Antimicrobial and de sloughing properties
    Absorbent
    Malodour
    Ease of application and removal in one piece
    Can be cut to size
    Available in various sizes
    Can be shaped to wound size and depth
    Cost effective
    03.04.01 Alimemazine  Second line- in children as per guidance
    02.12 Alirocumab Praluent® To be used in line with NICE TA393
    02.05.05.03 Aliskiren Rasilez® Supported by RICaD, see link below.
    13.05.01 Alitretinoin Toctino® Dermatologists only in line with NICE TA 177
    A5.03.03 Allevyn Ag®  A non adherent foam dressing impregnated with silver sulphadiazine that can be cut to suit the patient
    Type of wound product is suitable for
    For use around infected pin sites
    Duration dressing remains on wound before changing
    Daily or as directed
    Frequency of dressing change
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Patients who have a known sensitivity to Silver Sulphadiazine or Sulphonamides
    Females who are at or near full term pregnancy or lactating
    Not for use on neonates or new born infants during the first month of life
    Rationale for inclusion in formulary
    Used around infected pin sites in patients with external metalwork to help reduce bacterial load
    HOSPITAL USE ONLY
    A5.02.05 Allevyn Cavity  Type of wound product is suitable for
    Wound management by secondary intention on acute, chronic, full thickness or partial
    thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
    Can be used as a primary or secondary dressing

    Duration dressing remains on wound before changing
    Can stay in place up to 3-7 days

    Frequency of dressing change
    Dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
    It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
    If redness or sensitisation occur, discontinue use
    Caution under compression when exudate levels are moderate to high.

    Rationale for inclusion in formulary
    Can be used for low to moderate exudate levels
    Different sizes and shapes available
    Cost effective
    A5.02.03 Allevyn Life  Hydrocellular foam dressing
    Type of wound product is suitable for
    Shallow granulating wounds, acute and chronic exuding wounds, full and partial thickness wounds
    such as leg ulcer, malignant wound, surgical wound. Primary dressing
    Silicone adhesive
    Duration dressing remains on wound before changing
    Up to 7 days dependent on dressing indicators
    Frequency of dressing change
    Up to 3 times a week maximum
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use with oxidising agents such as hypochlorite solutions or hydrogen peroxide Discontinue if reddening or sensitivity occurs.
    Do not cut
    Caution under compression where exudate levels are moderate to high
    Rationale for inclusion in formulary
    Fragile skin with absorbency and conformability, problematic healing wounds. Odour control.
    A5.02.05 Allevyn Non-Adhesive  Type of wound product is suitable for
    Wound management by secondary intention on acute, chronic, full thickness or partial
    thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
    Can be used as a primary or secondary dressing

    Duration dressing remains on wound before changing
    Can stay in place up to 3-7 days

    Frequency of dressing change
    Dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
    It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
    If redness or sensitisation occur, discontinue use
    Caution under compression when exudate levels are moderate to high.

    Rationale for inclusion in formulary
    Can be used for low to moderate exudate levels
    Different sizes and shapes available
    Cost effective
    A5.02.05 Allevyn range   Available in adhesive, non adhesive and gentle
    Type of wound product is suitable for
    Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
    Can be used as a primary or secondary dressing
    Duration dressing remains on wound before changing
    Can stay in place up to 3-7 days

    Frequency of dressing change
    Dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
    It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
    If redness or sensitisation occur, discontinue use
    Caution under compression when exudate levels are moderate to high.
    Rationale for inclusion in formulary
    Can be used for low to moderate exudate levels
    Different sizes and shapes available
    Cost effective
    09.05.01.01 Alliance Calcium Syrup® 
  • Replacement for Calcium Sandoz ® (discontinued)
  • 10.01.04 Allopurinol 
    06.01.02.03 Alogliptin Vipidia®
    07.01.01.01 Alprostadil Prostin VR®
    07.04.05 Alprostadil cream Vitaros® Specialist initiation
  • For patients who would otherwise use alprostadil injection.
  • 07.04.05 Alprostadil Intracavernosal injection 
    02.10.02 Alteplase 
  • Hospital only drug
  • 09.04 Altraplen Compact® (formally known as Nutriplen®) 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Alternative to second line supplement choice
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–6 years.
    13.12 Aluminimum Salts 
    09.05.02.02 Aluminium Hydroxide 
  • Specialist Recommendation
  • 04.09.01 Amantadine Hydrochloride 
  • Capsules
  • Syrup- for patients with swallowing difficulties
  • 05.01.04 Amikacin 
    02.02.03 Amiloride Hydrochloride 
  • Tablets
  • Oral solution
  • 03.01.03 Aminophylline Phyllocontin Continus®
    03.01.03 Aminophylline IV 
    02.03.02 Amiodarone injection 
    02.03.02 Amiodarone tablets 
  • Specialist initiation
  • 04.02.01 Amisulpride (oral) 
  • tablets
  • solution

  • Supported by ESCA, see link below.
  • 04.03.01 Amitriptyline 
  • Tablets
  • Sugar Free solution £££
  • 04.07.03 Amitriptyline 
  • 1st line
  • low abuse potential, low cost
  • off label use
  • 04.07.04.02 Amitriptyline 
    02.06.02 Amlodipine 
    13.10.02 Amorolfine 5% nail lacquer  ££
    03.13 Amoxicillin  Hospital only
    05.01.01.03 Amoxicillin injection
    05.01.01.03 Amoxicillin oral presentations
    03.13 Amphotericin Fungizone® Hospital only
    05.02 Amphotericin lipid complex infusion
    05.02 Amphotericin infusion
    11.03.02 Amphotericin (eye) 
    09.01.04 Anagrelide Xagrid®
    10.01.03 Anakinra Kineret® Hospital only
    04.07.04.01 Analgesics Migraleve Pink ®
    08.03.04.01 Anastrozole 
    06.04.01.01 Angeliq® 
    • ££££
    05.02.04 Anidulafungin 
    01.01.01 Antacid and Oxetacaine   Suspension
    Specialist use only
    13.08.01 Anthelios XL® 
    • Approved at December 2015 APC meeting following a drug application.

      Non-formulary if not for ACBS approved indication
    14.05.03 Anti-D (Rh0) Immunoglobulin 
    01.07.02 Anusol-HC 
    02.08.02 Apixaban  APC preferred agent: this recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.

    Amber Traffic Light  Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Apixaban in AF

    Red Traffic Light  Use following Hip and Knee surgery- full course of treatment supplied on discharge.

    Amber Traffic Light  For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD.
    RICaD: Apixaban in DVT/ PE
    04.09.01 Apomorphine 
  • Pen injector
  • Injection

  • Supported by an ESCA, see link below.
  • A5.16 Appeel ®  available in 4 different applications
    Type of wound product is suitable for
    Adhesive dressing or appliance removal where skin stripping, loss of skin integrity and
    pain is a concern
  • Sachet– suitable for larger dressing removal
  • Wipes – ideal for adhesive around tubes
  • Foam applicator – ideal for infants or use of the face
  • Spray, single patient, multiple use product for all dressings and/or urinary sheath removal

    Frequency of use
    Use at each dressing change
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Should not be used when there is a known sensitivity to any of the ingredients
    If in doubt, patch test a small area, prior to use
    The product is flammable and should be used in a well ventilated area
    Avoid use around, flames and sources of ignition
    Rationale for inclusion in formulary
    For pain free removal of dressings where fragile skin is a concern

  • 11.08.02 Apraclonidine 1% SDU eye drops 
  • only PF sympathomimetic
  • 11.08.02 Apraclonidine 0.5% 
    13.05.03 Apremilast 
  • In line with NICE
  • Use in adults is commissioned by CCGs
  • 04.06 Aprepitant Emend®
  • for use with chemotherapy only
  • 09.04 Aptamil Pepti® 1 
    • Infant and child: Hydrolysate formula
    • Whey hydrolysate formula containing lactose. Use in infants (from birth – 6 mths) who have cow’s milk protein intolerance / allergy but no lactose intolerance. Tube or oral feed.
    • Established cows' milk protein intolerance, with or without secondary lactose intolerance
    09.04 Aptamil Pepti® 2 
    • Infant and child: Hydrolysate formula
    • Whey hydrolysate containing lactose. Use in infants (from 6 mths) who have cow’s milk protein intolerance / allergy but no lactose intolerance. Tube or oral feed
    • Established cows' milk protein allergy or intolerance. Not suitable for child under 6 months.
    09.04 Aptamil Pepti® Junior 
    A5.02.04 Aquacel range   Type of wound product is suitable for
    Moderate to heavy exudate, sloughy, necrotic or granulating wounds. Available in rope
    for cavities

    Duration dressing remains on wound before changing
    Maximum 7 days

    Frequency of dressing change
    1-7 days depends on clinical need

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for dry wounds. Non dissolvable. Known product or component sensitivity
    Do not cut

    Rationale for inclusion in formulary
    Aids debridement of slough or necrotic tissue
    Remains intact so easily removed in one piece
    Absorbs exudate which aids most wound healing facilitating atraumatic dressing change,
    Cost effective
    A5.03.03 Aquacel® Ag + Extra range   Hydrofibre with silver

    Type of wound product is suitable for
    Management of clinically infected, sloughy, necrotic or granulating wounds with moderate to heavy exudate.
    Moderate to highly exuding wounds.
    Aquacel Ag Plus Extra can be used to break down biofilms
    Requires a secondary dressing

    Duration dressing remains on wound before changing
    Dependent upon exudate 1 - 7 days

    Frequency of dressing change
    Dependent upon level of exudate and clinical presentation

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components.
    Not suitable for dry wounds.
    No haemostatic properties.

    Rationale for inclusion in formulary
    Specialist antimicrobial product
    Moderate to high exudate levels
    Can be used to break down biofilms
    Remains intact on wound bed and easily removable in one piece (non dispersible)
    13.02.01 Aquadrate® 

    Contains 10% urea

    Over the counter preparation suitable for self-care/purchase if appropriate

    A5.02.01 AquaForm   Hydrogel: Clear viscose sterile gel
    Aids autolytic debridement and removal of devitalised tissue.

    Type of wound product is suitable for
    Low exuding, necrotic or sloughy wounds

    Duration dressing remains on wound before changing
    Up to 3 days

    Frequency of dressing change
    1-3 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not suitable for heavily exuding wounds. Caution known product or component sensitivity.
    Full thickness burns or infected wounds
    Not for application to ischaemic wounds

    Rationale for inclusion in formulary
    Required for wound beds that need donation of moisture to rehydrate the wound bed and debride. Cost effective
    07.03.04 Arcing spring diaphragm 
  • Sizes 60-95mm (rising in 5mm)
  • 04.02.02 Aripiprazole Abilify Maintena®

    The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.

    04.02.01 Aripiprazole tablets 
  • Supported by ESCA, see link below.
  • use in Tourette's syndrome approved
  • 08.01.05 Arsenic Trioxide Trisenox®
    • In line with NICE
    05.04.01 Artemether with lumefantrine Riamet®
    15.02 Articaine Hydrochloride with Adrenaline Septanest®
  • Dental use
  • 09.06.03 Ascorbic Acid 
    09.08.01 Asfotase alfa  In line with NICE Highly Specialised Technology guidance
    02.09 Aspirin (antiplatelet)  Dispersible
    04.07.01 Aspirin 300mg dispersible tablets 
  • topical analgesia- for gargling
  • 05.03.01 Atazanavir Reyataz®
    02.04 Atenolol 
    08.02.03 Atezolizumab Tecentriq®
  • In line with NICE
  • 04.04 Atomoxetine Strattera® Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Traffic Light Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG

    Amber Traffic Light  Supported with an ESCA- Solihull CCG
    02.12 Atorvastatin tablets 
    07.01.03 Atosiban Tractocile®
    05.04.08 Atovaquone 
    09.04 Atraplen® Protein (formally known as Nutriplen® Protein) 
    • Used in cases where increased protein is required
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula.
    • Not suitable for child under 3 years; use with caution in child 3–6 years
    A5.01.01 Atrauman   Type of wound product is suitable for
    For flat granulating and epithelising wound for non to heavy exudate where adherence may occur. To be used as a primary dressing with a secondary for absorption.

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    1-7 days, depending on levels of exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.
    Known product or component sensitivity

    Rationale for inclusion in formulary
    Used to reduce adherence to wound bed. Most cost effective non adherent dressing.
    Dressing impregnated with neutraltriglycerides to prevent penetration of granulation tissue.
    Petroleum free.
    A5.03.03 Atrauman Ag®  Non adherent Primary Dressing containing metallic silver

    Type of wound product is suitable for
    For clinically infected shallow, granulating wounds with low exudate. To be used as a primary dressing with a secondary for absorption.

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    1-7 days, depending on levels of exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity
    Must be removed prior to x-ray, ultrasound, diathermy and MRI

    Rationale for inclusion in formulary
    Used to reduce adherence to wound bed with clinical signs of infection
    Most cost effective non adherent dressing containing silver.
    Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue.
    Petroleum free.
    Specialist Recommendation
    01.02 Atropine  Injection
    15.01.03 Atropine SF solution 
    15.01.03 Atropine sulphate 
    11.05 Atropine Sulphate 0.5% drops 
    11.05 Atropine Sulphate 1% drops 
    11.05 Atropine Sulphate single use Minims®
  • Specialist Ophthalmologist Recommendation -used by glaucoma surgeons for neovascular glaucoma.
  • 15.01.03 Atropine tablets 
  • For Myaesthenia Gravis only.
  • 13.02.01 Aveeno cream®  Green Traffic Light £££- Paediatrics only


    Amber Traffic Light £££- Recommended by specialist for oncology use only.


    08.02.03 Avelumab Bavencio®
    • Hospital only
    • In line with NICE
    10.01.03 Avelumab Bavencio ®

    In line with NICE

    Hospital only

    07.04.05 Aviptadil 25mcg / Phentolamine 2mg  Invicorp®
  • Approved on formulary December 2017
  • Specialist initiation.
  • 3rd line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil.
  • To be reviewed within 12 months to assess alprostadil supply issues and patent expiry
  • 08.02.04 Axicabtagene ciloleucel  YESCARTA®
    • In line with NICE
    09.04 Aymes® Complete 
    • 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Second line choice for 200ml ready-made. If powder is not tolerated or contraindicated
    09.04 Aymes® Creme 
    • More than 1.5 kcal/ml and 5g (or more) protein/100ml
    • Low energy per serving as a semi-solid supplement where low volume is required only.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, preoperative
      preparation of malnourished patients, dysphagia, proven inflammatory bowel
      disease, following total gastrectomy, short-bowel syndrome, bowel fistula Not suitable for child
      under 3 years; use with caution in child 3–6 years.
    09.04 Aymes® Shake/Savoury 
    • In line with food first
    • Not suitable for CKD 4-5, renal pts.
    • Not suitable for lactose intolerance
    • Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
    • To be made up with whole milk.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula . Use with caution in child 1–6 years.
    08.01.03 Azacitidine Vidaza®
    01.05.03 Azathioprine  Tablets 25mg, 50mg
    Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults– unlicensed but in line with national guidelines.

    For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below.
    03.12 Azathioprine 
  • in conjunction with prednisolone (plain tablets, not EC)
  • Supported by ESCA , see link below.
  • 04.13 Azathioprine 

    Specialist use only for neurological conditions

    08.02.01 Azathioprine 
  • Oncology/haematology
  • 10.01.03 Azathioprine  Supported by ESCA, see link below.
    13.05.03 Azathioprine (dermatology) 
    • supported by ESCA, see link below
    13.06.01 Azelaic Acid 15% gel Finacea®
    13.06.01 Azelaic Acid 20% cream Skinoren®
    11.04.02 Azelastine Optilast®
    12.02.01 Azelastine and fluticasone Dymista
  • Third line option for adults and children over 12 years with moderate to severe allergic rhinitis who have failed to respond to a steroid nasal spray with the addition of an oral antihistamine.

    Follow treatment algorithm
  • 05.01.05 Azithromycin 
    • Do not prescribe azithromycin as stand-alone medication for the indication of gonorrhoea. Refer to GUM clinic for IM ceftriaxone as per current UK guidelines.
    05.01.05 Azithromycin 


    Green Traffic Light  Tablets/ suspension. When used in line with Primary care antimicrobial guidelines


    Amber Traffic Light  Tablets only. For COPD or bronchiectasis patients who have ≥3 exacerbations per year. Off-label use. Supported by RICaD and Guidelines on Respiratory use of long term azithromycin in adults

    • Do not prescribe azithromycin as stand-alone medication for the indication of gonorrhoea. Refer to GUM clinic for IM ceftriaxone as per current UK guidelines.
    11.03.01 Azithromycin Azyter®
  • First line for ophthalmic chlamydia
  • 05.01.02.03 Aztreonam 
    10.02.02 Baclofen 
    10.02.02 Baclofen intrathecal   Hospital only
    13.02.01.01 Balneum Plus ®Bath Additive 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.02.01 Balneum® Plus cream 
    • urea 5%, lauromacrogols 3%

    Over the counter preparation suitable for self-care/purchase if appropriate

    01.05.01 Balsalazide Sodium Colazide®
    03.01.01.01 Bambuterol tablets Bambec® Specialist initiation for severe brittle asthma/ cystic fibrosis
    10.01.03 Baricitinib ® Olumiant In line with NICE
    09.04 Basecal® 
    • Fat and Carbohydrate
    • Over one year of age. Metabolic disorder pts
    • Also these are the only protein free (containing fat, carbohydrate, vitamins and minerals) powders aimed at children ≥1-year-old and adults with inborn errors of protein metabolism (particularly patients with urea cycle disorders and organic acidaemias). Basecal 100 and Basecal 200 are commonly added as an energy source in low protein module tube feeds. The dose will depend on energy requirements and tolerance to natural protein. It is commonly used in combination with a controlled amount of natural protein e.g. measured dose of standard enteral tube feed. It will help meet essential energy and nutrient requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    14.04 BCG vaccine diagnostic agent 
    14.04 BCG vaccine Intradermal 
    03.02 Beclometasone and formoterol Fostair®NEXThaler®

    03.02 Beclometasone and formoterol Fostair®
  • Alternative to Seretide Evohaler/ Seretide 250 Accuhaler
  • When reviewing/ stepping down, consider switch if appropriate
  • 03.02 Beclometasone Dipropionate Clenil Modulite®

    12.02.01 Beclometasone Dipropionate nasal preparations 
    03.02.03 Beclometasone/formoterol/glycopyrronium Trimbow®

    COPD Appendix 4 - Criteria for triple therapy and for triple inhaler use in COPD

     

    03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®
    08.01.01 Bendamustine 
    A5.02.04 BeneHold TASA 

    Approved April 2019

    Hydrocolloid Range with film border

    Type of wound product is suitable for
    Lightly to moderately exuding wounds

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Only when necessary - up to 7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on third-degree burns. Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components.

    Rationale for inclusion in formulary
    Reduced dressing changes. More cost effective. Reduce use of more expensive foam dressings.

    03.14 Benralizumab 

    In line with NICE

    13.06.01 Benzoyl Peroxide 
    13.06.01 Benzoyl Peroxide 3% with Clindamycin 1% Duac® Once Daily
    13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily
    12.03.01 Benzydamine 0.15% oral rinse 
    12.03.01 Benzydamine 0.15% oral spray 
    05.01.01.01 Benzylpenicillin 
    05.01.01.01 Benzylpenicillin Benzathine 
  • Only GUM STD services
  • 04.06 Betahistine Dihydrochloride 
    06.03.02 Betamethasone 
    13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Ointment® Potency: potent
    13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Scalp Application® Potency: potent
    13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD Ointment® Potency: Moderate
    13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD Cream® Potency: Moderate
    13.04 Betamethasone (as Valerate) 0.1% Betnovate ® Potency: Potent

  • Cream
  • Ointment
  • Scalp application
  • 13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet cream® Potency: potent
    11.04.01 Betamethasone 0.1% eye drops 
    11.04.01 Betamethasone 0.1% eye ointment 
    12.01.01 Betamethasone 0.1% with Neomycin 0.5% ear drops 
    11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops 
  • Short term use only
  • 13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® Potency: potent
    12.01.01 Betamethasone ear drops 
    12.02.01 Betamethasone Sodium Phosphate nasal preparations 
    09.04 Betaquick® 
    • High-energy supplements: fat
    • 21% MCT emulsion, used orally and in cooking as an energy source for children and adults on a ketogenic diet
    11.06 Betaxolol 0.25% eye drops 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Betaxolol 0.5% Unit Dose Eye Drops 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Betaxolol 0.5% eye drops 
  • Specialist Ophthalmologist Recommendation
  • 07.04.01 Bethanechol Chloride Myotonine®
    08.01.05 Bevacizumab 
  • Funding available through Cancer Drugs Fund (CDF) for indications listed in CDF list.
  • Click here to access latest CDF list.
  • 11.08.02 Bevacizumab intravitreal injection Avastin®
    08.01.05 Bexarotene 
    02.12 Bezafibrate 
  • immediate release formulation
  • modified release formulation
  • A5.02.05 Biatain dressings  Polyurethane foam dressing with bevelled edges

    Type of wound product is suitable for
    Moderately exuding wounds with signs of granulation, epithelialisation or slough.
    Can be used as primary or secondary

    Duration dressing remains on wound before changing
    1-7 days

    Frequency of dressing change
    Up to 7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use with oxidising solutions such as hydrogen peroxide
    Full thickness burns
    Surgical implantations

    Rationale for inclusion in formulary
    Simple to use on the foot and digits Can be cut to shape
    08.03.04.02 Bicalutamide 
    11.06 Bimatoprost 0.01% eye drops 
  • Specialist Ophthalmologist Recommendation.
  • 2nd line
  • 11.06 Bimatoprost with Timolol Ganfort®
  • Specialist Ophthalmologist Recommendation
  • 12.03.05 Biotene Oralbalance® Saliva replacement gel Approved for
  • ACBS conditions i.e. patients suffering from xerostomia (dry mouth) as a result of having or having undergone radiotherapy or sicca syndrome.
  • Palliative Care
  • Dental practitioners
  • 06.01.01.02 Biphasic Insulin Aspart NovoMix® 30
    06.01.01.02 Biphasic Insulin Lispro Humalog® Mix
  • Humalog Mix25
  • Humalog Mix50
  • 06.01.01.02 Biphasic Isophane Insulin Humulin® M3
    06.01.01.02 Biphasic Isophane Insulin Insuman® Comb
  • Insuman Comb 15
  • Insuman Comb 25
  • Insuman Comb 50
  • 01.06.02 Bisacodyl  Tablet E/C 5mg, Suppository 10mg
    12.04 Bismuth Iodine Paraffin Paste BIPP ®
    12.04 Bismuth Subnitrate and Iodoform Paste for Gauze 
    01.03.03 Bismuth subsalicylate Pepto Bismol® For use in H Pylori eradication in penicillin allergy and previous clarithromycin, as per antimicrobial guidelines.
    02.04 Bisoprolol 
    02.08.01 Bivalirudin Angiox®
    13.07 Bleomycin  
    08.02.03 Blinatumomab Blincyto® In line with NICE
    06.01.06 Blood Glucose Meters 
    05.03.03 Boceprevir Victrelis®
    12.03.01 Bonjela Junior Dental Gel Bonjela® Junior
  • From 3 months of age
  • 08.01.05 Bortezomib Velcade®
  • In line with NICE
  • 02.05.01 Bosentan Tracleer® NHS England commissioned
    08.01.05 Bosutinib Bosulif®
  • In line with NICE
  • Hospital only- NHSE commissioned
  • 01.02 Botulinium Toxin A 

    Achalasia

    • Use for SWB only in endoscopy
    • 100 units
    04.07.04.02 Botulinum Toxin Type A botox®
  • In line with NICE
  • 13.12 Botulinum toxin type A  
  • hyperhidrosis (commissioning discussion to take place)
  • 14.04 Botulism antitoxin 
    09.04.01 Bread 

    Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 slice ordinary bread = 4g protein and is not allowed in low protein diets.

    08.01.05 Brentuximab vedotin Adcetris®
    • In line with NICE
    08.01.05 Brigatinib Alunbrig®

    In line with NICE

    11.06 Brimonidine Tartrate 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan®
  • Specialist Ophthalmologist Recommendation
  • 13.06.03 Brimonidine tartrate gel Mirvaso®
  • For facial erythema in rosacea
  • 11.06 Brinzolamide 10mg/ml 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Brinzolamide 10mg/ml with Brimonidine 2mg/ml Simbrinza®
  • Specialist Ophthalmologist Recommendation
  • Third line option, after prostaglandin analogues (1st line) and beta-blocker/ prostaglandin analogue plus beta-blocker (2nd line)
  • For patients in whom monotherapy provides insufficient IOP reduction.
  • 11.06 Brinzolamide 10mg/ml with Timolol 5mg/ml 
  • Specialist Ophthalmologist Recommendation
  • 2nd/3rd line
  • 04.08.01 Brivaracetam Briviact®
    • Initiation by Tertiary Epilepsy Specialist only.
    • For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam.
    • Supported by an ESCA
    04.08.01 Brivaracetam Briviact ®
    10.01.03 Brodalumab Kyntheum ®

    In line with NICE

     

    13.05.02 Brodalumab Kyntheum®
    • Hospital only
    • In line with NICE
    11.08.02 Bromfenac  Yellox®

    Approved January 2018. Interim measure due to supply issues with ketorolac eye drops

    06.07.01 Bromocriptine 
    01.05.02 Budesonide Budenofalk®

    2mg/dose foam enema

    Approved July 2018

    03.02 Budesonide 
  • Dry powder Inhaler
  • Nebulised solution
  • 01.05.02 Budesonide 1mg orodispersible tablets Jorveza®

    Specialist use only.

    Formulary status to be reviewed on publication of NICE TA (expected October 2019)

    03.02 Budesonide and formoterol Symbicort Turbohaler®
  • Should be prescribed by the intended brand to ensure patients receive the device they are used to.

  • For asthma only
    Non-Formulary for COPD
  • 01.05.02 Budesonide capsules 
    01.05.02 Budesonide MMX Cortiment®
    02.02.02 Bumetanide 
    04.07.02 Buprenorphine patches 
    • for specialist initiation: specialist pain clinics, palliative care and for patients with swallowing difficulties

      Patches should be prescribed by BRAND
    04.10.03 Buprenorphine S/L tablets >
    04.07.02 Buprenorphine sublingual tablets  For use in opioid dependence, see section 4.10.3
    04.03.04 Bupropion 
  • off label use
  • 04.10.02 Bupropion Hydrochloride Zyban®
    06.07.02 Buserelin 
  • For assisted conception
  • 08.03.04.02 Buserelin 
  • Listed in Chapter 6 for other indications
  • 06.07.02 Buserelin nasal spray 
  • For assisted conception
  • 04.01.02 Buspirone Hydrochloride  ££ Second line
    08.01.01 Busulfan Tablets
    A5.02.02 C View   Vapour-permeable adhesive film

    Type of wound product is suitable for
    Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Up to 7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds

    Rationale for inclusion in formulary
    Retention of lines, protection of intact skin, fixation of other dressings. Waterproof
    03.04.03 C1 esterase inhibitor Cinryze®

    Hospital only- NHSE Commissioned

    03.04.03 C1 esterase Inhibitor Berinert®

    Hospital only- NHSE commissioned

    08.01.05 Cabazitaxel Jevtana®
  • In line with NICE
  • 06.07.01 Cabergoline 
    08.01.05 Cabozantinib Cabometyx® In line with NICE
    13.14.03 Cade oil 12% w/w and salicylic acid 6% w/w in emulsifying ointment 
    03.05.01 Caffeine citrate  unlicensedunlicensed
    09.04.01 Cake, biscuits, and snacks 

    Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein.

    13.03 Calamine Aqueous Cream 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.03 Calamine Lotion 

    Over the counter preparation suitable for self-care/purchase if appropriate

    09.05.01.01 Calcichew® 
    13.05.02 Calcipotriol 50mcg/g ointment 
    13.05.02 Calcipotriol 50mcg/ml scalp application 
  • ££££
  • 13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet Gel®
  • Scalp psoriasis: usual duration of treatment is 4 weeks
  • Mild to moderate plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily) for 8 weeks
  • 13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet ointment ®
  • 4 weeks therapy then assess
    Maximum 15g per day or 100g per week.
    Step down to calcipotrol oint as per NICE CG153
  • 13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g Enstilar®
  • Cutaneous foam formulation
  • The recommended treatment period is 4 weeks
  • Maximum 15g per day
  • Excipients include liquid paraffin and butane-
  • Extremely flammable aerosol
  • 06.06.01 Calcitonin (salmon) / Salcatonin 
  • Injection
  • Nasal spray
  • 09.06.04 Calcitriol 
    13.05.02 Calcitriol 3micrograms/g Silkis®
  • Specialist recommendation
  • For delicate areas,face and flexures
  • 09.06.04 Calcium and Vit D preparations 
  • Follow local guidance
  • 08.01 Calcium Folinate 
    09.05.02.02 Calcium Salts 
  • Specialist Recommendation
  • 09.04 Calogen® 
    • High-energy supplements: fat
    • Used as a source of LCT, as an energy supplement and additive to feed to enhance energy density.
    • Does not contain protein
    • Also this is the only LCT fat source that can be used as a fat energy source in patients with organic acidaemias e.g. propionic acidaemia and methyl malonic acidaemia and urea cycle disorders. It may also be used as part of a modular feed or protein-free energy source. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement. Liquid supplements
    09.04 Calogen® Extra 
    • Protein, fat, and carbohydrate
    • Only to be used on dietetic advice for oral and tube feeds
    • Used where energy, protein and micronutrients required.
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3–6 years. May require dilution for child 3–5 years.
    09.04 Calogen® Extra Shots 
    • Protein, fat, and carbohydrate
    • Used on dietetic advice only
    • Used where hygiene concerns/infection control – single use sterile dose – where Calogen Extra bottle is not appropriate
    • Used where energy, protein and micronutrients required in small volume
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement.
    • Not suitable for child under 3 years; use with caution in child 3–6 years. May require dilution for child 3–5 years.
    06.01.02.03 Canagliflozin Invokana®

    SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

    In line with NICE

    MHRA Alert: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) 

    02.05.05.02 Candesartan cilexetil tablets 
    13.09 Capasal® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    08.01.03 Capecitabine Tablets
    12.03.01 Caphosol® 
  • Oncology and haematology use
  • 05.01.09 Capreomycin 
    04.07.03 Capsaicin 
  • Only strength licensed for post-herpetic neuralgia and diabetic peripheral polyneuropathy.

    For other strength, see section 10.3.2

  • 10.03.02 Capsaicin cream  Tier 2 , £££
    10.03.02 Capsaicin cream  see chapter 4.7.3 for neuropathic pain

    02.05.05.01 Captopril tablets  For existing patients only
    04.02.03 Carbamazepine 
    04.07.03 Carbamazepine 
  • trigeminal neuralgia only
  • 04.08.01 Carbamazepine 
  • Tablets
  • M/R tablets
  • SF liquid
  • Suppositories

    MHRA Advice
    Patients being treated for epilepsy should be maintained on a specific manufacturer's product- APC preferred brand is TEGRETOL
  • 06.02.02 Carbimazole 
    03.07 Carbocisteine 
    A5.02.08 CarboFLEX  Odour absorbent wound contact dressings containing activated charcoal

    Type of wound product is suitable for
    For the management of moderate to heavily exuding malodorous wounds including
    fungating

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    As exudate level determines

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to the dressing or its components
    As soon as CarboFLEX becomes contaminated with exudate, odour control diminishes
    The underlying cause of wound odour should be identified prior to commencement of product

    Rationale for inclusion in formulary
    CarboFLEX is a layered dressing to provide higher levels of fluid handling
    On shallow or cavity wounds with moderate to heavy levels of exudate
    11.08.01 Carbomers Clinitas Gel®
  • Clinitas Gel does not have benzalkonium chloride (BAK) as a preservative. It is preserved with cetrimide.
  • 07.01.01 Carboprost 
    09.04 Carbzero 
    • High-energy supplements: fat
    • 20% LCT emulsion, used as an energy source for children and adults on a ketogenic diet, may be used orally or in cooking
    • For use in ketogenic diets. Long chain triglyceride liquid emulsion used as a milk replacement (when diluted) for some patients with PKU on very low protein diets who cannot tolerate other low protein milk replacements. It will help meet essential energy requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    08.01.05 Carfilzomib Kyprolis® In line with NICE
    11.08.01 Carmellose 0.5% SDU Xailin Fresh ®
    11.08.01 Carmellose1% multi Moorfields
    08.01.01 Carmustine Gliadel®
    02.04 Carvedilol 
    05.02.04 Caspofungin 
    05.01.02.01 Cefalexin oral presentations

    Green Traffic Light Only when used in line with Antimicrobial guidelines

    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    05.01.02.01 Cefotaxime injection

    Green Traffic Light Only when used in line with Antimicrobial guidelines

    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    03.13 Ceftazidime  Hospital only
    05.01.02.01 Ceftazidime 
    05.01.02.01 Ceftriaxone 
    03.13 Cefuroxime  Hospital only
    05.01.02.01 Cefuroxime 
    11.03.01 Cefuroxime  
  • Hospital only
  • 10.01.01 Celecoxib 

     

    • CVD risk assessment
    A5.08.07 Cellona®  Sub compression wadding bandage to pad and shape a limb prior to compression therapy

    Type of wound product is suitable for
    Provides padding for larger limbs under compression.

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advised not to apply directly to skin as can cause irritation.

    Rationale for inclusion in formulary
    Cost effective for use in larger quantities when used in lymphoedema management.
    09.04.01 Cereals 

    Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 2 regular Weetabix = 4.5g protein and this protein amount is more than the amount of protein that may be tolerated.

    08.01.05 Ceritinib  Zykadia®

    In line with NICE

    10.01.03 Certolizumab Pegol Cimzia® In line with NICE
    Hospital only

    Available via Home Care
    12.01.03 Cerumol® 
    03.04.01 Cetirizine 

    OTC preparation suitable for self-care/purchase if appropriate

    13.02.01 Cetraben emollient cream® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    A5.13 Cetraben Pump cream  Emollient containing white soft paraffin and light liquid paraffin
    Type of wound product is suitable for
    For inflamed, dry, chapped skin
    Frequency of use
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin
    Dermatology approved
    06.07.02 Cetrorelix Cetrotide®
    08.01.05 Cetuximab Erbitux®
    04.01.01 Chloral Hydrate 
    08.01.01 Chlorambucil Tablets
    05.01.07 Chloramphenicol injection
    11.03.01 Chloramphenicol 
  • 0.5% eye drops First line
  • 0.5% Minims (SDU)
  • 1% eye ointment
  • 12.01.01 Chloramphenicol ear drops 
  • Only with positive culture/sensitivity data.
  • 04.01.02 Chlordiazepoxide  Adjunct in acute alcohol withdrawal
    04.10.01 Chlordiazepoxide 
  • Adjunct in acute alcohol withdrawal
  • 13.11.02 Chlorhexidine acetate 0.015% with cetrimide 0.15% Travasept 100®
    12.03.04 Chlorhexidine gluconate 0.2% mouthwash 
    12.03.04 Chlorhexidine gluconate 1% dental gel 
    13.11.02 Chlorhexidine gluconate preparations 
    12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
  • Contains arachis (peanut) oil, not suitable for patients with allergy to peanuts.
  • Patients with soya allergy should also avoid Naseptin®
  • 03.04.01 Chlorphenamine 
    • Tablets
    • Syrup

    OTC preparation suitable for self-care/purchase if appropriate

    04.02.01 Chlorpromazine (oral) 
  • tablets
  • syrup

  • Supported by ESCA, see link below.
  • 04.06 Chlorpromazine Hydrochloride 
  • nausea
  • hyperemesis in pregnancy (off label use)
  • 04.02.01 Chlorpromazine injection 
    02.02.01 Chlortalidone Tablets 
    14.04 Cholera vaccine Dukoral®
  • via travel vaccine service
  • 12.03.01 Choline Salicylate dental gel  
  • For patients over 16 years
  • 06.05.01 Choriogonadotropin Alfa Ovitrelle®
  • Hospital only
  • A5.04.02 Cica-Care   Silicone sheet for scar treatment

    Type of wound product is suitable for
    Not for use on open wounds- to be applied on healed scar only.
    This is not a dressing but a scar treatment

    Duration dressing remains on wound before changing
    23 hours

    Frequency of dressing change
    Daily

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur.

    Rationale for inclusion in formulary
    Scar therapy
    Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function. Self adherent, Re-usable
    03.02 Ciclesonide Alvesco®
    • Initiation by a respiratory specialist
    • Supported by a RICaD
    01.05.03 Ciclosporin  Capsules 10mg, 25mg, 50mg, 100mg, IV infusion 50mg/ml
    Treatment of ulcerative colitis- for specialist use only
    MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands
    04.13 Ciclosporin 

    Specialist use only for neurological conditions

    08.02.02 Ciclosporin Neoral® Sandimmun®

    Red Traffic Light  Post transplant- new patients
    Amber Traffic Light  Post transplant-patients initiated pre April 2013

    10.01.03 Ciclosporin  Supported by ESCA, see link below.
    13.05.03 Ciclosporin 
    • supported by ESCA, see link below
    11.99.99.99 Ciclosporin 2mg/g eye ointment Optimmune®
    11.99.99.99 Ciclosporin 1 mg/mL eye drops, emulsion Ikervis®
  • Specialist initiation.
  • In line with NICE
  • 09.05.01.02 Cinacalcet Mimpara®
  • NHSE commissioned for dialysis only.
  • All prescribing retained by secondary care.
  • 04.06 Cinnarizine tablets 
    05.01.12 Ciprofloxacin infusion
    05.01.12 Ciprofloxacin oral presentations

    Green Traffic Light Only when used in line with Antimicrobial guidelines

    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    11.03.01 Ciprofloxacin 0.3%  
  • Specialist Ophthalmologist recommendation(Corneal consultant)
  • 12.01.01 Ciprofloxacin 0.3% drops 
  • Off label use of eye drops
  • Specialist Recommendation
  • 12.01.01 Ciprofloxacin 2mg/ml ear drops Cetraxal®
    04.03.03 Citalopram oral drops 
    • Not recommended routinely due to QT prolongation risk
    04.03.03 Citalopram tablets 
    • Not recommended routinely due to QT prolongation risk
    08.02.04 Cladribine Mavenclad®
  • In line with NICE
  • Hospital only- NHSE commissioned
  • 05.01.05 Clarithromycin injection
    05.01.05 Clarithromycin oral presentations
    06.04.01.01 Climanor® 
    05.01.06 Clindamycin Capsules

    Green Traffic Light Only when used in line with Antimicrobial guidelines

    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    07.02.02 Clindamycin Dalacin®
  • 2% cream
  • 13.06.02 Clindamycin 
  • Specialist initiation
  • 12 week course
  • 13.06.01 Clindamycin 1% gel Zindaclin®

    Approved on formulary April 2018

    To be reviewed in 12 months to assess clindamycin 1% solution supply issues.

    13.06.01 Clindamycin 1% topical solution Dalacin T ®
    05.01.06 Clindamycin 300mg/2mL Injection 
    A5.08.03 Clinifast  ££
    Elasticated Sub bandage lining

    Type of wound product is suitable for
    To be used under retention and compression bandages when conformity is required
    Can be used for wet/dry wrapping.

    Duration dressing remains on wound before changing
    As required

    Frequency of dressing change
    As required

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Ensure the correct size for a limb is selected

    Rationale for inclusion in formulary
    Cost effective choice when conformity to a limb is required
    A5.07.03 Clinipore  Permeable non woven, synthetic adhesive tape
    For securing bandages

    Frequency of dressing change
    Determined by wound type and dressing change

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed

    Rationale for inclusion in formulary
    Available on drug tariff, cost effective and evaluated as meeting the requirements of a tape including adherence.
    A5.02.08 Clinisorb   Odour absorbent charcoal dressing

    Type of wound product is suitable for
    Malodourous wounds such as fungating wounds

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    1-7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not indicated as a primary dressing in dry wounds
    Store at room temperature
    Exudate levels will reduce the effectiveness of the charcoal

    Rationale for inclusion in formulary
    Clinisorb is an activated charcoal dressing which adsorb toxins removing malodour from the wound
    Can be cut to size
    Cost effective
    06.04.01.01 Clinorette® tablets 
    04.08.01 Clobazam   MHRA Advice
    Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
    13.04 Clobetasol Propionate 0.05%  Dermovate® Potency: very potent
  • Cream
  • Ointment
  • Scalp application
  • 13.04 Clobetasone Butyrate 0.05% cream Eumovate® Potency: moderate
    13.04 Clobetasone Butyrate 0.05% ointment Eumovate® Potency: moderate
    06.05.01 Clomifene Citrate 
    • For ovulation induction
    • On specialist recommendation
    • Generic tablets
    04.03.01 Clomipramine 
    • Capsules
    04.08.01 Clonazepam tablets  MHRA Advice
    Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
    02.05.02 Clonidine Hydrochloride tablets Catapres®
    02.09 Clopidogrel 75mg tablets 
    07.02.02 Clotrimazole 
  • All formulations
  • 12.01.01 Clotrimazole Canesten®
  • Only with positive culture/sensitivity data.
  • 13.10.02 Clotrimazole 1% 
  • cream
  • powder
  • solution
  • 04.02.01 Clozapine tablets 
    13.14.03 Coal tar BP 10% w/w in YSP 
    13.14.03 Coal tar BP 2% w/w in YSP 
    13.14.03 Coal tar BP 5% w/w in YSP 
    13.09 Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1®

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.05.02 Coal tar lotion 5% Exorex®
    13.05.02 Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% Polytar Emollient®
  • contains peanut oil
  • 13.14.02 Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in Synalar® gel 
    13.14.02 Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment 
    13.14.03 coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment 
    13.14.03 Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. merck 
    02.02.04 Co-amilofruse (furosemide and amiloride)  Combination products should be avoided, unless compliance is an issue.
    05.01.01.03 Co-Amoxiclav oral presentations

    Green Traffic Light Only when used in line with Antimicrobial guidelines 
     
    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    05.01.01.03 Co-Amoxiclav injection
    A5.08.08 Coban, Coban Lite®  Two layer compression system available in full and reduced compression (Coban Lite). Comprises of a latex free foam padding and cohesive bandage.

    Type of wound product is suitable for
    Treatment of venous and mixed aetiology leg ulcers

    Duration dressing remains on wound before changing
    1 to 7 days

    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Arterial disease
    Not to be used with other padding or wadding

    Rationale for inclusion in formulary
    Two layer compression kit, Once applied the two layers form a band to become a single
    layer bandage.
    Bandage technique can be adapted to reduce forefoot oedema (Extra training required)
    04.09.01 Co-Beneldopa 
  • Capsules
  • M/R capsules
  • Dispersible tablets
  • 04.09.01 Co-Careldopa 
  • Tablets
  • M/R tablets
  • 04.09.01 Co-Careldopa and Entacapone Stalevo®
    • Tablets
    13.14.06 Coconut oil 25% w/w in emulsifying ointment 
    13.06.02 Co-Cyprindiol 2000/35 
  • Prescribe as generic
  • 01.06.02 Co-danthramer  Capsules 25/200, 75/1000
    Suspension 25/200 in 5ml, Strong suspension 75/1000 in 5ml
    Co-dantramer strong preferred as per palliative care formulary guidance

    For constipation in terminally ill patients only
    01.06.02 Co-danthrusate  Capsules 50/60
    For constipation in terminally ill patients only
    01.04.02 Codeine  Tablets 15mg, 30mg, Syrup 25mg/5ml
    04.07.02 Codeine Phosphate 
    • tablets
    • 25mg/5ml syrup
    • Use with caution in patients aged over 65
    • Contraindicated in children below the age of 12
    04.07.02 Codeine Phosphate injection 
    10.01.04 Colchicine 
    09.06.04 Colecalciferol oral  Please see guidance below to support prescribing

    Please prescribe generically as listed below

    Oral Capsules or Tablets
    Colecalciferol 800 unit capsules
    Colecalciferol 800 unit tablets
    Colecalciferol 1,000unit capsules
    Colecalciferol 1,000unit tablets
    Colecalciferol 3,200unit capsules
    Colecalciferol 4,000unit tablets
    Colecalciferol 20,000unit capsules
    Colecalciferol 25,000unit tablets
    Colecalciferol 40,000unit capsules

    Oral Solution
    Colecalciferol 2,740units/ml oral drops sugar free
    Colecalciferol 10,000units/ml oral drops sugar free
    Colecalciferol 10,000units/ml oral solution sugar free
    Colecalciferol 15,000units/5ml oral solution
    Colecalciferol 25,000units/1ml oral solution unit dose ampoules sugar free
    Colecalciferol 50,000units/1ml oral solution unit dose ampoules sugar free


    Licensed brands currently available (updated March 2017)
    Aviticol 800 IU Capsules
    Aviticol 1,000 IU Capsules (Listed in the Drug Tariff)
    Aviticol 20,000 IU Capsules

    Desunin 800 IU Tablets (Listed in the Drug Tariff)
    Desunin 4,000 IU Tablets (Listed in the Drug Tariff)

    Fultium-D3 800 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 3,200 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 20,000 IU Capsules (Listed in the Drug Tariff)
    Fultium-D3 2740 IU/ml oral drops, solution (Listed in the Drug Tariff)

    InVita D3 800 IU Capsules
    InVita D3 2,400 IU/ml oral drops, solution
    InVita D3 25,000 IU oral solution (Listed in the Drug Tariff)
    InVitaD3 50,000 IU oral solution (Listed in the Drug Tariff)

    Plenachol 20,000 IU Capsules
    Plenachol 40,000 IU Capsules (Listed in the Drug Tariff)

    Stexerol-D3 1,000 IU Tablets (Listed in the Drug Tariff)
    Stexerol-D3 25,000 IU Tablets (Listed in the Drug Tariff)

    STRIVIT-D3 800 IU Capsules

    THORENS 10 000 I.U. /ml oral drops, solution (Listed in the Drug Tariff)
    THORENS 25 000 I.U. /2.5 ml oral solution

    01.09.02 Colestyramine  Powder
    02.12 Colestyramine sachets 

    Jaundice and Primary Biliary Cholangitis (PBC)

    05.01.07 Colistimethate injection
    05.01.07 Colistimethate for nebulisation 
    • See Chapter 3 for respiratory specific indications
    05.01.07 Colistimethate inhaler Colobreathe®
    03.13 Colistimethate sodium  Colistin sulfomethate sodium nebulised Commissioned by NHS England for Cystic Fibrosis only

    Red Traffic Light  New patients

    Amber Traffic Light  Existing patients (initiated prior to April 2013)
    10.03.01 Collagenase clostridium histolyticum Xiapex® In line with NICE
    01.01.01 Co-magaldrox  When low sodium content is required. ££
    Mucogel is most cost effective brand

    Use with caution in renal impairment
    07.03.01 Combined Hormonal Contraceptive Patches Evra®
  • For patients with poor compliance or absorption problems
  • A5.08.07 Comprilan®  100 % cotton short stretch compression bandage

    Type of wound product is suitable for
    Venous leg ulceration
    Varicosis
    Management of chronic oedema
    Management of primary and secondary lymphoedema
    Deep venous thrombosis
    Thrombophlebitis

    Duration dressing remains on wound before changing
    1 to 7 days

    Frequency of dressing change
    Dependant on exudate levels if wound present or oedema management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advanced Peripheral arterial occlusive disease
    Decompensated cardiac insufficiency
    Septic phlebitis
    Phlegmasia coerula doleris

    Rationale for inclusion in formulary
    Cotton short stretch bandage. Used by lymphoedema nurse specialists
    03.04.03 Conestat Alfa Ruconest® Hospital Only- NHSE commissioned
    A5.15 Conotrane cream  Barrier cream
    Type of wound product is suitable for
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing.
    Frequency of use
    Application at every episode of hygiene. Apply a thin layer sparingly
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of liquid paraffin in the ingredients, which will repel urine/faeces back onto
    the skin.
    Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Conotrane® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    07.03.05 Copper Intra-uterine devices  
  • Various
  • 09.04 Corn flour and corn starch 
    • For glycogen storage disease
    • Slow release CHO to prevent hypoglycaemia in GSD
    • Slow release carbohydrate to prevent hypoglycaemia in all types of GSD. Cheaper than glycosade and easier to mix. Used in less severe forms of GSD. Between 1 to 2g/kg body weight is prescribed dependent on age, weight and clinical symptoms of hypoglycaemia. Doses may be given at regular intervals during the day and night or at bedtime only. The dose and frequency of dose should always be advised by the specialist dietitian according to the needs of the patient.
    05.01.08 Co-trimoxazole IV infusion
    05.01.08 Co-trimoxazole oral presentations
    A5.08.03 Cotton Stokinette BP  Sub bandage lining

    Type of wound product is suitable for
    To be used under retention and compression bandages

    Duration dressing remains on wound before changing
    As required

    Frequency of dressing change
    As required

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used under Coban compression therapy
    Not to be used under compression hosiery
    Does not conform to a limb shape. If conformity is required, choose Clinifast

    Rationale for inclusion in formulary
    Cost effective choice when conformity to a limb is not required
    09.04 Cow & Gate Pepti-Junior®  
    • Infant and child: Hydrolysate formula
    • Whey hydrolysate. Use in infants who have malabsorption problems and require a peptide and MCT containing feed. Eg after gut surgery. Use as tube or oral feed
    • Disaccharide and/or whole protein intolerance, or where amino acids and peptides are indicated in conjunction with medium chain triglycerides.
    08.01.05 Crisantaspase Erwinase®
    08.01.05 Crizotinib Xalkori®
  • Hospital only- NHSE commissioned
  • In line with NICE
  • 13.03 Crotamiton Eurax®

    Over the counter preparation suitable for self-care/purchase if appropriate

    A5.03.04 Cutimed ®Sorbact  DACC coated dressings providing antimicrobial properties, available in a pad, gel, gel sheet, ribbon, round swab and rectangular swab

    Type of wound product is suitable for
    Colonised or clinically infected moist wound, suitable for any wound type

    Duration dressing remains on wound before changing
    1-3 days

    Frequency of dressing change
    1-3 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in combination with oils and creams
    Known hypersensitivity to ingredients
    Not for dry wound
    Not for heavily exuding wounds

    Rationale for inclusion in formulary
    Alternative to available antimicrobials
    A5.02.02 C-View Post-Op   Vapour-permeable adhesive film with absorbent pad
    Type of wound product is suitable for
    Dry non infected wounds, low exuding wounds, minor burns, protection of intact skin, protection of newly epithelialized wounds
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds
    Rationale for inclusion in formulary Protection of intact skin, low exuding wounds. Waterproof
    04.06 Cyclizine 
  • tablets
  • injection- for palliative care
  • 11.05 Cyclopentolate Hydrochloride 0.5% eye drops 
    11.05 Cyclopentolate Hydrochloride 1% eye drops 
    11.05 Cyclopentolate Hydrochloride single use Minims®
  • Specialist Ophthalmologist Recommendation.
  • 08.01.01 Cyclophosphamide Tablets
  • For oncology
  • 05.01.09 Cycloserine 
    06.04.02 Cyproterone Acetate 
    08.03.04.02 Cyproterone Acetate 
    09.04 Cystine500® 
    • To correct cysteine deficiency in homocystinuria
    • The only pre-measured sachet of cysteine to correct cysteine deficiency in homocystinuria. The dose and frequency of administration will be determined by the specialist dietitian.
    • Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
    08.01.03 Cytarabine–daunorubicin liposomal Vyxeos®

    In line with NICE

    02.08.02 Dabigatran  Amber Traffic Light  Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Dabigatran in AF

    Red Traffic Light  Use following Hip and Knee surgery- full course of treatment supplied on discharge.

    Amber Traffic Light  For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD.
    RICaD: Dabigatran in DVT / PE

    08.01.05 Dabrafenib with Trametinib 

    In line with NICE

    08.01.05 Dacarbazine 
    05.03.03.02 Daclatasvir Daklinza® In line with NICE
    09.04 Dalia 
    • Low protein milk for children and adults with phenylketonuria and other disorders of protein metabolism
    • Low protein milk (similar energy content to cow’s milk) for children and adults with phenylketonuria and other disorders of protein metabolism.
    02.08.01 Danaparoid Orgaran®
    06.07.02 Danazol 
  • For hereditary angioedema (off label use)
  • 10.02.02 Dantrolene capsules 
    01.06.02 Dantron  For constipation in terminally ill patients only
    06.01.02.03 Dapagliflozin Forxiga®

    SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

    In line with NICE

    05.01.10 Dapsone 
  • See Chapter 13 for use in dermatology
  • 05.01.07 Daptomycin injection
    08.01.05 Daratumumab Darzalex ®

    In line with NICE

    09.01.03 Darbepoetin Alfa Aranesp®
  • NHSE commissioned for use in renal dialysis
  • Primary Care commissioned for use in cancer- in line with NICE TA323
  • 05.03.01 Darunavir Prezista®
    08.01.05 Dasatinib Sprycel® In line with NICE
    A5.05.03 Debrisoft®  £££
    Debridement pad to cleanse and debride wounds.
    Type of wound product is suitable for
    Acute or chronic wounds with surface debris eg pressure ulcers, leg ulcers, diabetic foot ulcers
    Hyperkeratosis
    Duration dressing remains on wound before changing
    Not applicable
    Frequency of dressing change
    At each dressing change or as required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to polyester
    Heavy slough and necrotic tissue may require autolytic debridement to soften prior to
    use
    Thick hyperkeratosis may take more than one treatment
    Must be wet with clean warm water prior to use
    Do not get an emollient on the pad as this blocks the monofilaments
    Rationale for inclusion in formulary
    Lifts debris, superficial slough and exudate without damaging new granulation or
    epithelial cells
    Removes biofilms
    Lifts hyperkeratosis and dry flaking skin peri-wound
    Recommended by NICE
    Treatment well tolerated
    Convenient, easy to use, disposable single use pad
    09.01.03 Deferasirox Exjade®
  • NHSE commissioned
  • 09.01.03 Deferiprone Ferriprox®
  • NHSE commissioned
  • 08.03.04.02 Degarelix 
    • Commissioned by CCGs, in line with NICE
    • Transfer to Primary Care supported by an ESCA. Click here
      to access
    05.01.03 Demeclocycline capsules
  • See Chapter 6 for non-infection indications
  • 06.05.02 Demeclocycline capsules
  • in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone. UNLICENSED
  • 06.06.02 Denosumab Prolia®
  • Use in postmenopausal osteoporosis is supported by an ESCA, see link below.
  • 06.06.02 Denosumab XGEVA®
    13.08.02 Dermablend® 
  • Specialist recommendation
  • 13.10.05 Dermabond ProPen®  Hospital only
    13.08.02 Dermacolor® 
  • First line
  • Specialist recommendation
  • 100 shades available
  • FP10 prescriptions should be endorsed "ACBS"
  • A5.13 Dermatonics Once Heel balm  Cream containing 25% urea
    Type of wound product is suitable for
    To moisturise dry skin on the soles of feet
    For use on adults and children over 12 years of age
    Frequency of use
    Reapply daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients, contains beeswax and lanolin
    Not to be used on children under 12
    Rationale for inclusion in formulary
    Treatment of dry skin conditions of the foot. Dermatology approved
    13.02.01 Dermatonics Once Heel Balm® 

    specialist recommendation for epidermolysis bullosa

     

    A5.13 Dermol 500 Lotion  Emollient lotion containing an antimicrobial
    Type of wound product is suitable for
    For dry and pruritic skin conditions including eczema and dermatitis. Can be applied to skin as an emollient or used as a soap substitute
    Frequency of use
    Reapply daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients, contains benzalkonium chloride,
    0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin, isopropyl myristate. Should not be used unless infection is present or is a frequent complication
    Rationale for inclusion in formulary
    Treatment of dry skin requiring antimicrobial properties
    Dermatology approved
    13.02.01 Dermol 500 lotion ® 

    short term use only

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.02.01.01 Dermol 600® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    09.01.03 Desferrioxamine Mesilate 
  • NHSE commissioned
  • 06.05.02 Desmopressin 
  • Tablets
  • Melts (60mcg, 120mcg and 240mcg only)£££
  • Nasal solution
  • Nasal spray (10mcg/dose)
  • 07.03.02.01 Desogestrel 75mcg 
  • Prescribe generically
  • 09.04.01 Desserts 

    Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein.

    06.03.02 Dexamethasone 
  • Tablets £££
  • Oral solution SF £££
  • 11.04.01 Dexamethasone 0.1% eye drops Maxidex®
    11.04.01 Dexamethasone 0.1% eye drops Single dose units
  • for post corneal implants or OSD
  • Use the agent with the lowest acquisition cost
  • 11.04.01 Dexamethasone 700mcg intravitreal implant Ozurdex®
  • For macular oedema secondary to retinal vein occlusion -use in line with NICE
  • For diabetic macular oedema- use in line with NICE
  • 04.06 Dexamethasone injection 
  • palliative care only
  • 06.03.02 Dexamethasone phosphate injection 
    04.06 Dexamethasone tablets 
  • for resistant nausea and vomitting
  • £££
  • 12.01.01 Dexamethasone with Antibacterial Sofradex®
    11.04.01 Dexamethasone with Antibacterials Tobradex®
    12.01.01 Dexamethasone with neomycin and glacial acetic acid  Otomize®
    11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®
  • Specialist Ophthalmologist Recommendation.
  • 04.04 Dexamfetamine  Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Traffic Light Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG

    Amber Traffic Light Supported with an ESCA- Solihull CCG
    08.01 Dexrazoxane Savene®
    09.04 Dialamine® 
    • Protein and carbohydrate
    • This is a source of essential amino acids for use in low protein diets with urea cycle disorders. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Hypoproteinaemia, chronic renal failure, wound fistula leakage with excessive protein loss, conditions requiring a controlled nitrogen intake, and haemodialysis. Not suitable for child under 6 months.
    04.07.02 Diamorphine salts 
    04.01.02 Diazepam 
    04.01.02 Diazepam 
    04.10.01 Diazepam 
    10.02.02 Diazepam 
    04.01.01 Diazepam liquid 

    Inpatient use and prison settings only

    04.08.02 Diazepam rectal tubes 
    10.01.01 Diclofenac 
  • Short term use only
  • assess CVD risk
  • Not first line NSAID
  • Renal colic and severe acute painful conditions
  • 10.01.01 Diclofenac 
  • Short term use only
  • assess CVD risk
  • Not first line NSAID
  • For patients with swallowing diffulties
  • Renal colic and severe acute painful conditions
  • 11.08.02 Diclofenac Voltarol® Ophtha SDU
    11.08.02 Diclofenac Sodium Voltarol® Ophtha multidose
    13.08.01 Diclofenac sodium 3% gel 
  • ££
  • 05.03.01 Didanosine Videx®
    08.03.01 Diethylstilbestrol 
    13.04 Diflucortolone Valerate 0.3% oily cream  Potency: very potent
    02.01.01 Digoxin Elixir  Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation.

    Take extra caution in the elderly who may be more susceptible to digitalis toxicity.
    02.01.01 Digoxin Injection 
    02.01.01 Digoxin specific antibody fragments Digifab®
    02.01.01 Digoxin Tablets 
    Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation.

    Take extra caution in the elderly who may be more susceptible to digitalis toxicity.
    04.07.02 Dihydrocodeine 
  • tablets
  • oral solution- for patients with swallowing difficulties
  • 05.04.02 Diloxanide Furoate Diloxanide®
    02.06.02 Diltiazem  60mg tablets - FIRST LINE. For administration three times a day. No requirement for brand name prescribing.

    Modified- release formulations should be prescribed by brand name.

    Brand rationalisation- APC preferred brands:(in alphabetical order, does not suggest order of preference)
  • Adizem SR capsules and tablets
  • Adizem XL capsules
  • Angitil SR capsules
  • Angitil XL capsules
  • Tildiem LA capsules
  • Tildiem Retard tablets
  • 01.07.04 Diltiazem Cream 2%  Cream
    ££££
    Unlicensed - for use only in patients intolerant of or unresponsive to GTN ointment
    Store in fridge
    One tube will last a month if used as 2cm application TWICE DAILY
    08.02.04 Dimethyl fumarate Tecfidera®
  • For use in relapsing-remitting Multiple Sclerosis- NHSE commissioned
  • In line with NICE
  • 13.05.03 Dimethyl fumarate Skilarence®
  • For use in moderate to severe plaque psoriasis- CCG commissioned
  • In line with NICE
  • 07.04.04 DIMETHYL SULPHOXIDE Bladder Instillation 50%  Hospital only
    13.10.04 Dimeticone 

    Over the counter preparation suitable for self-care/purchase if appropriate

    07.01.01 Dinoprostone 
    07.01.01.01 Dinoprostone Prostin E2®
    08.02.03 Dinutuximab 

    In line with NICE

    13.14.07 Diphenylcyclopropenone in acetone 0.00001-6.0% w/v 
    02.09 Dipyridamole MR capsules Persantin® Retard
    02.09 Dipyridamole tablets 
    06.06.02 Disodium Pamidronate 
    02.03.02 Disopyramide capsules 
    02.03.02 Disopyramide injection 
    04.10.01 Disulfiram Antabuse®
    13.05.02 Dithranol Dithrocream®
  • All Strengths. Specialist Recommendation
  • 13.14.05 Dithranol in Lassar’s paste 0.1% w/w 
    13.14.05 Dithranol in Lassar’s paste 0.5% w/w 
    13.14.05 Dithranol in Lassar’s paste 1% w/w 
    13.14.05 Dithranol in Lassar’s paste 10% w/w  
    13.14.05 Dithranol in Lassar’s paste 15% w/w 
    13.14.05 Dithranol in Lassar’s paste 2% w/w 
    13.14.05 Dithranol in Lassar’s paste 4% w/w 
    13.14.05 Dithranol in Lassar’s paste 8% w/w 
    13.14.05 Dithranol pomade 0.4% w/w   dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100%
    02.07.01 Dobutamine 
    08.01.05 Docetaxel  In line with NICE
    09.04 DocOmega® 
    • DHA supplement for low chain fatty acid and low protein diets
    • The only ACBS prescribed DHA supplement for low protein diets. The dose and frequency of administration will be determined by the specialist dietitian.
    • Nutritional supplement for the dietary management of inborn errors of metabolism for adults and children from birth.
    01.06.02 Docusate Sodium  Capsules 100mg, Liquid 50mg/5ml
    - Solution is utterly unpalatable - only fit for use down tubes)
    - Probably acts as a softening laxative as well as a stimulant
    - Time to effect is approximately 24 to 48 hours
    01.02 Domperidone  Second line

    Domperidone is no longer recommended for the management of heartburn, bloating and stomach discomfort. See the link below for more information
    04.06 Domperidone 
  • tablets- short term use only
  • suppositories
  • SF suspension £££ - for patients with swallowing difficulties only
  • 04.11 Donepezil 
  • tablets
  • orodispersible 10mg tablets sugar free (pack of 28)


    The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.

  • 02.07.01 Dopamine 
    03.07 Dornase Alfa Pulmozyme® Commissioned by NHS England for Cystic Fibrosis only

    Red Traffic Light  New patients


    Amber Traffic Light  For existing patients (initiated pre April 2013)



    11.06 Dorzolamide 2% 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Dorzolamide 2% with Timolol 0.5% 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Dorzolamide 2% with Timolol 0.5% SDU Eye Drops Cosopt®
  • Specialist Ophthalmologist Recommendation
  • 11.06 Dorzolamide 2% eye drops (SDU) Trusopt®
  • Specialist Ophthalmologist Recommendation
  • 13.02.01 DoubleBase Gel ® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    03.05.01 Doxapram Dopram® Hospital only
    02.05.04 Doxazosin tablets  Plain tablets

    Black Traffic Light  Modified release tablets are non- formulary
    07.04.01 Doxazosin tablets 

    Plain tablets only

    Black Modified release tablets are non formulary.

    13.03 Doxepin Hcl cream Xepin ®
    • Supported by a RICaD

     

    08.01.02 Doxorubicin Hydrochloride Lipid formulation
    05.01.03 Doxycycline oral
    05.01.03 Doxycycline injection
    13.06.02 Doxycycline 
  • Topical treatments should be used first line.
  • Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.

    Please refer to Antimicrobial guidelines
  • 02.03.02 Dronedarone tablets Multaq® To be used in line with NICE guidance
    03.01.05 Drug Delivery Device Haleraid®
  • Please note this device is not prescribable, but can be obtained on request from community pharmacies but will incur a small cost.
  • 03.01.05 Drug Delivery Devices 

    All spacer devices

    06.04.01.01 Duavive® 
    • Specialist recommendation
    06.01.02.03 Dulaglutide Trulicity®
    • NOT for monotherapy
    04.03.04 Duloxetine Cymbalta®
    04.07.03 Duloxetine Cymbalta®
  • 3rd line after gabapentin
  • low abuse potential , high cost £££
  • on advice of specialist
  • not licensed for use in children
  • 07.04.02 Duloxetine 
    09.04 Duocal® Super Soluble 
    • Fat and Carbohydrate
    • For renal children with fluid restriction
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.
    A5.02.04 Duoderm range of dressings   The adhesive layer forms a cohesive gel when in contact with wound exudate
    Available as Extra thin or Signal (Bordered)

    Type of wound product is suitable for
    Dry to lightly exuding wounds
    Non infected
    Acute or Chronic wounds

    Duration dressing remains on wound before changing
    Up to 7 days maximum

    Frequency of dressing change
    3-7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not suitable for infected wounds, full thickness burns or wounds with exposed bone, muscle or tendon or wounds that are likely to macerate, particularly on plantar surface of foot
    Not for diabetic foot ulcers
    Not for ischaemic wounds
    Known product or component sensitivity

    Rationale for inclusion in formulary
    Conformable, waterproof, aids autolysis. Protect surrounding skin , reduced risk of
    blistering. Cost effective
    08.01.05 Dupilumab 

    In line with NICE

    08.01.05 Durvalumab 

    In line with NICE

    06.04.02 Dutasteride Avodart®
    • When finasteride has failed or is contraindicated/not tolerated
    09.04 EAA® Supplement 
    • Consists of essential amino acids for the treatment of urea cycle disorders
    • Essential amino acid supplement for use in urea cycle disorders and the cerebral creatine deficiency syndrome: guanidinoacetate methyltransferase (GAMT) deficiency. The only pre-measured sachet of essential amino acids with added vitamins and minerals for the treatment of urea cycle disorders. This is particularly important as most of our families with UCD do not speak English as their first language so require pre-measured products. Unmeasured use of essential amino acid supplements in UCD could lead to hyperammonaemia, acute brain encephalopathy and ITU admission. The dose and frequency of administration will be determined by the specialist dietitian.
    • Nutritional supplement for the dietary management of disorders of protein metabolism including urea cycle disorders in children over 3 years.
    A5.11 Easy-Slide   Application aid for open toe compression hosiery garments
    A5.01.02 Eclypse 

    Approved June 2018 to replace Flivasorb®

    11.03.02 Econazole 1% eye drops 
    07.02.02 Econazole pessaries Gyno-Pevaryl®
    02.08.02 Edoxaban Restricted Item Amber Traffic Light For treating and for preventing recurrent DVT and PE- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
    RICaD: Edoxaban in DVT/PE


    Amber Traffic Light  Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
    RICaD: Edoxaban in AF
    10.02.01 Edrophonium Chloride  Hospital only
    05.03.01 Efavirenz Sustiva®
    09.04.02 Elemental 028®Extra 
    • Less than 1 kcal/mL and less than 5 g protein/100 mL
    • Amino acid formula (essential and non-essential amino acids)
    • Pts with IBD, multiple allergy
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
    09.04.02 Elemental 028®Extra 
    • Less than 1 kcal/mL and less than 5 g protein/100 mL
    • Amino acid formula (essential and non-essential amino acids)
    • Pts with IBD, multiple allergies. For tube feed and oral feeding. Alter concentration of feed to support individual patient’s nutritional needs.
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
    09.08.01 Eliglustat Cerdelga® In line with NICE Highly Specialised Technology guidance- NHSE commissioned
    06.04.01.01 Elleste Solo MX® Patch 
    • If a 40mcg or 80mcg strength required
    06.04.01.01 Elleste Solo® 
    • Elleste Solo® 1mg and 2mg tablets
    06.04.01.01 Elleste-Duet Conti® tablets 
    06.04.01.01 Elleste-Duet® tablets (sequential) 
    09.01.04 Eltrombopag Revolade®
    01.05 Eluxadoline 
  • In line with NICE
  • Specialist initiation, transfer of prescribing supported by RICaD.
  • RICaD: Eluxadoline
  • 06.01.02.03 Empagliflozin Jardiance®

    SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

    In line with NICE

    05.03.01 Emtricitabine Emtriva®
    A5.14 Emulsifying Ointment  Emollient ointment containing emulsifying wax, white soft paraffin and liquid paraffin
    Type of wound product is suitable for
    For treatment of dry skin conditions
    Frequency of use
    Daily
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin
    Dermatology approved
    13.02.01 Emulsifying Ointment BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    02.05.05.01 Enalapril tablets  For existing patients only.
    08.01.05 Encorafenib with binimetinib  

    In line with NICE

    09.04 Energivit® 
    • Fat and Carbohydrate
    • Infant feed - Metabolic disorder pts
    • Also protein-free (containing fat, carbohydrate, vitamins and minerals) powder necessary for infants with inborn errors of protein metabolism. It is the only protein-free infant feed for patients with urea cycle disorders and organic acidaemias. It is commonly used in combination with a measured amount of natural protein e.g. expressed breast milk. It will help meet essential energy and nutrient requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • For children requiring additional energy, vitamins, minerals, and trace elements following a protein-restricted diet
    02.08.01 Enoxaparin  Green Traffic Light  Single use in suspected DVT

    Red Traffic Light  For all other indications.

    The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.(ESCAs to be developed).
    02.01.02 Enoximone Perfan®
    09.04 Enshake® 
    • Protein, fat, and carbohydrate
    • First choice for patients with very high energy requirement eg cystic fibrosis
    • In adults with cystic fibrosis, nutritional advice and interventions should be aimed at maintaining a BMI of 22kg/m2 in women and 23kg/m2 in men, as these are associated with better lung function (Nutritional management of CF – Consensus document – 2016)
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year; use with caution in child 1–6 years.
    09.04.02 Ensure®Twocal 
    • More than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High calorie vegetarian fish oil free
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also haemodialysis and CAPD
    04.09.01 Entacapone 
    • Tablets
    05.03.03 Entecavir Baraclude®
    08.03.04.02 Enzalutamide Xtandi®
  • Hospital only- NHSE commissioned
  • In line with NICE and available from day 91 following publication of TA.
  • 13.14.07 Eosin solution 2% w/v 
    A5.14 Epaderm ®Ointment  Emollient ointment containing liquid paraffin, yellow soft paraffin and emulsifying wax
    Type of wound product is suitable for
    For use on all dry skin conditions and with dry or wet wrapping techniques
    Frequency of use
    Daily or more frequently if required
    Caution/contraindications
    Non listed
    Rationale for inclusion in formulary Treatment of dry skin conditions. Dermatology approved
    13.02.01 Epaderm® ointment 

    Over the counter preparation suitable for self-care/purchase if appropriate

    02.07.02 Ephedrine 
    12.02.02 Ephedrine nose drops 
  • Short Term Use Only
  • 13.02.01 Epimax ® cream 
    02.02.03 Eplerenone tablets 
    09.01.03 Epoetin beta NeoRecormon®
  • NHSE commissioned for use in renal dialysis
  • Primary Care commissioned for use in cancer- in line with NICE TA323
  • 02.08.01 Epoprostenol Flolan®
    03.07 Erdosteine 
    09.06.04 Ergocalciferol 
    07.01.01 Ergometrine Maleate 
    07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
    08.01.05 Eribulin Halaven®
  • In line with NICE
  • Hospital only- NHSE commissioned
  • 08.01.05 Erlotinib Tarceva®
  • in line with NICE and available from day 91 following publication of TA.
  • 05.01.02.02 Ertapenem 
    06.01.02.03 Ertugliflozin  Steglatro®

    In line with NICE

    05.01.05 Erythromycin tablets
    05.01.05 Erythromycin Ethyl succinate oral suspension
    05.01.05 Erythromycin Lactobionate Injection
    04.08.01 Eslicarbazepine 
    • Supported by an ESCA
    02.04 Esmolol injection 
    01.03.05 Esomeprazole Injection 
    • Secondary care use only
    06.04.01.01 Estraderm MX® Patch 
    07.03.01 Estradiol/dienogest Qlaira®
  • Phasic (28-day ‘Every day’ preparation)
  • For Synphase failure
  • 06.04.01.01 Estradot® 
    • Estradot® patch 
    08.01.01 Estramustine Phosphate capsules
    06.04.01.01 Estriol® 0.01% 
    02.11 Etamsylate Dicynene®
    10.01.03 Etanercept Enbrel® Hospital only
    13.05.03 Etanercept 
  • use in line with NICE TA 103
  • 09.05.01.02 Etelcalcetide Parsabiv® In line with NICE, NHSE commissioned
    Restricted Item Black Triangle
    05.01.09 Ethambutol  

    Ethambutol liquid 400mg in 5ml (unlicensed)

    07.03.01 Ethinylestradiol / levonorgestrel phased pill TriRegol®
  • Phasic standard strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20®
  • Monophasic low strength (21-day preparation)
  • For pubertal induction in adolescent patient or premature ovarian failure ONLY
  • 07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®20/150/ Lestramyl®20/150
  • Monophasic low strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg Millinette®20/75
  • Monophasic low strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg 
  • Monophasic standard strength (21-day preparation)

    Brands approved by APC:
  • Yacella ®
  • Acondro ®
  • Dretine ®
  • 07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®30/150, Lestramyl®30/150
  • Monophasic standard strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®30/75
  • Monophasic standard strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg 
  • Monophasic standard strength (21-day preparation)
  • Rigevidon®
  • Levest®
  • 07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Microgynon 30 ED ®
  • Monophasic standard strength (28-day ‘Every day’ preparation)
  • 07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor®
  • Monophasic standard strength (21-day preparation)
  • 07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Lizinna®
  • Monophasic standard strength (21-day preparation)
  • 06.04.01.01 Ethinylestradiol tablets  
    • For induction of puberty in female patients who cannot tolerate or are allergic to first-line patches.
    • Red 2 microgram- unlicensed special
    • Amber Specialist recommendation - 10 microgram ££
    07.03.01 Ethinylestradiol/ Norethisterone  Synphase®
  • Phasic 21-day preparation
  • Added to formulary May 2017 as alternative to Trinovum which was discontinued in 2016.
  • 04.08.01 Ethosuximide capsules  MHRA Advice
    When prescribing for epilepsy, the potential for clinically relevant differences to exist between different manufacturers’ products is considered to be extremely low. However, consider other patient/carer-related factors, such as negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability.
    07.03.02.02 Etonorgestrel 68mg implant Nexplanon®
    05.03.01 Etravirine Intelence®
    13.02.01 Eucerin® Intensive lotion 10%urea 

    Over the counter preparation suitable for self-care/purchase if appropriate

    08.01.05 Everolimus Afinitor® In line with NICE
    Hospital only-NHSE commissioned
    08.01.05 Everolimus Votubia®
    02.11 Evicel ®
    02.12 Evolocumab Repatha® To be used in line with NICE TA 394
    06.04.01.01 Evorel Conti® patch 
    06.04.01.01 Evorel Sequi® patch 
    06.04.01.01 Evorel® 
    • Evorel® patch 
    08.03.04.01 Exemestane 
    02.12 Ezetimibe Ezetrol® in line with NICE
    02.11 Factor VIIa (Recombinant) Eptacog alfa
    05.03.02.01 Famciclovir 
    10.01.04 Febuxostat Adenuric®

    Second line

    02.06.02 Felodipine  Brand rationalisation - APC preferred brands:-
  • Cardioplen XL
  • Felotens XL
  • 06.04.01.01 Femoston Conti® 
    06.04.01.01 Femoston® (sequential) 
    06.04.01.01 Femseven Conti® patch 
    06.04.01.01 Femseven Sequi® patch 
    • 2nd line to Evorel Sequi®
    02.12 Fenofibrate 
  • tablets
  • capsules
  • 04.07.02 Fentanyl lozenges 
  • Palliative care only
  • 04.07.02 Fentanyl Nasal Spray 
    04.07.02 Fentanyl patches 
    04.07.02 Fentanyl sublingual tablets 
  • Palliative care only
  • 09.01.01.02 Ferric Carboxymaltose Ferinject® Hospital only
    09.01.01.01 Ferric maltol Feraccru®
    • Approved on formulary December 2017
    • For the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD), unable to tolerate other oral iron formulations.
    • Supported by a RICaD
    09.01.01.01 Ferrous Fumarate liquid Fersamal®
    09.01.01.01 Ferrous Fumarate tablets 
    09.01.01.01 Ferrous Gluconate 
  • If patient is intolerant of ferrous sulphate
  • 09.01.01.01 Ferrous Sulphate 
    03.04.01 Fexofenadine  Second Line
    05.01.07 Fidaxomicin 
    09.01.06 Filgrastim 
  • Hospital only
  • 06.04.02 Finasteride 5mg tablets
  • In men only
  • 06.04.02 Finasteride 1mg tablets
    • for Hyperandrogenism in women (unlicensed)

    • Black listed in NHS primary care
    13.09 Finasteride Propecia®

    Red Traffic Light  for hyperandrogenism in women (unlicensed)

    Black listed in NHS primary care

    Not NHS Not NHS

    08.02.04 Fingolimod 
  • In line with NICE
  • A5.03.04 Flaminal ® Forte Gel  Alginate gel. Moderate to heavily exuding wounds. Contains antimicrobial enzymes.

    Type of wound product is suitable for
    Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
    Useful for cavity wounds and sinus’s
    Requires a secondary dressing

    Duration dressing remains on wound before changing
    1-7 days

    Frequency of dressing change
    1-7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to alginate dressings or polyethylene glycol
    Full thickness burns

    Rationale for inclusion in formulary
    1st line antimicrobial in paediatrics
    Consider as first line product if signs of colonisation or clinical infection
    Does not cause cellular damage
    A5.03.04 Flaminal ®Hydro Gel   Alginate gel. Low to moderate exuding wounds. Contains antimicrobial enzymes

    Type of wound product is suitable for
    Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
    Useful for cavity wounds and sinus’s
    Requires a secondary dressing

    Duration dressing remains on wound before changing
    1-7 days

    Frequency of dressing change
    1-7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to alginate dressings or polyethylene glycol
    Full thickness burns

    Rationale for inclusion in formulary
    1st line antimicrobial in paediatrics
    Consider as first line product if signs of colonisation or clinical infection
    Does not cause cellular damage
    06.01.06 Flash glucose monitoring system  FreeStyle Libre®
    07.03.04 Flat spring diaphragm 
  • Sizes 55-95mm (rising in 5mm)
  • 09.04 FlavourPac® 
    • Flavouring preparations
    • For flavouring unpalatable flavouring amino acid supplements or feeds in inborn errors of metabolism
    • Essential for flavouring different unflavoured amino acid supplements in inborn errors of metabolism particularly for non PKU conditions. They offer common children’s favourite flavours: e.g. orange or raspberry. Flavourings are important, as amino acid formulations are unpalatable and unacceptable particularly for patients with late diagnosed conditions. They cannot be purchased from a supermarket.
    • For use with Vitaflo's range of unflavoured protein substitutes for metabolic diseases; not suitable for child under 3 years.
    02.03.02 Flecainide injection 
    02.03.02 Flecainide tablets 
    01.06.05 Fleet Phospho-soda®  Oral solution
    09.04.01 Flour mixes and egg substitutes 

    Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 ordinary egg = 6g protein. 100g flour = 10g protein.

    13.04 Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® Paeds use only
    Potency :Mild

    February 2017: aware of unavailability, use alternative mild potency preparation.
    13.04 Flucinolone Acetonide 0.025% Synalar Gel® £££
    Potency:Potent
    05.01.01.02 Flucloxacillin injection
    05.01.01.02 Flucloxacillin oral presentations

    As per antimicrobial guidelines

    05.02 Fluconazole 
  • Capsules
  • Suspension- For patients with swallowing difficulties only
  • 07.02.02 Fluconazole 150mg oral capsule 
    05.02 Flucytosine 
    08.01.03 Fludarabine Phosphate 
    06.03.01 Fludrocortisone 
    13.04 Fludroxycortide 7.5cm x 200cm tape previously known as Haelan® ££
    Potency: moderate
    A5.16 Fludroxycortide tape   Adhesive, waterproof, occlusive tape impregnated with 4mg/cm2 fludroxycortide (topical steroid)
    Type of wound product is suitable for
    Chronic overgranulation, non acute or weeping.
    Duration dressing remains on wound before changing
    Cut the tape to size. Apply for 12 hours at a time, remove and discard. Apply to clean, dry skin that is shorn of any hair.
    Frequency of dressing change
    Apply daily for 12 hours at a time. Maximum treatment time 7 days.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Chicken pox
    Tuberculosis of the skin
    Hypersensitivity to any components in the tape (steroid fludroxycortide)
    Facial rosacea
    Acne vulgaris
    Perioral dermatitis
    Perianal and genital pruritis
    Dermatoses in infants Dermatitis napkin eruption Bacterial, viral and fungal infections
    Keep away from the eyes
    Avoid prolonged use on the face
    Not for untreated bacterial, fungal or viral skin lesions
    Rationale for inclusion in formulary
    Treatment of overgranulation
    12.01.01 Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform®
    04.07.04.02 Flunarizine 

    Unlicensed medicine

    13.04 fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® Potency: potent

  • Cream
  • Ointment
  • 11.04.01 Fluocinolone intravitreal implant Iluvien®
    11.04.01 Fluorometholone 0.1% FML®
  • Specialist Ophthalmologist Recommendation.
  • 11.99.99.99 Fluorouracil 
  • hospital only
  • 13.08.01 Fluorouracil Efudix®
    13.08.01 fluorouracil 0.5%, salicylic acid 10% Actikerall® For hyperkeratotic lesions
    04.03.03 Fluoxetine capsules 
    04.03.03 Fluoxetine liquid 
    04.02.02 Flupentixol Decanoate  The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    04.02.01 Flupentixol tablets 
  • Supported by ESCA, see link below.
  • 04.02.02 Fluphenazine Decanoate Modecate®

    The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.

    • Discontinued by manufacturer by the end of 2018.
    08.03.04.02 Flutamide 
    03.02 Fluticasone and formoterol Flutiform®
  • Alternative to Seretide Evohaler/ Seretide 250 Accuhaler
  • When reviewing/stepping down, consider switch if appropriate
  • 03.02 Fluticasone and salmeterol Seretide®

    For paediatric use ONLY (i.e. up to 18 years of age)

    • Seretide Evohalers
    • Seretide Accuhalers
    • Should be prescribed by the intended brand to ensure patients are maintained on the formulation they are used to.
    • When reviewing patients on Seretide 250 Accuhaler,consider switch to Fostair or Flutiform if appropriate.

    12.02.01 Fluticasone furoate Avamys®
  • previous APC decision reviewed in December 2015.
  • Approved for use in children and adults.
  • 03.02 Fluticasone furoate & vilanterol Relvar Ellipta®
    • For COPD- 92mcg/22mcg
    • For asthma- both strengths

    03.02 Fluticasone inhalers  For paediatric use ONLY (i.e. up to 18 years of age)

    Green Traffic Light  Fluticasone Evohaler 50, Fluticasone Accuhaler 50,100


    Amber Traffic Light  Fluticasone Evohaler 125, Fluticasone Accuhaler 250

    03.02 Fluticasone nebules 


    12.02.01 Fluticasone Propionate Flixonase Nasule®
  • Specialist Recommendations for Nasal Polyps.
  • 03.02.03 Fluticasone/vilanterol/umeclidinium Trelegy Ellipta®

    COPD Appendix 4 : Criteria for triple therapy and for triple inhaler use in COPD

     

    02.12 Fluvastatin capsules 
    09.01.02 Folic Acid   Green Traffic Light  Tablets
    Amber Traffic Light  SF solution- Lexpec®
    02.08.01 Fondaparinux Arixtra® Hospital only
    09.04 Food First 

    Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition.

    09.04.02 Food First  Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition.
    09.04 Foodlink® Complete 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • First line product
    • Not suitable for CKD 4-5, renal pts.
    • Not suitable for lactose intolerance
    • Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
    • To be made up with whole milk.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04 Foodlink® Complete with Fibre 
    • First line with added fibre
    • Not suitable for CKD 4-5, renal pts.
    • Not suitable for lactose intolerance
    • Not suitable for bile acid malabsorption or fat maldigestion associated with biliary conditions
    • To be made up with whole milk.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04 Forceval caps and soluble tabs 
    • Special additives for conditions of intolerance
    • Vitamin and mineral deficiency and as adjunct in synthetic diets
    03.01.01.01 Formoterol  
    09.04 Fortijuce®  
    • More than 1 kcal/mL and less than 5 g protein/100 mL
    • Juice style fat free, low K+
    • Patients who dislike milky tasting drinks
    • Caution advised – not milk free and high sugar content
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula Not suitable for child under 3 years
    09.04 Fortini® 
    • More than 1 kcal/ml and less than 4g protein/100ml
    • Sip feed for children over 8kg with faltering growth
    • Disease-related malnutrition and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04.02 Fortini® 1.0 Multi Fibre  Child under 12 years
  • 1 kcal/mL and less than 4g protein/100 mL
  • Standard 1 kcal/mL with fibre
  • 09.04 Fortini® Compact Multifibre 
    • Child: More than 1 kcal/mL and less than 4 g protein/100 mL
    • Low volume supplement
    • Supporting an unmet paediatric nutritional need
    • No other product is current available to meet this need.
    09.04 Fortini® Creamy Fruit 
    • Child: More than 1 kcal/mL and less than 4 g protein/100 mL
    • High energy fruit pudding for children with faltering growth
    09.04 Fortini® Multifibre 
    • Child: More than 1 kcal/mL and less than 4 g protein/100 mL
    • Sip feed for children over 8kg with faltering growth, with added fibre
    • Disease-related malnutrition and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04 Fortini® Smoothie Multifibre 
    • Child: More than 1 kcal/mL and less than 4 g protein/100 mL
    • Sip feed for children over 8kg with faltering growth
    09.04 Fortisip® 2kcal 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • For bolus tube feeding only
    • Only on dietetic advice sip feed in small volume.
    • Nutritionally complete in 2 bottles.
    09.04 Fortisip® Bottle 
    • Restricted for use where fluid volume is a benefit
    • Restricted for patients who are lactose intolerant
    • Maybe used as an alternative as a bolus feeds
    • Low fibre
    • Low osmolality.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    09.04 Fortisip® Compact 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Second line supplements choice.
    • Low volume supplement and for bolus feeding
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    09.04 Fortisip® Compact Fibre 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Second line supplements choice for use when fibre is indicated as advised by dietitian only. Low volume supplement and for bolus feeding
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    09.04 Fortisip® Compact Protein 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Not to be used without dietetic advice that higher protein is clinically appropriate.
    • With added protein
    • Low volume supplement and for bolus feeding advised by dietitian only.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula.
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    09.04 Fortisip® Yogurt Style 
    • 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • For dysgeusia and flavour fatigue only
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable for child under 3 years
    05.03.01 Fosamprenavir Telzir®
    05.03.02.02 Foscarnet Sodium Foscavir®
    05.01.13 Fosfomycin sachets
    • Second line treatment if high risk of resistance
    • In line with Antimicrobial Guidelines
    05.01.13 Fosfomycin Capsules

    Second line treatment if high risk of resistance. In line with antimicrobial guidelines

    02.11 Fresh Frozen Plasma 
    09.04 Fresubin® 2kcal 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • First line choice for 2kcal/ml sip feed
    • Small volume required and based on taste preference
    • Nutritionally complete in 2 bottles.
    • High Cal low Vol
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula; also CAPD, haemodialysis.
    • Not suitable for use in child under 1 year; use with caution in child 1–5 years.
    09.04 Fresubin® 2kcal Fibre Drink 
    • Used where 2kcal/ml sip feed in small volume with fibre is required
    • High Cal low Vol with added fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD, haemodialysis.Not suitable for use in child under 1 year; use with caution in child 1–5 years.
    09.04 Fresubin® Juicy Drink 
    • More than 1 kcal/mL and less than 5 g protein/100 mL
    • Juice style fat free, low K+
    • Patients who dislike milky tasting drinks 
    • Caution advised – not milk free and high sugar content
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD, haemodialysis

     

    09.04 Fresubin® Thickened 
    • 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Used for dysphagia pts only
    • Dysphagia or disease-related malnutrition. Not suitable for child under 3 years; use with caution in child 3–4 years.
    09.04 Fresubin® YOcreme 
    • 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • For dysgeusia and flavour fatigue only
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, preoperative
      preparation of malnourished patients, dysphagia, proven inflammatory bowel
      disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable
      for child under 3 years
    09.04.02 Fresubin®HP Energy 
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Only available product with high protein and high MCT (burns pts, tumour pts, and liver pts.)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD and haemodialysis
    09.04.02 Fresubin®HP Energy Fibre 
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Only available product with high protein and high MCT with fibre (burns pts, tumour pts, liver pts)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD and haemodialysis
    09.04 Fructose 
    • Special additives for conditions of intolerance
    • Used as a partial CHO source in modular feeds for infants and children with malabsorption secondary to short bowel syndrome or other malabsorption states
    • (Laevulose) For proven glucose/galactose intolerance
    09.06.07 FruitiVits® 
    • For patients with inborn errors of metabolism and for enteral feed patients.
    • For use in children 3 years and over with inborn errors of metabolism. This is a small volume, flavoured, carbohydrate free vitamin/mineral supplement used in conditions like citrin deficiency. There are no other carbohydrate free preparations available. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Vitamin, mineral, and trace element supplement in children 3–10 years with restrictive therapeutic diets
    08.03.04.01 Fulvestrant Faslodex®
    02.02.02 Furosemide 
  • Tablets
  • Oral solution
  • Injection
  • 11.03.01 Fusidic Acid 1% 
  • NICU Use as per guideline -1st Line
  • Bacterial Conjunctivitis infection 2nd line as per Antimicrobial Guidelines
    £££
  • 13.10.01.02 Fusidic Acid 2% 
    09.04 GA Amino 5 
    • Amino acid supplement without lysine – low in tryptophan for infants with GA1 - used for tube feeding in emergencies
    • The only pre-measured amino acid supplement without lysine, low in tryptophan for children with GA1 that can be administered via a tube in emergency feeds. It is essential it is easy to use in an emergency and pre-measured is safer, particularly for non-English speaking families. It can also be used in pyridoxine responsive epilepsy.
    09.04 GA Anamix Junior 
    • An unthickened amino acid supplement without lysine, low in tryptophan for children with GA1 that can be given as a drink. It can also be used in pyridoxine responsive epilepsy.
    09.04 GA Express 15 (not ACBS approved) 
    • Amino acid supplement without lysine and low in tryptophan for children and adults with GA1
    • The only low volume, vitamin and mineral amino acid supplement without lysine, low in tryptophan for use in patients > the age of 6 years’ children and adults with GA1 and pyridoxine responsive epilepsy.
    09.04 GA Gel® 
    • Amino acid supplement without lysine – low in tryptophan for infants with GA1
    • The only weaning (thickened) amino acid supplement without lysine, low in tryptophan for children with GA1. It can also be used in pyridoxine responsive epilepsy.
    • Nutritional supplement for dietary management of type 1 glutaric aciduria in children 6 months–10 years.
    09.04 GA1 Anamix® Infant 
    • Amino acid supplement without lysine – low in tryptophan for infants with GA1
    • The only amino acid supplement without lysine, low in tryptophan for infants with GA1 and pyridoxine responsive epilepsy.
    • Nutritional supplement for the dietary management of proven glutaric aciduria (type 1) in children from birth to 3 years.
    04.07.03 Gabapentin 
    • 2nd line
    • please be aware of the abuse potential associated with this class of agent

    Schedule 3 Controlled Drug as of 01/04/2019

    04.08.01 Gabapentin 
    • Capsules
    • Tablets £££

      MHRA Advice
      It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors

    Schedule 3 Controlled Drug as of 01/04/2019

    09.04 Galactomin 17® 
    • Specialised formulas: Infant and child: Residual lactose formula
    • Lactose free feed for use in adults metabolic disease only
    • Used as a milk alternative in adults, lactose free with galactosaemia. This is not used for infants by Birmingham Children’s Hospital. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Proven lactose intolerance in pre-school children, galactosaemia, and galactokinase deficiency.
    09.04 Galactomin 19® 
    • Specialised formulas: Infant and child: Fructose-based formula
    • Disease specific fructose containing formula for infants and children with glucose galactose malabsorption.
    • Conditions of glucose plus galactose intolerance
    04.11 Galantamine 
  • tablets
  • M/R capsules
  • Oral solution

    The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.

  • A5.05.01 Gamgee  Sterile or non sterile highly absorbent cotton wool enclosed in an absorbent cotton cover
    Type of wound product is suitable for
    Full thickness burns
    Can be cut to required size
    Secondary dressing
    Duration dressing remains on wound before changing
    Dependent on exudate levels
    Frequency of dressing change
    Dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used as a primary dressing
    Only to be used in UHB burns unit
    Rationale for inclusion in formulary
    UHB burns unit only
    05.03.02.02 Ganciclovir Cymevene®
    11.03.03 Ganciclovir 0.15% ophthalmic gel Virgan®
  • Specialist Ophthalmologist Recommendation.
  • A5.07.02 gauze swabs, non-woven swabs  7.5cm x 7.5cm only

    Type of wound product is suitable for
    Cleansing wounds via aseptic technique

    Duration dressing remains on wound before changing
    N/A

    Frequency of dressing change
    N/A

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be applied to a wound as a dressing

    Rationale for inclusion in formulary
    Necessity for wound cleansing
    Cost effective
    Included in Sterile wound packs or used to supplement sterile packs
    01.01.02 Gaviscon Infant  Oral powder
    08.01.05 Gefitinib Iressa®
    09.02.02.02 Gelatin Gelofusine®

    For Endoscopy use only

    12.03.01 Gelclair® 
  • Oncology and haematology use only
  • 08.01.03 Gemcitabine Gemzar®
    07.01.01 Gemeprost 
    08.02.03 Gemtuzumab Mylotarg®

    In line with NICE

    03.13 Gentamicin   Hospital only
    05.01.04 Gentamicin 
    11.03.01 Gentamicin 0.3% eye drops 
  • Possible 2nd Line after chloramphenicol- specialist opthalmologist recommendation.
  • 12.01.01 Gentamicin ear drops Genticin®
  • Only with positive culture/sensitivity data.
  • 06.04.01.01 Gestone® injection 
    • Fertility use only
    08.02.04 Glatiramer Acetate Copaxone®
    • Hospital use only
    05.03.03.02 Glecaprevir–pibrentasvir Maviret®

    In line with NICE

     

    06.01.02.01 Glibenclamide 
    • Use in pregnancy (as per NICE) for patients who do not want to move to insulin but are not responding to metformin
    06.01.02.01 Gliclazide 
    06.01.02.01 Gliclazide M/R  
    06.01.04 Glucagon GlucaGen® HypoKit
    06.01.04 GlucoGel® 
    09.04 Glucose 
    • Special additives for conditions of intolerance
    • Used as a partial CHO source in modular feeds for infants and children with malabsorption secondary to short bowel syndrome or other malabsorption states
    • (Dextrose monohydrate) For use as an energy supplement in sucrose-isomaltase deficiency
    13.07 Glutaraldehyde 10% solution 

    Over the counter preparation suitable for self-care/purchase if appropriate

    09.04.01 Gluten free foods 

    Department of Health and Social Care (DHSC) guidance – 

    • GF, GF & Wheat Free (WF) bread (includes rolls, part baked bread, and pizza bases)
    • GF, GF&WF mixes

    Follow Coeliac UK prescribing guidance for monthly quantities (based on age)

    01.06.02 Glycerol (Glycerin)  Suppository
    01.07.04 Glyceryl Trinitrate 0.4% Rectogesic® Ointment
    02.06.01 Glyceryl Trinitrate Injection 

    Secondary Care use only

    02.06.01 Glyceryl Trinitrate MR Bucaal Tabletsq 
    02.06.01 Glyceryl Trinitrate patches 
    02.06.01 Glyceryl Trinitrate SL spray and SL tablets 
    07.04.04 Glycine  Hospital only
    13.14.07 Glycopyrrolate 0.05% w/v in water 
    13.14.07 Glycopyrrolate 2% w/w in cetomacrogol cream 
    03.01.02 Glycopyrronium Seebri breezhaler®
          • For COPD only

    13.12 Glycopyrronium 
    • Unlicensed
    • For specialist initiation for hyperhidrosis
    • ££££
    04.12 Glycopyrronium bromide Sialanar®
  • Approved on formulary December 2017
  • Specialist initiation and stabilisation
  • £££
  • 03.01.04 Glycopyrronium/ indacaterol inhaler Ultibro Breezhaler®

    09.04 Glycosade® 
    • Slow release CHO to prevent hypoglycaemia in GSD
    • The only specially formulated slow release carbohydrate to prevent hypoglycaemia in severe forms of GSD e.g. Type I and III which allows extended fasting time. The dosage is dependent on age, weight and clinical symptoms of hypoglycaemia. Doses may be given at regular intervals during the day and night or at bedtime only. The dose and frequency of dose should always be advised by the specialist dietitian according to the needs of the patient. Glycosade is in a pre-measured sachet. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • A nutritional supplement for use in the dietary management of glycogen storage disease and other metabolic conditions where a constant supply of glucose is essential. Not suitable for use in children under 2 years.
    09.04 Glytactin Bettermilk 15 
    • A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years
    09.04 Glytactin Bettermilk RTD 15 (original and chocolate) 
    • A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years
    10.01.03 Golimumab Simponi®

    Hospital only

    Available via Home Care

    06.07.02 Goserelin 
  • For assisted conception
  • 06.07.02 Goserelin 
  • For endometriosis or breast cancer
  • Specialist initiation
  • 08.03.04.02 Goserelin Zoladex®
    08.03.04.02 Goserelin Zoladex® LA
    A5.09.01 Graduated compression hosiery   Based on assessment
    04.06 Granisetron tablets 
    04.06 Granisetron transdermal patch Sancuso®
  • for use in oncology patients only
  • A5.02.04 Granuflex  Type of wound product is suitable for
    Hyperkeratosis, granulating wounds, forms cohesive gel on contact with exudate

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    3-7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to ingredients - contains pectin and gelatine
    Not for diabetic foot ulcers or ischaemic wounds
    Not for infected wounds

    Rationale for inclusion in formulary
    Comformable waterproof dressing, aids rehydration.
    Reduces and softens hyperkeratosis
    03.04.02 Grass and Tree Pollen Extract Pollinex®
    03.04.02 Grass pollen extract Grazax®
  • Supported by RICaD
    RICaD: Grazax
  • 09.04 GTO oil 
    • A cooking oil for dietary treatment of adrenoleukodystrophy. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    04.04 Guanfacine Intuniv® for the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
    13.05.03 Guselkumab Tremfya ®

    Use in line with NICE

    14.04 Haemophilus influenzae type B Combined Vaccine Menitorix®
    01.07.01 Haemorrhoid relief ointment  Anusol® - other brands also available
    01.07.01 Haemorrhoid relief suppositories  Anusol® - other brands also available
    04.02.02 Haloperidol Haldol Decanoate® The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    04.09.03 Haloperidol 
    04.02.01 Haloperidol (oral) 
  • tablets
  • capsules
  • oral liquid sugar-free

  • Supported by ESCA, see link below.
  • 04.02.01 Haloperidol injection 
    • For rapid tranquilisation
    09.04 HCU Anamix® Infant 
    • Amino acid supplement without methionine for infants with homocystinuria
    • The only amino acid supplement without methionine for infants with homocystinuria. It is given to screened infants for HCU. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Nutritional supplement for the dietary management of proven vitamin B6 non-responsive homocystinuria or hypermethioninaemia in children from birth to 3 years.
    09.04 HCU Cooler® 10 
    • Amino acid supplement without methionine for children and adults with homocystinuria
    • The only liquid amino acid supplement without methionine for children with homocystinuria aged 3 to 6 years. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
    09.04 HCU Cooler® 15 
    • Amino acid supplement without methionine for teenagers and adults with homocystinuria
    • The only liquid amino acid supplements without methionine for children with homocystinuria aged 7 to 12 years. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
    09.04 HCU Cooler® 20 
    • Amino acid supplement without methionine for teenagers and adults with homocystinuria
    • One of two liquid amino acid supplements without methionine for children with homocystinuria aged >12 years. They need the larger sachets (20g protein equivalent) meet their non-methionine protein requirements.
    09.04 HCU Express® 15 
    • Amino acid supplement without methionine for teenagers and adults with homocystinuria
    • The only powdered amino acid supplement without methionine that provides 15g protein equivalent per sachet for children with homocystinuria aged 7 to 12 years. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
    • A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria
    09.04 HCU Express® 20 
    • Amino acid supplement without methionine for teenagers and adults with homocystinuria
    • One of 2 powdered amino acid supplements without methionine that provides 20g protein equivalent per sachet for teenagers with homocystinuria aged >12 years. They need the larger pouches to meet their non-methionine protein requirements. It is important we have a choice of more than 1 product for this age group as adherence is poor.
    • A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria.
    09.04 HCU gel® 
    • Amino acid supplement without methionine for children with homocystinuria
    • The only weaning (thickened) amino acid supplement without methionine for children with homocystinuria.
    • A methionine-free protein substitute for use as a nutritional supplement for the dietary management of children 1–10 years with homocystinuria.
    09.04 HCU Lophlex® LQ 20 
    • Amino acid supplement without methionine for teenagers and adults with homocystinuria
    • One of 2 powdered amino acid supplements without methionine that provides 20g protein equivalent per sachet for teenagers with homocystinuria aged >12 years. They need the larger pouches to meet their non-methionine protein requirements. It is important we have a choice of more than 1 product for this age group as adherence is poor.
    • Nutritional supplement for the dietary management of homocystinuria in children over 3 years.
    09.06.07 Healthy Start Vitamins 
  • Available free of charge from designated centres
  • 01.03 Helicobacter Stool Antigen Test 
  • in line with NICE/PHE guidance
  • check availibility of test in local laboratory.
  • 01.03 Helicobacter Urea Breath Test  
  • in line with NICE/PHE guidance
  • 02.08.01 Heparin sodium injection 
    13.13 Heparinoid 0.3% Hirudoid®
    14.04 Hepatitis A vaccine Single Component Avaxim®
    14.04 Hepatitis A vaccine Single Component Epaxal®
    14.04 Hepatitis A vaccine Single Component Havrix Monodose®
    14.04 Hepatitis A vaccine Single Component Vaqta® Paediatric
    14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
    14.05.02 Hepatitis B immunoglobulin 
    14.04 Hepatitis B vaccine Single Component Engerix B®
    14.04 Hepatitis B vaccine Single Component Fendrix®
    14.04 Hepatitis B vaccine Single Component HBvaxPRO®
    13.11.02 Hibitane Obstetric® 
    13.10.05 Histoacryl®  Hospital only
    09.04 Homemade milkshake 

    Where clinically appropriate encourage a standardised home-made nutritious
    drink at least equivalent to a standard 1.5KCal/ml prescribed bottle supplement
    in terms of calories and protein

    09.04.02 Homemade milkshake  Where clinically appropriate encourage a standardised home-made nutritious drink equivalent to a standard 1.5 KCal/mL prescribed bottle supplement in terms of calories and protein.
    06.05.01 Human Chorionic Gonadotrophin 
    06.05.01 Human Menopausal Gonadotrophins 
    12.04 Human papilloma virus vaccine Gardasil®
  • For use by ENT Specialists in recurrent respiratory papillomatosis (RRP)
  • 14.04 Human papilloma virus vaccine Gardasil®
  • For use by ENT Specialists only in recurrent respiratory papillomatosis (RRP)
  • 14.04 Human papilloma virus vaccine Cervarix®
    14.04 Human papilloma virus vaccine Gardasil®
  • For national immunisation campaign in adolescent girls ONLY
  • 11.99.99.99 Hyaluronidase Hyalase®
  • Hospital only
  • 02.05.01 Hydralazine tablets 
    01.05.02 Hydrocortisone Colifoam®

    July 2018 - supply problem expected to last until late 2018/early 2019

    Foam enema 125mg /metered application
    First choice steroid foam enema for IBD
    However, mesalazine preparations preferred to steroids overall

    06.03.02 Hydrocortisone 
  • Standard release tablets only
  • 13.04 Hydrocortisone   Potency: mild

    Hydrocortisone 0.5% cream & ointment
    Hydrocortisone 1% cream & ointment
    13.04 Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® Potency: mild
    Use post scabies once infection has cleared but itch remains present
    13.04 Hydrocortisone 0.5% ,chlorhexidine HCl 1% & nystatin  Nystaform-HC® Potency: mild
  • Cream
  • Ointment

    Paeds use only

    Replacement for discontinued Vioform HC
  • 13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC® Potency: mild
    13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort Cream® Potency: mild
    12.03.01 Hydrocortisone 2.5mg buccal tablets 
  • Specialist Recommendation
  • 10.01.02.02 Hydrocortisone acetate Hydrocortistab®
    13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H Cream® Potency: mild
    12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC
  • Only with positive culture/sensitivity data
  • 13.04 Hydrocortisone Butyrate Locoid ® Potency: potent

    Cream
    Lipocream
    Ointment
    Scalp lotion
    06.03.02 Hydrocortisone sodium succinate Solu-Cortef®
    A5.02.02 Hydrofilm  Vapour-permeable adhesive film

    Type of wound product is suitable for
    Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Up to 7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Clinically infected wounds, bleeding or exuding wounds

    Rationale for inclusion in formulary
    Retention of lines, protection of intact skin, fixation of other dressings. Cost effective
    Waterproof
    13.11.06 Hydrogen Peroxide Crystacide®
    13.11.06 Hydrogen Peroxide 3% Solution (10vols) 
    13.11.06 Hydrogen Peroxide 6% Solution (20vols) 
    12.03.04 Hydrogen Peroxide mouthwash BP 
    09.04 Hydrolysed whey protein maltodextrin powder 
    • High-energy supplements: protein
    • Hydrolysed protein powder to be used in a modular feed.
    13.02.01 Hydromol Cream® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.02.01 Hydromol ointment ® 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.02.01.01 Hydromol® bath and shower 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.14.07 Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w in a non-aqueous gel 0.3% w/v
    13.02.01 Hydrous ointment BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    09.01.02 Hydroxocobalamin 1mg/ml injection
    08.01.05 Hydroxycarbamide 
  • For myeloproliferative disorders.
  • Supported by an ESCA (in development)

  • For use in sickle cell- see chapter 9
  • 09.01.03 Hydroxycarbamide 
  • For use in sickle cell
  • 13.05.03 Hydroxycarbamide 
    10.01.03 Hydroxychloroquine 
    10.01.03 Hydroxychloroquine 
    • Please note: ESCA is not required - Common practice
    13.05.03 Hydroxychloroquine 
    03.04.01 Hydroxyzine 
  • Tablets
  • Syrup
  • 04.02.03 Hyoscine 
    01.02 Hyoscine Butylbromide Buscopan® Tablet 10mg, Injection 20mg/ml
    04.06 Hyoscine Hydrobromide 
    04.06 Hyoscine Hydrobromide  £££
    15.01.03 Hyoscine Hydrobromide  For hyoscine patch, See chapter 4.6
    03.07 Hypertonic sodium chloride 7% Resp-Ease®
  • Accepted onto formulary December 2016- to replace Nebusal brand.
  • 11.08.01 Hypromellose 0.5% eye drops 
  • All other strengths are non formulary
  • 06.06.02 Ibandronic Acid 150mg 
    06.06.02 Ibandronic Acid 50mg 
  • For skeletal events in metastatic breast cancer.
  • Supported by an ESCA, see link below.
  • 06.06.02 Ibandronic Acid injection 
    08.01.05 Ibrutinib Imbruvica®
    • In line with NICE
    • Hospital only- NHSE commissioned
    07.01.01.01 Ibuprofen Pedea® injection
    10.01.01 Ibuprofen 
    10.01.01 Ibuprofen 
  • For patients with swallowing difficulties
  • Paediatric use
  • 10.03.02 Ibuprofen gel 
    03.04.03 Icatibant Firazyr® Hospital Only- NHSE commissioned
    13.14.04 Ichthammol 1% w/w and zinc oxide 15% w/w in YSP 
    A5.08.09 Ichthopaste  Zinc and Ichthammol bandage.

    Type of wound product is suitable for
    Venous leg ulcers Chronic eczema Dermatitis

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Daily up to weekly dependant on skin and wound management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in any cases of sensitivity or allergy to ingredients

    Rationale for inclusion in formulary
    For treatment of dermatitis and chronic eczema when
    venous insufficiency is present.
    08.01.02 Idarubicin Hydrochloride Capsules
    08.01.05 Idelalisib Zydelig®
  • NHS England is responsible commissioner for its use in chronic lymphocytic leukaemia(as per NICE TA 359)
  • 02.05.01 Iloprost nebules Vantavis® NHS England commissioned
    08.01.05 Imatinib Glivec® in line with NICE
    05.01.02.02 Imipenem with cilastatin Primaxin®
    04.03.01 Imipramine 
  • Tablets
  • 13.08.01 Imiquimod 3.75%  Zyclara®
  • £££
  • For field changes >25cm2
  • 13.07 Imiquimod 5% Aldara®
    13.08.01 Imiquimod 5%  Aldara®
    14.04 Inactivated Influenza Vaccine (Split Virion) 
    A5.03.02 Inadine ®  Non-adherent dressing impregnated with povidone iodine (10%)

    Type of wound product is suitable for
    Mild local infection where there is low exudate levels, ischaemic wounds, dry, gangrenous digits with the aim to desiccate and auto-amputate.
    Dry-manage fixator sites
    Minor burns or skin trauma with local infection

    Duration dressing remains on wound before changing
    1-3 days depending on uptake of iodine from dressing

    Frequency of dressing change
    1-3 days depending on uptake of iodine from dressing
    Look at colour change of dressing (orange initially to white when all used)

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Iodine allergy or sensitivity
    Thyroid disorders
    Renal impairment
    Not suitable for children, pregnant or lactating women

    Rationale for inclusion in formulary
    Topical antimicrobial
    Non-adherent/pain free use
    No damage to granular or epithelial cells
    Easy application and removal
    Drying properties
    Efficacy against bacteria, fungi and viruses
    Cost effective.
    02.02.01 Indapamide  Use 2.5mg tablets only
    13.10.05 Indermil®  Hospital only
    20 Indigo carmine 
    • For use by endoscopy only
    06.04.01.01 Indivina® tablets 
    07.01.01.01 Indometacin Indocid PDA®
    10.01.01 Indometacin 
  • For gout and resistant cases
  • 10.01.01 Indometacin 
  • Special product (100ml)
  • For gout and resistant cases
  • 14.04 Infanrix-IPV® 
    09.04 Infatrini® 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • 1 kcal infant feed for faltering growth
    • Varying volume size available to support nutritional requirements of the patients.
    • Single use only in acute setting – risk of increased waste. Once open must be used within 24 hours.
    • Failure to thrive, disease-related malnutrition and malabsorption, in child from birth up to body-weight 8 kg. Up to 18 months.
    09.04 Infatrini® Peptisorb 
    • Infant and child: Hydrolysate formula
    • Whey hydrolysate. Use in infants (birth – 18 mths) who are unable to tolerate Infatrini (eg gut intolerance) and also require a higher calorie feed for faltering growth. Use as tube or oral feed
    • Disease-related malnutrition, intractable malabsorption, proven inflammatory bowel disease, short bowel syndrome, bowel fistula, and intolerance to whole protein feeds
    01.05.03 Infliximab Remicade® Infusion
    For specialist use only in line with NICE guidance below
    Commissioned in paediatrics by NHSE
    10.01.03 Infliximab 
    • Hospital only
    • Biosimilar brands available:
      • Flixabi®
      • Inflectra®
      • Remsima®
      • Zessly®
    13.05.03 Infliximab 
  • For treatment of adults with psoriasis- use in line with NICE TA134
  • 14.04 Influenza vaccine  
  • As per Green Book, Health Service circular, National Flu campaign
  • 13.08.01 Ingenol mebutate Picato®
  • £
  • 08.02.03 Inotuzumab ozogamicin Besponsa ®

    In line with NICE

    Hospital only- NHSE commissioned

    09.09 Instant Carobel® 

     

    • Used as a feed thickener for infants with GORD and in children with swallowing issues who require thickened fluids
    • Used in dysphagic patients or those requiring thickened feeds
    • For thickening feeds in the treatment of vomiting
    06.01.01.01 Insulin Actrapid®
    06.01.01.01 Insulin Humulin® S
    06.01.01.01 Insulin Insuman® Rapid
    06.01.01.01 Insulin Aspart  NovoRapid®
    06.01.01.01 Insulin Aspart Fiasp®
    • For use in pregnant women with either gestational diabetes or pre-existing diabetes, after other insulins have been tried and failed to reach post-prandial glucose targets
    • As per Effective Shared Care Agreement (ESCA)
    06.01.01.02 Insulin degludec 100 units/mL Tresiba®
    • Specialist use only
    • For the treatment of patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission

     

    06.01.01.02 Insulin degludec 100 units/mL Tresiba®
    • To avoid the use of an insulin pump in patients with Type 1 diabetes who have nocturnal/severe hypoglycaemia as defined in NICE TA 151 OR recurrent DKA despite good compliance with current insulin regime
    • Specialist initiation
    • Supported by a RICaD, see link below.
    06.01.01.02 Insulin detemir Levemir®
    06.01.01.02 Insulin glargine 100 units/mL Lantus® £

  • Prescribe by brand
  • 06.01.01.02 Insulin glargine 100 units/mL biosimilar Abasaglar®
    • Prescribe by brand as recommended by MHRA.
    • Substitution and automatic switching from Lantus® to Abasaglar®CANNOT BE UNDERTAKEN.
    06.01.01.02 Insulin glargine 300 units/mL Toujeo® Prescribe by brand

  • Reconsidered and approved in April 2017
  • Specialist initiation.
  • Supported by RICaD

  • For patients who require more than 80 units of insulin glargine per day and who are troubled by nocturnal hypos. Transfer to Primary Care should not happen until specialists can demonstrate reduction in nocturnal hypos (e.g. after 3-4 months).
  • 06.01.01.02 Insulin Glargine biosimilar Semglee®
    • First line glargine for new patients initiated on insulin glargine 100 units/mL.
    • Prescribe by brand
    06.01.01.01 Insulin Glulisine Apidra®
    06.01.01.01 Insulin Lispro 100 units/mL Humalog 100 units/mL ®
    08.02.04 Interferon Alfa 
  • Hospital only
  • In line with NICE
  • 08.02.04 Interferon Beta Avonex®
    08.02.04 Interferon Beta Rebif®
    08.02.04 Interferon Beta Betaferon®
    08.02.04 Interferon Beta Proleukin®
    08.02.04 Interferon beta Extavia®
    07.03.04 Intra-uterine Contraceptive Devices Mini TT ®380 Slimline
    07.03.04 Intra-uterine Contraceptive Devices Nova-T® 380
    07.03.04 Intra-uterine Contraceptive Devices T-Safe® CU 380 A QuickLoad
    07.03.02.03 Intra-uterine Progestogen Only System Mirena®
  • GP will not prescribe for supply. Only prescribe if fitting.
  • Effective for 5 years
  • 07.03.02.03 Intra-uterine Progestogen Only System Jaydess®
  • GP will not prescribe for supply. Only prescribe if fitting.
  • Effective for 3 years
  • 06.02.02 Iodine and Iodide 
    • Potassium iodide tablets 65mg
    • Potassium iodate 85mg
    • Aqueous Iodine Oral solution
    • Also known as Lugol's Iodine
    A5.03.02 Iodoflex®  Cadexomer dressing containing iodine

    Type of wound product is suitable for
    Iodine paste in mesh form for chronic infected, sloughy wounds with moderate exudate eg pressure ulcers, leg ulcers, diabetic foot ulcers
    Can be used under compression bandaging

    MAX Duration dressing remains on wound before changing
    Up to 3 days

    Frequency of dressing change
    Daily for acute infection
    Up to 3 days for chronic wounds and infection, depending on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or sensitivity to iodine
    Precaution with large wounds due to absorption. Do not use more than 50g in a single application and no more than 150g in 7 days
    Dry necrotic wounds
    Thyroid disorders
    Renal impairment
    Not suitable for children, pregnant or lactating mothers
    Concurrent Lithium therapy

    Rationale for inclusion in formulary
    Anti microbial, broad spectrum, long acting/high absorption capacity
    Removes slough and debris to clean the wound bed
    Can be moulded to shape of the wound
    Alternative to honey products if allergy to bees
    A5.03.02 Iodosorb®  Cadexomer powder or ointment with iodine

    Type of wound product is suitable for
    Chronic exuding sloughy wounds eg leg ulcers, pressure ulcers, diabetic foot ulcers. Can be used under compression bandaging

    Duration dressing remains on wound before changing
    Up to 3 days

    Frequency of dressing change
    Daily for acute infection
    Up to 3 days for chronic infection

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to iodine products
    Dry necrotic tissue
    Not suitable for Children, pregnant or lactating mothers
    Thyroid disorders
    Renal impairment
    Needs at least twice weekly dressings for iodine to be effective

    Rationale for inclusion in formulary
    Antimicrobial, broad spectrum, long acting
    De-slough and cleans wound debris
    Non-adherant. Reduces trauma to wound and pain on dressing changes
    Easy application. Can fill cavities or awkward shaped wounds
    Alternative to honey based products if allergy to bees
    08.01.05 Ipilimumab Yervoy®
    03.01.02 Ipratropium 
  • Inhaler
  • Nebules
  • 02.05.05.02 Irbesartan tablets 
    09.01.01.01 Iron and Folic Acid Pregaday®
    09.01.01.02 Iron Isomaltoside Monofer® Hospital only
    09.01.01.02 Iron Sucrose Venofer® Hospital use only
    A5.12 Irripod  Sterile sodium chloride solution
    Type of wound product is suitable for
    Wound cleansing, for topical irrigation of the eye
    Duration dressing remains on wound before changing
    As required
    Frequency of dressing change
    As required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Single use
    External use only
    Rationale for inclusion in formulary
    Cost effective
    Cleansing of wounds
    09.04 Isolecuine50® 
    • To correct isoleucine deficiency in MSUD
    • The only pre-measured sachet of isoleucine that provides 50 mg/dose to correct isoleucine deficiency in MSUD. A pre-measured sachet is particularly important as most of our families with MSUD do not speak English as their first language so require pre-measured products. The dose and frequency of administration will be determined by the specialist dietitian.
    • Nutritional supplement for use in the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
    09.04 Isoleucine 1000 
    • Used as an inpatient only
    • Used at the time of diagnosis when on haemofiltration and an isoleucine supplement is necessary.
    05.01.09 Isoniazid 
    • RED status also applies to post renal transplant use ( for prophylaxis of TB in renal transplant patients)

    Isoniazid liquid 50mg in 5ml (unlicensed)

    06.01.01.02 Isophane Insulin Insulatard®
    06.01.01.02 Isophane Insulin Humulin® I
    06.01.01.02 Isophane Insulin Insuman® Basal
    02.07.01 Isoprenaline 
    02.06.01 Isosorbide Dinatrate 
    02.06.01 Isosorbide Mononitrate  Tablets
    02.06.01 Isosorbide Mononitrate MR  APC preferred brands:-
  • Chemydur XL tablets
  • Monomil XL tablets
  • 13.06.02 Isotretinoin 
  • Dermatologists only.
  • Contraindicated in Pregnancy.
  • 01.06.01 Ispaghula Husk  Granules
    - Adequate fluid intake is important to prevent obstruction (6 – 8 cups per day) and should not to be taken immediately before bed
    - Unsuitable for frail patients who are likely to drink less than daily required volume of fluid
    - Fluid thickens on standing so should be taken as soon as possible as after mixing
    - Time to effect is approximately 48 – 72 hours
    05.02 Itraconazole 
  • Capsules
  • SF liquid ££
  • 05.02 Itraconazole injection
    A5.02.02 IV 3000  Fixation dressing
    Type of wound product is suitable for
    For fixation of intravenous and subcutaneous catheter sites
    Duration dressing remains on wound before changing
    Up to 7 days
    Frequency of dressing change
    Up to 7 days or when wet/soiled
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to any of the product components
    Not for use on pressure ulcers, burns or donor sites
    Strips and documentation label are not to be used as suture replacements or primary wound closure methods
    Rationale for inclusion in formulary
    Fixation of intravenous and subcutaneous devices
    09.04 IVA Anamix® Infant 
    • Amino acid supplement without leucine for infants with isovaleric acidaemia
    • The only infant amino acid supplement without leucine, for infants with isovaleric acidaemia. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Nutritional supplement for the dietary management of proven isovaleric acidaemia or other proven disorders of leucine metabolism in children from birth to 3 years.
    02.06.03 Ivabradine tablets  Supported by a RICaD, see link below.
    03.07 Ivacaftor Kalydeco®

    In line with NICE

    05.05.06 Ivermectin 
  • Unlicensed, for crusted scabies, on specialist advice
  • 13.06.03 Ivermectin 1% cream Soolantra®
  • For topical treatment of inflammatory lesions of rosacea (papulopustular) in adults.
  • Alternative treatment option to metronidazole 0.75% cream/gel (see section 13.10.1.2) or azelaic acid 15% gel (see section 13.6.1)
  • 08.01.05 Ixazomib 

    In line with NICE

    Hospital only - NHSE commissioned.

    13.05.03 Ixekizumab Taltz®
    • In line with NICE
    A5.17 Jelonet®  Paraffin gauze dressing
    Type of wound product is suitable for
    As a primary layer for use with Flamazine® or Flammercerium®
    Duration dressing remains on wound before changing
    24 hours
    Frequency of dressing change
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Rationale for inclusion in formulary
    Cost effective primary layer
    09.04.02 Jevity® 
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Pt requires 1 kcal/mL vegetarian feed fish oil free (contains fibre)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except bowel fistula. Not suitable for child under 2 years
    09.04.02 Jevity®1.5 kcal  
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High energy vegetarian feed, fish oil free with fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Jevity®Plus  
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Pt requires 1.2kcal/mL, fibre, vegetarian feed fish oil free
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Jevity®Plus HP 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Pt requires 1.3kcal/mL high protein fibre vegetarian as fish oil free
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Jevity®Promote 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Pt requires 1 kcal/mL, fibre, vegetarian feed fish oil free
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.05.02.01 Joulies Phosphate Solution 
    • paediatrics
    A5.08.04 K- Lite  Lightweight knitted bandage

    Type of wound product is suitable for
    Designed for use on sprains/strains
    Can be used to prevent oedema, would require a wadding bandage to be applied
    beneath
    It is the second layer of a four layer compression bandage kit
    Where there is open skin, a primary dressing must be used

    Duration dressing remains on wound before changing
    Change in line with primary dressing

    Frequency of dressing change
    1-7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known allergy to any components
    Not suitable for application of pressure on its own and therefore should be used with other bandage components for the treatment of venous ulcers
    Caution over bony prominences where the bandage can cause pressure

    Rationale for inclusion in formulary
    Cost effective
    Essential for providing support to a limb and as part of a bandage compression therapy kit


    A5.08.07 K Soft®  An absorbent non –woven, sub bandage wadding.

    Type of wound product is suitable for
    Provides padding , shaping and protection of the limb prior to the application of
    compression bandage therapy.

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Daily up to weekly dependant on exudate and oedema management.

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Advised not to apply directly to skin as can cause irritation.

    Rationale for inclusion in formulary
    Essential for protecting a limb, padding and shaping
    Forms part of the compression bandage regime. Suitable for use with other formulary products.
    A5.03.04 Kendall AMD®  Absorbent, non adherent foam disc impregnated with PHMB. Double sided with a centre hole and radial slit
    Type of wound product is suitable for
    For use on pin sites, drains and tubes.
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not intended as a primary treatment for infection
    Do not use as a primary treatment for full thickness burns
    Not for patients sensitive to PHMB
    Rationale for inclusion in formulary
    Provides local exudate management and antimicrobial properties
    Absorbent
    Non adherent and semi occlusive
    For specialist use only
    A5.17 Kerlix ®  Gauze roll containing 0.2% Polyhexamethylene Biguanide (PHMB)
    Type of wound product is suitable for
    Colonised or infected wounds, with moderate to heavy exudate
    Duration dressing remains on wound before changing
    3 days
    Frequency of dressing change
    3 days
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to PHMB
    Do not use with Sodium hypochlorite ( Eusol) solutions, as this will deactivate PHM Do not apply gauze circumferentially as it has no stretch, and can become tight restricting circulation
    Rationale for inclusion in formulary
    Broad-spectrum antimicrobial agent that reduces bacterial colonization within the dressing and bacterial penetration through the dressing.
    Can be used in conjunction with Renasys Negative Pressure Therapy
    13.08.02 Keromask® 
  • Specialist recommendation
  • FP10 prescriptions should be endorsed "ACBS"
  • A5.01.02 KerraMaxCare  Superabsorbent dressing
    Type of wound product is suitable for
    Highly exuding wounds as a primary or secondary dressing. Can be used under compression therapy
    Stackable as no backing present to hold exudate

    Duration dressing remains on wound before changing
    1-7 days.
    Frequency of dressing change
    Dependent on level of exudate, usually daily or more frequently
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not cut or tear
    Rationale for inclusion in formulary
    Required for heavily exuding wounds. Hospital Use Only
    A5.16 Kerraped 
  • First consider client's own footwear options.

    A shoe to accommodate bandages and offload pressure from the front of the foot

    Type of wound product is suitable for
    Neuropathic foot ulcers or patients with bulky bandages who cannot wear their own footwear

    Duration product remains on wound before changing
    As required

    Frequency of use
    As required

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Ensure correct size is selected

    Rationale for inclusion in formulary
    Only footwear available for patients with neuropathic ulcers or bulky bandages
  • A5.16 KerraPro®  Silicone pads designed to redistribute pressure from bony prominences.
    Type of wound product is suitable for
    Prevention and treatment of category (Stage/Grade) 1 pressure ulcers
    Duration dressing remains on wound before changing
    As required. Check skin daily.
    Frequency of dressing change
    As required, check skin daily. Pads will last up to 3 months

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Must only be used as part of a pressure ulcer prevention programme
    Not to be used on a grade 2, 3 4, unstageable or deep tissue injury pressure ulcer unless directed by a clinical specialist
    Known sensitivity to silicone
    Do not use as a wound dressing
    Do not apply directly onto broken skin
    If skin macerates beneath, ensure the area is being checked and washed daily and consider utilising a cotton stockinette to reduce humidity
    Rationale for inclusion in formulary
    Cost effective
    Available in a large range of shapes and sizes
    Accessible pressure ulcer prevention medical device
    Reusable on the same patient for up to 3 months by washing with soap and water and thoroughly drying
    09.04 KetoCal® 3:1 
    • Specialised formulas for specific clinical conditions
    • High fat, low carbohydrate, nutritionally complete formula for infants and children from birth to 6 yrs, or as a supplementary feed for children over 6 years and adults on a ketogenic diet. May also be used in cooking
    • Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children from birth to 6 years; as a nutritional supplement in children over 6 years.
    09.04 KetoCal® 4.1 
    • Specialised formulas for specific clinical conditions
    • High fat, low carbohydrate powdered formula for children on a ketogenic diet as oral or tube feed, or used in cooking or as a supplementary feed for adults on a ketogenic diet
    • Enteral feed or nutritional supplement as part of ketogenic diet in management of epilepsy resistant to drug therapy, in children over 1 year, only on the advice of secondary care physician with experience of ketogenic diet.
    09.04 KetoCal® 4:1 LQ 
    • Specialised formulas for specific clinical conditions
    • High fat, low carbohydrate nutritionally complete liquid for children over 1 year of age and adults on a ketogenic diet, suitable for oral or tube feeding
    • Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children 1–10 years; as a nutritional supplement in children over 10 years.
    13.10.02 Ketoconazole 2%  ££
    13.09 Ketoconazole 2% shampoo 

    Over the counter preparation suitable for self-care/purchase if appropriate

    11.08.02 Ketorolac Acular®
    09.04 KeyOmega® 
    • Long chain fatty acid supplementation in very low fat diets
    • Nutritional supplement for the dietary management of inborn errors of metabolism.
    09.04 Kindergen® 
    • Specialised formulas for specific clinical conditions
    • Used in infants and children with renal disease when low potassium and low phosphate feed is required, can be given orally or as a tube feed
    • Enteral feed or nutritional supplement for children with chronic renal failure receiving peritoneal rapid overnight dialysis.
    A5.02.03 kliniderm Foam Silicone  
  • November 2016: approved for use, replacing Mepilex®

    Polyurethane foam with adhesive silicone wound contact layer

    Type of wound product is suitable for
    Suitable for acute and chronic wounds including leg ulcers, pressure ulcers, superficial and partial thickness burns, donor sites, post operative wounds and skin abrasions. Suitable for low to moderately exuding wounds for patients with fragile skin
    Available in border and non border

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    1-7 days – dependant on exudate level

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity eg Silicone

    Rationale for inclusion in formulary
    Wound contact surface is coated with a layer of soft silicone which reduces trauma to delicate tissue. Range of shapes and sizes available.
  • 06.04.01.01 Kliofem® tablets 
    06.04.01.01 Kliovance® 
    • Lower dose
    A5.08.02 Knit -band®  Cellulose contour bandage used for retention of non adhesive dressing products

    Type of wound product is suitable for
    Retention bandage

    Duration dressing remains on wound before changing
    Change in line with dressing change

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Take care to apply joint below to joint above. Always use a primary dressing

    Rationale for inclusion in formulary
    Most cost effective choice.
    A5.08.06 Ko-Flex®  A water resistant vapour permeable cohesive bandage

    Type of wound product is suitable for
    Venous ulceration, oedema, Managing sprains and strains and following orthopaedic
    surgery
    Forms part of the K four bandage system

    Duration dressing remains on wound before changing
    1 to 7 days

    Frequency of dressing change
    Dependant on exudate levels if wound present or oedema management .

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not recommended on those patients with an ABPI lower than 0.8.
    Contains latex

    Rationale for inclusion in formulary
    Cohesive bandage that can be used alongside other formulary products
    Forms the 4th layer of a four layer compression bandage system
    A5.03.04 Kytocel®  Absorbent gelling fibre wound dressing

    Type of wound product is suitable for
    Moderate to heavily exuding chronic and acute wounds that are sloughy and clinically infected.
    Haemostatic properties for minor bleeds in superficial wounds
    Autolytic debridement properties

    Duration dressing remains on wound before changing
    1-3 days

    Frequency of dressing change
    1-3 days, dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to Shellfish (Chitin)
    Full thickness burns
    Heavily bleeding wounds
    Dry wounds

    Rationale for inclusion in formulary
    Cost effective
    Alternative to available antimicrobials
    Can be used on heavily exuding wounds
    02.04 Labetalol injection 
    02.04 Labetalol tablets  Restricted Item Specific indication- Pregnancy
    04.08.01 Lacosamide  
  • Tablets
  • Syrup

  • Supported by an ESCA, see link below.
  • 01.06.04 Lactulose  Solution
    05.03.01 Lamivudine Epivir®
    05.03.01 Lamivudine Zeffix®
    04.02.03 Lamotrigine 
    04.08.01 Lamotrigine 
  • Tablets
  • Dispersible tablets

    MHRA Advice
    Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
  • 08.03.04.03 Lanreotide Somatuline® LA Amber Traffic Light Palliative Care use only
    Red Traffic Light Oncology
    Red Traffic Light Acromegaly
    08.03.04.03 Lanreotide Somatuline Autogel® Amber Traffic Light  Palliative Care use only
    Red Traffic Light  Oncology
    Red Traffic Light  Acromegaly
    01.03.05 Lansoprazole  Capsules 15mg, 30mg
    - Capsules are more cost effective than tablets
    - Can be opened and beads swallowed without crushing, or can be mixed with food or drink
    01.03.05 Lansoprazole dispersible  Orodispersible tablets 15mg, 30mg
    Orodispersible tablets cost twice as much as capsules
    Restricted Second choice - for use in patients with swallowing difficulties or who are on enteral tube feeding.
    Also licensed to be given via a NG tube or oral syringe if diluted in 5-10 ml water
    09.05.02.02 Lanthanum 
    • Specialist Recommendation
    • No ESCA
    • Common Practice
    08.01.05 Lapatinib Tyverb®
    A5.10 LarvE  Free range: Biomonde Larvae 100/200 or BioBag
    Biosurgical treatment for the debridement and cleansing of wounds consisting of aseptically produced living larvae.
    The BioBag is presented in the five (5) configurations listed below. The larvae are Lucilia sericata contained in a sterile polyester net bag with a sterile PVA spacer cube, presented in a sterile transport container.
    BioBag 50 at least 50 larvae 25 x 40mm 1 8x8x10
    BioBag 100 at least 100 larvae 50 x 40mm 1 12x12x10
    BioBag 200 at least 200 larvae 60 x 50mm 1 25x10x10
    BioBag 300 at least 300 larvae 120 x 60mm 2 25x10x10
    BioBag 400 at least 400 larvae 100 x 100mm 2 25x10x10
    Free range larvae, larvae and 30 x 30 flat retention net plus kit pack, larvae and 40 x
    60cm boot retention net plus kit pack. Additional 100 or 200 larvae available.
    Type of wound product is suitable for
    The BioMonde Larval Debridement Therapy Products are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
    Duration dressing remains on wound before changing and frequency of dressing change
    An application of BioBag can be left in place for up to 4 days, dependent on the
    condition of the wound. If the wound is not sufficiently debrided after 4 days, the treatment can be repeated with a fresh application of BioBag. The treatment should be stopped as soon as the wound is sufficiently debrided or if no improvement is observed after 3 or more applications. The total number of treatment cycles will depend on the characteristics of the wound, the response of the patient to LDT and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles. If exudate production is excessive, the secondary dressing may be changed as required while leaving the BioBag undisturbed. Frequent removal of the outer dressing will also help to control the odour associated with the liquefied necrotic tissue
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Larvae should not be used in patients with known hypersensitivities to fly larvae, polyester, PVA (polyvinyl alcohol) or the components of the media on which the larvae are raised (including soya protein, yeast protein, potato starch and bovine protein) as this may result in dermatitis or more severe immunological reactions in susceptible individuals. If treatment is undertaken then these patients should be under strict medical supervision for the duration of the treatment with immediate access to care. Patients with life or limb-threatening, rapidly advancing infections should not be
    treated with as LDT may interfere with the close and frequent observation that these
    patients require.
    Should not be used as first line therapy of infected tendon and bone. These wounds
    should be treated surgically and/or with antibiotics before using LDT.
    Should not be used to treat wounds which are not directly exposed to the outside.
    Wounds should never be allowed to close over the larvae either intentionally or unintentionally.
    Should not be used on wounds with an inadequate blood supply as this ultimately reduces the ability of the wound to heal. LDT will enlarge the wound as necrotic tissue is debrided but the resulting clean wound is at risk from re-infection.
    Although some mild bleeding is common during LDT, larvae should not be used on wounds that have a tendency to bleed or wounds close to an exposed major blood vessel, especially if considered to be necrotic as this can lead to rupture of the blood vessels which could be life-threatening. If LDT is attempted, the patient must remain under strict medical supervision for the duration of the treatment.
    Should not be used on patients with an inborn or medication-induced coagulopathy or
    in patients being treated with anticoagulants. If these patients are treated with LDT, they should remain under strict medical supervision for the duration of the treatment. Should never be used in sterile body cavities.
    Should be used with caution on wounds over adjacent exposed organs or leading to a body cavity, and only under close medical supervision for the duration of the treatment. Data are not available concerning the antibiotic / antiseptic activity of maggots and therefore any infected wound should receive standard antibiotic care.
    Rationale for inclusion in formulary
    Only available larval therapy on prescription.
    Rapid debridement of chronic wounds
    Can be utilised in the community
    11.06 Latanoprost 0.005% with Timolol 0.5% 
  • Specialist Ophthalmologist Recommendation
  • 11.06 Latanoprost eye drops 
  • Specialist Ophthalmologist Recommendation
  • 1st Line
  • 11.06 Latanoprost PF Eye Drops Monopost
  • Specialist Ophthalmologist Recommendation
  • 1st Line PF option
  • 05.03.03.02 Ledipasvir- sofosbuvir Harvoni® In line with NICE
    10.01.03 Leflunomide  Supported by ESCA, see link below.
    08.02.04 Lenalidomide 
  • In line with NICE
  • 09.01.06 Lenograstim 
  • Hospital only
  • 08.01.05 Lenvatinib Kisplyx ®

    In line with NICE

    08.03.04.01 Letrozole 
    06.07.02 Leuprorelin 
  • For endometrosis or breast cancer
  • Specialist initiation
  • 08.03.04.02 Leuprorelin Acetate Prostap® SR
    08.03.04.02 Leuprorelin Acetate Prostap® 3
    05.05.02 Levamisole 
  • Unlicensed
  • 04.08.01 Levetiracetam Desitrend®
  • Paediatrician initiation.
  • For patients up to and including 16 years of age unable to swallow tablets and in whom the liquid formulation is not appropriate or tolerated.

    MHRA Advice
    It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
  • 04.08.01 Levetiracetam 
  • Tablets
  • SF oral solution
  • Coated granules in sachets (see Desitrend®)

    MHRA Advice
    It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
  • 05.01.12 Levofloxacin tablets
  • For multi resistant organisms, on advice of specialist
  • 05.01.12 Levofloxacin infusion
    11.03.01 Levofloxacin Oftaquix
  • Amber £££ 2nd line
  • Use SDU if using 1or 2 hourly or if significant OSD/toxicity.
  • 04.06 Levomepromazine 
  • palliative care only
  • 04.02.01 Levomepromazine injection 
    04.02.01 Levomepromazine tablets 
  • Supported by ESCA, see link below.
  • 07.03.05 Levonogrestrel Levonelle® 1500
    07.03.02.01 Levonorgestrel 30mcg Norgeston®
    06.02.01 Levothyroxine 
    15.02 Lidocaine laryngojet®
  • Hospital only

  • Dental use under review
  • 12.03.01 Lidocaine 10% mouth spray 
  • Hospital only
  • 15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
    15.02 Lidocaine 4% cream  LMX®
  • Paediatrics only
  • 15.02 Lidocaine 5% ointment 
    04.07.03 Lidocaine 5% patch Versatis®

    Approved only in patients who have been treated in line with NICE CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia)

     

    02.03.02 Lidocaine hydrochloride  
    15.02 Lidocaine injection 
    15.02 Lidocaine with Adrenaline Lignospan®
    15.02 Lidocaine with Adrenaline Xylocaine®
    15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®
    A5.11 LimbO Waterproof protector  Waterproof protector, non slip latex free with a flexible seal at the opening
    Type of wound product is suitable for
    Used to keep arm, PICC, leg and foot dressings dry, can be fully submerged in water
    Rationale for inclusion in formulary
    Multiple sizing for legs and arms
    01.06.07 Linaclotide Constella▼®
    • For moderate to severe IBS-Constipation.
    • For patients who have not responded adequately to or cannot tolerate all other suitable treatment options BUT BEFORE other agents with higher costs.
    06.01.02.03 Linagliptin Trajenta® In line with NICE
    05.01.07 Linezolid oral formulations
  • On advice from microbiologist for MRSA
  • 05.01.07 Linezolid infusion
    06.02.01 Liothyronine 
  • Tablets
  • Injection
  • 20 Lipiodol 
    • For andoscopy use only
    09.04 Lipistart® 
    • Specialised formulas: Infant and child: MCT-enhanced formula
    • Essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT but require normal proportions of carbohydrate e.g. CPT1 and CPT2 deficiency. High carbohydrate formulas are unnecessary.
    • Also essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT but require normal proportions of carbohydrate e.g. CPT1 deficiency (i.e. high carbohydrate formulas may be unnecessary). There should always be 2 powdered high MCT formulae in the formulary in case of supply issues. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Dietary management of fat malabsorption, long-chain fatty acid oxidation disorders, and other disorders requiring a high MCT, low LCT formula.
    13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 

    Over the counter preparation suitable for self-care/purchase if appropriate

    A5.13 Liquid paraffin / white soft paraffin 50:50  Emollient ointment containing liquid paraffin and white soft paraffin
    To assist the skin in retaining moisture
    Type of wound product is suitable for
    For use on all dry skin conditions including eczema and psoriasis
    Frequency of use
    Daily or more frequently if required
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy or hypersensitivity to any of the ingredients
    Rationale for inclusion in formulary
    Treatment of dry skin conditions. Dermatology approved
    09.04 Liquigen® 
    • High-energy supplements: fat
    • Used as a source of MCT when required for children and adults with LCT intolerance and on a low LCT diet and for adults and children on a ketogenic diet - ££
    • Also this is used as a milk replacement and as part of module tube feeds for patients with long chain fatty acid disorders such as LCHADD and VLCADD who require ≥10% fat calories from long chain fat and a diet supplemented with MCT. It is essential to provide essential energy on fat restricted diets if MCT is tolerated by the patient. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease, liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in epilepsy, and in type 1 lipoproteinaemia. Not suitable for child under 1 year
    06.01.02.03 Liraglutide Victoza®
  • For the treatment of type 2 diabetes ONLY.
  • In line with NICE
  • 04.04 Lisdexamfetamine Elvanse®

    Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Traffic Light Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG

    Amber Traffic Light Supported with an ESCA- Solihull CCG
      

    02.05.05.01 Lisinopril tablets 
    04.02.03 Lithium Carbonate M/R tablets Priadel®
  • Supported by an ESCA, see link below.

  • APC preferred brand is Priadel
  • 04.02.03 Lithium Citrate liquid 
  • Supported by an ESCA, see link below.

  • APC preferred brand Priadel
  • A5.03.01 L-Mesitran ®  A hydro active gel dressing containing medical grade honey available without or with an adhesive film border. L- Mesitran has anti bacterial properties and can debride and reduce malodour.

    Type of wound product is suitable for
    Burns, chronic wounds, necrotic/sloughy wounds, surgical wounds, diabetic ulcers with caution, donor sites, fungating wounds.

    Max Duration dressing remains on wound before changing
    3-7 days

    Frequency of dressing change
    3- 7 days, dependent on exudate level

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to dressing and any of its components use with caution in patients with bee venom allergy
    Not suitable for full thickness burns/deep narrow cavities
    Caution must be exercised when applying to diabetic patients. Blood glucose levels must be monitored.

    Rationale for inclusion in formulary
    Desloughing, Antimicrobial, Deodorising
    09.04 Locasol ® 
    • Specialised formulas: Infant and child: Low calcium formula
    • Use in children with high blood calcium levels eg Noonan’s syndrome
    • Conditions of calcium intolerance requiring restriction of calcium and vitamin D intake
    04.03.01 Lofepramine 
  • Tablets
  • Suspension
  • 04.10.03 Lofexidine BritLofex®
    08.01.01 Lomustine capsules
    01.04.02 Loperamide 
    • Capsule 2mg, Syrup 1mg/5ml
      Capsules are more cost effective than tablets
    • Loperamide melts (orodispersible) tablets are reserved for high output stoma patients only
    • Not to be used if C.diff is suspected
      Caution in patients with a history of recent or repeated antibiotic use as increased risk of C.diff infection in this group
    09.04 Lophlex® 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important we have a choice of more than 1 product for this age group as compliance is reported to be poor and the potential outcome of poor compliance is poor executive functioning. The 2 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.
    05.03.01 Lopinavir and Ritonavir Kaletra®
    09.04 Loprofin SnoPro 
    • Specialised formulas for specific clinical conditions
    • Low protein, low potassium, low Phosphate milk substitute , used as a milk replacement in children with renal disease and IMD
    • Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.
    09.04 Loprofin® PKU Drink 
    • Low protein milk for children and adults with phenylketonuria and other disorders of protein metabolism
    • Low energy protein milk for children and adults with phenylketonuria and other disorders of protein metabolism who are overweight
    • Nutritional supplement for the dietary management of phenylketonuria in children over 1 year and adults.
    09.04 Loprofin® Sno-Pro 
    • Specialised formulas for specific clinical conditions
    • Low protein, low potassium, low Phosphate milk substitute , used as a milk
      replacement in children with renal disease and IMD
    • Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.
    03.04.01 Loratadine 

    OTC preparation suitable for self-care/purchase if appropriate

    04.01.02 Lorazepam 
    04.01.02 Lorazepam 

    Oct 2018: supply issues with injection

    09.04 Lorenzo’s oil 
    • For dietary treatment of adrenoleukodystrophy. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    02.05.05.02 Losartan tablets 
    11.04.01 Loteprednol Etabonate 0.5% Lotemax®
    09.04 Low fat 1+ module 
    • Specialised formulas: Infant and child: MCT-enhanced formula
    • Children and adults with a fatty acid disorder
    • Also fat free preparation. Used by patients with long chain fatty acid oxidation disorders who cannot tolerate MCT and require a very low-fat diet. Suitable for children and adults with a fatty acid disorder. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    03.01.05 Low range peak flow meter 
    06.04.01.01 Lubion® Injection 
    • Fertility use only
    03.15 Lumacaftor-ivacaftor Orkambi®

    In line with NICE

    08.03.04.03 Lutetium (177Lu) oxodotreotide 

    In line with NICE

    Hospital only - NHSE commissioned

    05.01.03 Lymecycline 
    13.06.02 Lymecycline 
  • Topical treatments should be used first line.
  • Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.

    Please refer to Antimicrobial guidelines
  • A5.09.02 Lymphoedema garments  Based on assessment
    01.06.04 Macrogol Laxido® Oral powder
    Prescribe as Laxido
    01.06.05 Macrogols Klean-Prep® Oral powder
    01.06.05 Macrogols Moviprep® Oral powder sachet
    09.05.01.03 Magnaspartate ® sachets 
    09.05.01.03 Magnesium citrate tablets 
    09.05.01.03 Magnesium Glycerophosphate oral  
    09.05.01.03 Magnesium Sulphate 
  • Hospital only
  • 13.10.05 Magnesium Sulphate Paste BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    01.01.01 Magnesium Trisilicate Mixture BP  Suspension
    High sodium content
    Use with caution in renal impairment
    A5.11 Magnide  Application aid for closed toe stockings/ compression garments
    13.10.04 Malathion 

    Over the counter preparation suitable for self-care/purchase if appropriate

    02.02.05 Mannitol infusion 
    03.07 Mannitol inhalation Bronchitol ® Hospital only
    05.03.01 Maraviroc 
    09.04 Maxijul® Super Soluble 
    • High-energy supplements: carbohydrate
    • High calorie modular powder, to be added to other food, drink and feeds e.g. faltering growth, to increase carbohydrate content.
    • Also used as an additional energy supplement when IMD patients require a modified, low protein or low-fat feed or are on a glucose polymer based energy supplement and require other Nutricia products such as Monogen or Nutrini fibre, so it can be delivered using the same home delivery service so less burdensome for families. It is also used as a core ingredient for glucose based emergency feeds. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.
    09.04 MCT Procal® 
    • Protein, fat, and carbohydrate
    • Used in children and adults on a ketogenic diet as an energy source for use with long chain fatty acid disorders and in metabolic disorders.
    • Used in liver/hepatobiliary disease/conditions
    • Essential for use with log chain fatty acid disorders such as LCHADD, VLCADD, CACT. It provides a pre-measured source of MCT energy at breakfast, midday and evening to ensure patients do not become energy depleted when performing usual daytime activities. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Dietary management of disorders of long-chain fatty acid oxidation, fat malabsorption, and other disorders requiring a low LCT, high MCT supplement.
    • Not suitable for child under 1 year.
    14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 
    05.05.01 Mebendazole 
    01.02 Mebeverine Hydrochloride  Tablet 135mg
    Prescribe standard release tablets only; modified release (MR) preparations are non-formulary
    06.07.04 Mecasermin Increlex®
  • NHSE commissioned.
  • A5.15 MediHoney barrier cream  Barrier cream containing active Medihoney.
    Helps to reduce inflammation

    Type of wound product is suitable for
    Treatment of incontinence related lesions
    Treats blistered skin
    Prevention and treatment of maceration and excoriation
    Treats candidiasis and intertrigo

    Frequency of use
    At each episode of hygiene

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Patch test before use

    Rationale for inclusion in formulary
    Suitable for neonates and children
    Treats fungal infections as well as incontinence associated lesions
    Reduces inflammation
    Can be applied to broken skin
    09.04 Medium-chain Triglyceride (MCT) Oil 
    • High-energy supplements: fat
    • Used as a source of energy for children and adults requiring a low LCT/ High MCT diet
    • Also this is used as a MCT cooking oil to improve diet palatability in patients with long chain fatty acid disorders such as LCHADD and VLCADD who require ≥10% fat calories from long chain fat. It is used to make MCT margarine, add to toast or to cook potatoes and other vegetables. It is essential to provide essential energy on fat restricted diets if MCT is tolerated by the patient. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Nutritional supplement for steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease and liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in management of epilepsy, type 1 hyperlipoproteinaemia
    06.04.01.02 Medroxyprogesterone Acetate 
  • Climanor®
  • Provera®
  • 07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®
    07.03.02.02 Medroxyprogesterone acetate Sayana Press®
  • Suitable for self-injection in patients who have had appropriate training
  • 08.03.02 Medroxyprogesterone Acetate 
    10.01.01 Mefenamic Acid 
  • For dysmenorrhoea
  • A5.07.03 Mefix  Permeable, aperture non woven, synthetic adhesive tape
    For securing dressings.

    Frequency of dressing change
    Determined by wound type and dressing change

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed

    Rationale for inclusion in formulary
    Available on drug tariff. Different availability of sizes in comparison to Clinipore for
    difficult to dress areas. Some stretch and flexibility to improve conformity and adhesion. Can be used to secure dressings rather than bandages.
    05.04.01 Mefloquine Lariam®
  • Private prescription in Primary Care
  • 08.03.02 Megestrol Acetate 
    04.01.01 Melatonin 
    04.01.01 Melatonin  Circadin ®
    08.01.01 Melphalan Tablets
    04.11 Memantine 
  • Tablets

    The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
  • 09.06.06 Menadiol Sodium Phosphate 
    14.04 Meningococcal A, C, W135, and Y conjugate vaccine 
    14.04 Meningococcal group B Vaccine Bexsero®
    14.04 Meningococcal group C conjugate vaccine 
    13.03 Menthol in Aqueous cream 
    • Dermacool-££

    Over the counter preparation suitable for self-care/purchase if appropriate

    05.04.04 Mepacrine Hydrochloride 
    13.15 Mepacrine Hydrochloride  
  • For Discoid lupus erythematosus (DLE)
  • A5.04.02 Mepiform  Silicone sheet for scar treatment

    Type of wound product is suitable for
    Not for use on open wounds- to be applied on healed scar only.
    This is not a dressing but a scar treatment

    Duration dressing remains on wound before changing
    23 hours

    Frequency of dressing change
    Daily

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur.

    Rationale for inclusion in formulary
    Scar therapy
    Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function.
    Cost effective.
    A5.02.03 Mepitel   Soft polymer non-adherent dressing without pad

    Type of wound product is suitable for
    Primary wound contact layer, non adherent, traumatic and chronic wounds
    Requires secondary dressing

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    Up to 7 days

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Heavily bleeding wounds
    Any sensitivity to silicone

    Rationale for inclusion in formulary
    Non-adherent primary wound contact layer to protect skin tears, fragile skin, primary contact layer for use under topical negative pressure


    03.14 Mepolizumab (Nucala®) 

    In line with NHSE

    A5.01.02 Mepore  Type of wound product is suitable for
    Post operative closed surgical wounds or simple wounds with up to light amounts of exudate.
    Can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds.

    Duration dressing remains on wound before changing
    Up to 7 days

    Frequency of dressing change
    1-7 days. If daily change is required - review product choice

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity

    Rationale for inclusion in formulary
    Sutured surgical wounds for protection. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds.
    04.07.02 Meptazinol Meptid®
    09.08.01 Mercaptamine Cystagon®
    • Secondary care use only
    01.05.03 Mercaptopurine  Tablet 50mg
    Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults – unlicensed but in line with national guidelines

    For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below.
    08.01.03 Mercaptopurine Tablets
    09.04 Meritene energis 
    • Prescribed for liver patients, at request of UHB liver/dietetic team only
    • Liver/hepatobiliary and pancreatic conditions.
    • Hospital supply only.
    03.13 Meropenem  Hospital only
    05.01.02.02 Meropenem 
    01.05.01 Mesalazine  Mezavant® XL

    For initiation by Consultant Gastroenterologists only, for patients non-compliant with other oral mesalazine preparations.

    01.05.01 Mesalazine tablets, MR tablets, granules, suppositories, enemas

    Octasa is preferred brand of choice UHB NHS FT
     
    Other brands – Pentasa, Asacol, Asacol MR, Salofalk (granules/enema), Mezavant XL.

    01.05.01 Mesalazine Salofalk®

    Granules and enemas

    01.05.01 Mesalazine Octasa®

    Octasa is currently the preferred brand - name changed from Mesren® in Nov/Dec 2012

    Both strengths are more cost effective compared to Asacol®.
    Mesalazine should be prescribed by brand.

    08.01 Mesna 
    07.03.01 Mestranol 50mcg/norethisterone 1mg Norinyl-1®
  • Monophasic standard strength (21-day preparation)
  • For patients who need high oestrogen
  • For patients on anticonvulsant treatment
  • A5.15 Metanium ointment  Barrier preparation
    Type of wound product is suitable for
    For relief of the symptoms of nappy rash
    Frequency of use
    Spread the ointment thinly so the skin texture can be clearly seen through it. Repeat at each nappy change.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used on adults in conjunction with containment products for incontinence
    due to the inclusion of light liquid and white paraffin in the ingredients, which will repel urine/faeces back onto the skin.
    Any allergy to the listed ingredients
    Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for treating nappy rash. However, as this product contains titanium salicylate, accidental ingestion or excessive topical application could lead to symptoms of salicylate poisoning.
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Metanium® 
    • specialist recommendation

    Over the counter preparation suitable for self-care/purchase if appropriate

    02.07.02 Metaraminol 
    06.01.02.02 Metformin 
    06.01.02.02 Metformin M/R  
  • Only for patients intolerant of slowly titrated standard release metformin
  • 06.01.02.02 Metformin oral solution SF 
  • For patients with swallowing difficulties £££
  • 04.07.02 Methadone  For use in opioid dependence, see section 4.10.3
    03.09.01 Methadone Hydrochloride Methadone® Linctus Palliative care only
    04.10.03 Methadone injection 
    04.10.03 Methadone oral solution 
    04.10.03 Methadone tablets 
    05.01.13 Methenamine Hippurate 
    01.05.03 Methotrexate 
  • Tablets 2.5mg (2.5mg tablets preferred as per NPSA alert)
    Cytotoxic- do not crush and disperse in water
  • Parenteral injection:Metoject®PEN is the APC preferred brand.
  • Unlicensed liquid may be available if required

    For use in active Crohn's disease (unlicensed indication supported by APC) as per effective shared care agreement (ESCA). See link below.
  • 04.13 Methotrexate 

    Specialist use only for neurological conditions

    13.05.03 Methotrexate 
  • supported by ESCA (to be developed)
  • 08.01.03 Methotrexate 2.5mg Tablets
    10.01.03 Methotrexate 2.5mg tablets  Supported by ESCA, see link below.

    Should only be prescribed as 2.5mg tablets (Local agreement following National Patient Safety Agency alert)
    03.12 Methotrexate tablets 
    • Supported by ESCA , see link below.
    • 2.5mg tablets 
    09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®
  • NHSE commissioned for use in renal dialysis
  • Primary Care commissioned for use in cancer- in line with NICE TA323
  • 13.05.02 Methoxypsoralen 
    13.08.01 Methyl-5-Aminolevulinate Metvix®
    02.05.02 Methyldopa tablets 
    04.04 Methylphenidate Modified-Release  Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Traffic Light Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG

    Amber Traffic Light Supported with an ESCA- Solihull CCG
    04.04 Methylphenidate tablets  Please note that commissioning discussion is underway. However the present status is as follows:-
    Red Traffic Light Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG

    Amber Traffic Light Supported with an ESCA- Solihull CCG
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
    06.03.02 Methylprednisolone acetate injection Depo-Medrone®
    10.01.02.02 Methylprednisolone Acetate/ Lidocaine Depo-Medrone® with Lidocaine
    06.03.02 Methylprednisolone sodium succinate injection Solu-Medrone ®
    06.03.02 Methylprednisolone tablets  In line with NICE
    02.05.01 Metirosine 
    01.02 Metoclopramide  Not recommended for patients aged 20 years and below due to risk of dystonic reactions
    See MHRA guidance below for restrictions on use in younger patients
    04.06 Metoclopramide 
  • tablets
  • SF solution- £££-for patients with swallowing difficulties only
  • 04.06 Metoclopramide injection  Green Traffic Light  in palliative care


    Red Traffic Light  other indications

    10.01.03 Metoject®  Metoject is APC preferred brand in view of additional patient safety characteristics.
    Supported by ESCA, see link below.
    Check cytotoxic disposal arrangements locally
    02.02.01 Metolazone  Specialist recommendation (unlicensed)
    Use with local trust approval.
    Available from "special-order" manufacturers or specialist-importing companies.
    02.04 Metoprolol tartrate 
  • Tablets
  • Modified Release tablets
  • 02.04 Metoprolol tartrate injection 
    05.01.11 Metronidazole 
  • Tablets
  • Suspension ££
  • 05.01.11 Metronidazole infusion
    05.01.11 Metronidazole Suppositories
    07.02.02 Metronidazole Zidoval®
  • 0.75% vaginal gel
  • 13.10.01.02 Metronidazole 0.75% Anabact®
  • for wounds
  • 13.10.01.02 Metronidazole 0.75% Rozex®
  • For acne rosacea
  • 13.10.01.02 Metronidazole 0.75% Acea®
  • For acne rosacea
  • A5.16 metronidazole 0.75% gel Anabact® Type of wound product is suitable for
    Malodourous fungating wounds. Requires a secondary dressing

    Duration preparation remains on wound before changing
    Apply 1-2 times daily following cleansing
    Frequency of use
    1-2 times daily for a maximum of 8 weeks.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Avoid exposure to strong sunlight or UV light
    Not to be used on a patient with known sensitivity to any components
    Avoid contact with eyes
    Not for use of any other aetiology of wound as odour control.
    Rationale for inclusion in formulary
    Odour control for fungating tumours
    06.07.03 Metyrapone Metopirone®
    02.03.02 Mexiletine hydrochloride   unlicensedunlicensed
    Use with local trust approval.
    Available from "special-order" manufacturers or specialist importing companies.
    05.02.04 Micafungin 
    07.02.02 Miconazole Gyno-Daktarin®
    • 2% intravaginal cream
    • 1.2g ovule (vaginal capsule) - discontinued by manufacturer 2018
    11.03.02 Miconazole 1% eye drops 
    13.10.02 Miconazole 2% 
    12.03.02 Miconazole oral gel 
    04.08.02 Midazolam buccal liquid Buccolam®
    02.07.02 Midodrine Bramox®
  • Transfer to Primary Care supported by an ESCA.
  • Click here for ESCA
  • 08.01.05 Midostaurin  Rydapt®

    In line with NICE

    NHSE commissioned

    08.02.04 Mifamurtide 
  • In line with NICE
  • 07.01.02 Mifepristone Mifegyne®
    05.01.03 Minocycline 
    07.04.02 Mirabegron Betmiga®
  • for patients not tolerating/ with contra-indications to antimuscarinics
  • in line with NICE
  • 04.03.04 Mirtazapine 
  • tablets
  • orodispersible tablets ££
  • 01.03.04 Misoprostol Cytotec® Tablet 200mg
    For specialist initiation only
    07.01.01 Misoprostol 
  • oral
  • PV
  • 11.99.99.99 Mitomycin C  
  • Hospital only
  • 08.01.05 Mitotane Lysodren®
    09.04 MMA/PA amp 5 
    • Methionine, threonine and valine free, and low isoleucine aa supplement
    • The only pre-measured sachet of methionine, threonine, valine free and low isoleucine amino acid supplement for patients with propionic acidaemia and methyl malonic acidaemia reliant on tube feeding. A pre-measured sachet is particularly important as most of our families with MSUD do not speak English as their first language so require pre-measured products.
    09.04 MMA/PA Anamix® Infant 
    • Amino acid supplement without methionine, threonine, valine and isoleucine for infants with propionic acidaemia and methyl malonic acidaemia
    • The only infant amino acid supplement without methionine, threonine, valine and isoleucine for patients with propionic acidaemia and methyl malonic acidaemia
    • Nutritional supplement for the dietary management of proven methylmalonic acidaemia or propionic acidaemia in children from birth to 3 years.
    04.03.02 Moclobemide tablets 
    04.04 Modafinil 
    • for narcolepsy
    09.04 Modjul® Flavour System 
    • Flavouring preparations
    • For flavouring unpalatable flavouring amino acid supplements or feeds in inborn errors of metabolism
    • Essential for flavouring different unflavoured amino acid supplements in inborn errors of metabolism- particularly for non PKU conditions. They offer alternative flavours to Vitaflo pacs. This is important as amino acid formulations are unpalatable and unacceptable particularly for patients with late diagnosed conditions. They cannot be purchased from a supermarket.
    • For use with unflavoured SHS products based on peptides or amino acids; not suitable for child under 6 months.
    09.04 Modulen IBD® 
    • Specialised formulas for specific clinical conditions
    • For treatment of Crohn’s Disease
    • Crohn's disease active phase, and in remission if malnourished
    13.04 Mometasone Furoate 0.1% 

    Potency: potent

    Cream
    Ointment
    Scalp lotion ££

    12.02.01 Mometasone Furoate nasal spray 
    09.04 Monogen® 
    • Specialised formulas: Infant and child: MCT-enhanced formula
    • Used in infants who require high MCT feed eg following chylothorax and in inborn errors of metabolism where MCT is required
    • Also essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT and high intake of carbohydrate e.g. LCHADD and trifunctional protein deficiency (i.e. lower carbohydrate formulas are inappropriate). There should always be 2 powdered high MCT formulae in the formulary in case of supply issues. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Long-chain acyl-CoA dehydrogenase deficiency (LCAD), carnitine palmitoyl transferase deficiency (CPTD), primary and secondary lipoprotein lipase deficiency, chylothorax, and lymphangiectasia
    03.03.02 Montelukast 
    04.07.02 Morphine 
  • suppositories
  • 100mg/100ml PCA
  • 5mg/5ml intrathecal injection
  • pre-filled syringes
  • 04.07.02 Morphine 
  • tablets
  • M/R tablets
  • M/R capsules
  • Oral solution
  • injection
  • 05.01.12 Moxifloxacin 
    02.05.02 Moxonidine tablets 
    09.04 MSUD Amino 5 
    • Amino acid supplement without leucine, valine and isoleucine for infants/children with MSUD
    • The only pre-measured amino acid supplement, without leucine, valine, isoleucine for infants/children with maple syrup urine disease used for emergency regimens and tube feeds. This is particularly important as most of our families with MSUD do not speak English as their first language.
    09.04 MSUD Anamix® Infant 
    • Amino acid supplement without leucine, valine and isoleucine for infants with MSUD
    • The only infant amino acid supplement without leucine, valine, isoleucine for maple syrup urine disease.
    • Nutritional supplement for the dietary management of proven maple syrup urine disease in children from birth to 3 years.
    09.04 MSUD Anamix® Junior 
    • Amino acid supplement without leucine, valine and isoleucine for children with MSUD
    • The only infant amino acid supplement without leucine, valine, isoleucine for maple syrup urine disease.
    • Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
    09.04 MSUD Anamix® Junior LQ 
    • Amino acid supplement without leucine, valine and isoleucine for children with MSUD. Can be used in adults
    • An unthickened powdered amino acid supplement without leucine, valine, isoleucine for children aged 1 to 10y with maple syrup urine disease which can be given as a drink.
    • Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
    09.04 MSUD cooler® 10 
    • Amino acid supplement without leucine, valine and isoleucine for children and adults with MSUD
    • An oral liquid amino acid supplement without leucine, valine, isoleucine formulated for children aged 3 to 6 years with maple syrup urine disease. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements
    09.04 MSUD cooler® 15 
    • Amino acid supplement without leucine, valine and isoleucine for teenagers with MSUD
    • An oral liquid amino acid supplement without leucine, valine, isoleucine for children aged 7 to 12 years with maple syrup urine disease. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
    09.04 MSUD cooler® 20 
    • Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
    • One of 2 oral flavoured liquid amino acid supplements without leucine, valine, isoleucine for teenagers over 12 years of age and adults. This age group need the larger pouches to meet their non-leucine protein requirements. It is important we have a choice of more than 1 product as compliance is poor. It is essential that patients are offered choice of more than 1 protein substitute.
    09.04 MSUD express® 15 
    • Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
    • The only powdered amino acid supplement without leucine, valine, isoleucine for 7 to 12-year olds with maple syrup urine disease. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
    • Nutritional supplement for the dietary management of maple syrup urine disease in children over 8 years and adults.
    09.04 MSUD express® 20 
    • Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
    • The only powdered amino acid supplement without leucine, valine, isoleucine for teenagers and adults with maple syrup urine disease that will met their higher BCAA-free amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-methionine protein requirements
    • Nutritional supplement for the dietary management of maple syrup urine disease in children over 8 years and adults.
    09.04 MSUD Gel® 
    • Amino acid supplement without leucine, valine and isoleucine for children with MSUD
    • The only weaning (thickened) amino acid supplement without leucine, valine, isoleucine for infants/young children with maple syrup urine disease.
    • Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
    09.04 MSUD Lophlex® LQ 20 
    • Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
    • One of 2 oral flavoured amino acid supplement without leucine, valine, isoleucine for teenagers over 12 years of age and adults with maple syrup urine disease. They need the larger pouches to meet their BCAA-free amino acid requirements. It is important we have a choice of more than 1 product for this age group as compliance is poor. It is essential that patients are offered choice of more than 1 protein substitute.
    • Nutritional supplement for the dietary management of maple syrup urine disease in children over 3 years.
    09.06.07 Multivitamin preparations Abidec®
  • contains arachis ( peanut) oil
  • 09.06.07 Multivitamin preparations Dalivit®
    09.06.07 Multivitamin Supplement Paravit-CF®

    Capsule, liquid.

    • Specialist initiation or recommendation for GP initiation by specialist in cystic fibrosis.
    13.10.01.01 Mupirocin 2%  Please refer to Primary care antimicrobial guidelines
    12.02.03 Mupirocin 2% in White Soft Paraffin Bactroban Nasal®
  • Long term disruption to supply until second or third quarter of 2018.
  • 09.06.07 Mutivitamins 
    04.13 Mycophenolate 

    Specialist use only for neurological conditions

    13.05.03 Mycophenolate 
  • supported by ESCA (to be developed)
  • 08.02.01 Mycophenolate Mofetil 

    Red Traffic Light  Renal Post transplant- new patients
    Amber Traffic Light  Renal Post transplant-patients initiated pre April 2013

    • For use in connective tissue diseases (Rheumatology)Click here
    08.02.01 Mycophenolate Sodium Myfortic®
    10.02.01 Mycophenolate mofetil 
    • For use in connective tissue diseases
    • For specialist initiation and dose stabilisation.
    • Supported by an ESCA.

    20 N acetyl cysteine 
    • For use in endoscopy
    A5.01.01 N/A Ultra  Type of wound product is suitable for
    For flat granulating and epithelising wound for non to heavy exudate levels where
    adherence may occur. To be used as a primary dressing with a secondary for absorption.

    Duration dressing remains on wound before changing
    7 days maximum

    Frequency of dressing change
    1-7 days, depending on levels of exudate

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity eg silicone
    Use with care if wound is bleeding heavily

    Rationale for inclusion in formulary
    To be used to reduce adherence to wound bed
    03.07 N-Acetylcysteine nebulised  Hospital only
    02.06.04 Naftidrofuryl Oxalate capsules 
    04.10.01 Nalmefene  Restricted to Specialist Substance Misuse Services only
  • Reach Out Recovery (CRI) in Birmingham. Single point of contact 24/7 Tel: 0121 227 5890 Link Reach Out Recovery website
  • Swanswell in Sandwell Tel: 0121 553 1333 Link to Swanswell website
  • SIAS in Solihull Tel:0121 301 3600 Link to SIAS website


    The Nalmefene for reducing alcohol consumption technology appraisal (TA325) recommends this drug as a possible treatment for people with alcohol dependence who:
    • are still drinking more than 7.5 units per day (for men) and more than 5 units per day (for women) 2 weeks after an initial assessment and
    • do not have physical withdrawal symptoms and
    • do not need to either stop drinking straight away or stop drinking completely
    The guidance also recommends that nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.
  • 01.06.06 Naloxegol Moventig ®
  • £££
  • For treating opioid-induced constipation- use in line with NICE.
  • 04.10.03 Naloxone 
  • Used to reverse opioid overdose.
  • 04.10.01 Naltrexone 
  • Useful as an adjunct in the treatment of alcohol dependence after a successful withdrawal.
  • 04.10.03 Naltrexone Nalorex®
    06.04.03 Nandrolone Deca-Durabolin®
  • Hospital only
  • 10.01.01 Naproxen 
  • NOT Enteric Coated tablets
  • 08.02.04 Natalizumab Tysabri®
  • In line with NICE
  • 09.04 Neocate® Junior 
    • Infant and child: Amino acid-based formula
    • Replacement for Neocate Active and Neocate Advance on the formulary.
    • Use in children over 12 mths who require amino acid based feed / have multiple food allergies.
    • Used as tube or oral feed, provides complete nutritional support
    • For the dietary management of proven whole protein allergy, short bowel syndrome, intractable malabsorption and other gastrointestinal disorders where an amino acid diet is recommended, for children from 1 year onwards
    • ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
    09.04 Neocate® LCP 
    • Infant and child: Amino acid-based formula
    • Use in infants ( birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed as unable to tolerate standard or peptide feed. Used as tube and oral feed.
    • Cows' milk allergy, multiple food protein intolerance, and conditions requiring an elemental diet
    • ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
    09.04 Neocate® Syneo 
    • Infant and child: Amino acid-based formula - ACBS Indications:Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
    • Contains Bifidobacterium breve M-16V to combat gut flora dysbiosis, shown by infants with allergies.
    • Use in infants ( birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed as unable to tolerate standard or peptide feed. Used as tube and oral feed.
    • Not suitable for premature infants or infants who maybe immunocompromised. Not for use in postpyloric tube feeding.
      Not recommended for infants with central venous catheter or SHORT BOWEL SYNDROME without full consideration of risks/benefits and monitoring by/on advice of a specialist.
    • Cows' milk allergy, multiple food protein intolerance, and conditions requiring an elemental diet
    11.04.02 Neodocromil 2% eye drps Rapitil®
    05.01.04 Neomycin Sulphate 
    10.02.01 Neostigmine injection  Hospital only
    10.02.01 Neostigmine tablets 
    09.04 Nepro® 
    • Specialised formulas for specific clinical conditions
    • Used for renal in and outpatients – adults only Useful on occasion due to reduced Vitamin A content – adults only
    • Enteral feed or nutritional supplement in patients with chronic renal failure who are on haemodialysis or CAPD, or with cirrhosis, or other conditions requiring a high energy, low fluid, low electrolyte diet.Not suitable for child under 1 year; use with caution in child 1–5 years.
    05.03.01 Nevirapine 
    02.06.03 Nicorandil tablets  Specialist initiation
    09.06.02 Nicotinamide 
    13.06.01 Nicotinamide 4% gel 
  • 3rd Line
  • 04.10.02 Nicotine replacement therapy 
    02.06.02 Nifedipine  Standard release capsules
    and
    Modified Release preparations: Brand rationalisation- APC preferred brands:-
  • Adipine MR tablets
  • Adipine XL tablets
  • Coracten SR capsules
  • Coracten XL capsules
  • 07.01.03 Nifedipine 
    08.01.05 Nilotinib Tasigna® In line with NICE
    02.06.02 Nimodipine Nimotop®
    03.11 Nintedanib Ofev®Restricted Item
  • Hospital only- NHSE commissioned
  • In line with NICE and available from day 91 following publication of TA.
  • 08.01.05 Nintedanib Vargatef ®
    • Hospital only- NHSE commissioned
    • In line with NICE and available from day 91 following publication of TA.
    08.01.05 Niraparib 
    08.01.05 Niraparib 
    05.01.07 Nitazoxanide 

    Hospital use only

    05.01.13 Nitrofurantoin 
  • Tablets
  • M/R Capsules
  • 08.02.03 Nivolumab Opdivo® In line with NICE
    Hospital only- NHSE Commissioned
    02.07.02 Noradrenaline / Norepinephrine 
    06.04.01.02 Norethisterone 
    • Green Generic tablets 
    • Green Utovlan®
    • Amber Noriday® - if used in HRT - Specialist initiation
    07.03.02.01 Norethisterone Noriday®
  • Alternative to discontinued Micronor®
  • 08.03.02 Norethisterone 
    05.01.12 Norfloxacin 
    14.05 Normal immunoglobulin 

    List of brands available for use:

    • Intratect (5%)
    • Gammaplex
    • Subgam
    • Hizentra
    • Privigen
    • Gamunex (10%)
    • Iqymune
    • Gammanorm
    • Octagam 10%
    • Panzyga
    • Cuvitru
    • Subcuvia
    14.05.01 Normal immunoglobulin for Intramuscular use 
    14.05.01 Normal immunoglobulin for Subcutaneous use 
    06.04.01.01 Novofem® tablets 
    09.09 Nutilis® Clear 
    • Recommended by SALTs for patients with dysphagia requiring thickened fluids
    • For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
    • Gum based products are generally preferred as they thicken to a more stable end point (unlike starch based products, they do not continue thickening over time) and provide a smoother texture, which improves acceptability and palatability for patients.
    09.04 Nutilis® Complete Stage 1 
    • Used for dysphagia pts only
    • Where first line pre-thickened product – Slo Milkshake – is not suitable
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    09.04 Nutramigen® 1 with LGG 
    • Specialised formulas: Infant and child: Hydrolysate formula
    • Casein hydrolysate. Use in infants (from birth – 6 mths) who have cow’s milk protein intolerance / allergy. Tube or oral feed.
    • Nutramigen has all the fat as LCT and CHO as glucose polymer and is more suitable for CMPI
    • If patient has a cow’s milk protein intolerance / allergy GP may initiate Nutramigen® Lipil 1 and refer to dietetics – in line NICE CG 116
    • Disaccharide and/or whole protein intolerance where additional medium chain triglycerides are not included.
    09.04 Nutramigen® 2 with LGG 
    • Specialised formulas: Infant and child: Hydrolysate formula
    • Casein hydrolysate. Use in infants from 6 mths who have cow’s milk protein intolerance/ allergy and soya intolerance/allergy. Tube or oral feed. If patient has a cow’s milk protein intolerance / allergy GP may initiate Nutramigen® Lipil 2 and refer to dietetics – in line NICE CG 116
    • Established disaccharide and/or whole protein intolerance (where additional chain triglycerides are not indicated) Not suitable for child under 6 months.
    09.04 Nutramigen® Puramino 
    • Infant and child: Amino acid-based formula
    • Use in infants (birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed. Unlike other products contains 33% MCT fat so useful in children requiring amino acid feed who also have fat malabsorption. Used as tube and oral feed.
    • For use in the management of severe protein intolerance, multiple food intolerance and other gastro-intestinal disorders where an amino acid based diet is specifically indicated for infants and young children.
    • ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
    09.04 Nutricrem® 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Lactose free diet
    • Low energy per serving as a semi-solid supplement where low volume is required only.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–6 years.
    09.04 Nutrini® 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • 1 kcal feed without fibre, used in children 8-20kg. Up to 6 years.
    • Also essential low protein tube feed for children with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) aged 2 to 10y due to its low protein and amino profile as a source of natural protein. It is used when IMD children cannot tolerate fibre. To change to an alternative enteral feed with children with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04 Nutrini® Energy 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml tube feed for children over 8kg
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg

     

    09.04 Nutrini® Energy Multi Fibre 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml tube feed for children over 8kg with added fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04.02 Nutrini® Low Energy Multi Fibre 

    Child under 12 years

    • Low energy with fibre. 8-20kg
    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula except bowel fistula, in child 1–6 years, body-weight 8–20 kg
    09.04 Nutrini® Multi Fibre 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • 1 kcal feed with fibre, used in children 8-20kg. Up to 6 years.
    • Also, used in low protein tube feeds for children with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) aged 2 to 10y due to its protein and amino acid profile. It provides a source of natural protein. It is used in IMD children who can tolerate fibre. To change to an alternative enteral feed with children with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04 Nutrini® Peptisorb 

     

    • Hydrolysate formula
    • 1.0kcal/ml polymeric feed used 8 -20kg where hydrolysed protein is required
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg Follow trust guidance on use of acidic tube feeds.

     

    09.04 Nutrini® Peptisorb Energy 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml hydrolysed protein feed used in children over 8kg where whole protein is not tolerated. Additional information re pH of the product?
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
    09.04.02 Nutriprem® 1 

    Child under 12 years

    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • Low birth - weight formula
    • For premature infant up to 2kg
    09.04.02 Nutriprem® 2 

    Child under 12 years

    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • Post discharge formula for pre-term infants <34 weeks to aid growth
    • Catch-up growth in pre-term infants (less than 35 weeks at birth) and small for gestational-age infants up to 6 months corrected age.
    09.04.02 Nutriprem® 2 

    Child under 12 years

    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • Post discharge formula for pre-term infants for immunocompromised infants
    • Catch-up growth in pre-term infants (less than 35 weeks at birth) and small for gestational-age infants up to 6 months corrected age.
    09.04.02 Nutrison Peptisorb®  
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Peptide-based formula
    • Pts with malabsorption
    • Short bowel syndrome, intractable malabsoprtion, proven inflammatory bowel disease, bowel fistula.
    • Follow Trust guidance on use of acidic tube feeds
    09.04.02 Nutrison® 

    First line

    • 1 kcal/mL and less than 5 g protein/100 mL
    • Standard 1 kcal/mL, No fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison® Soya 
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Soya protein formula
    • Dietary restriction or intolerance to standard feeds
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison® Soya Multi Fibre 
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Soya protein formula
    • Dietary restriction or intolerance to standard feeds requiring fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®1000 Complete Multi Fibre 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • 1000 kcal/L, nutritionally complete in 1 litre, low volume
    • Disease related malnutrition in patients with low energy and/or low fluid
      requirements
    09.04.02 Nutrison®1200 Complete Multi Fibre 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • 1200 kcal/L, nutritionally complete in 1 litre, low volume
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®800 Complete Multi Fibre 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • 800 kcal/L, nutritionally complete in 1 litre, low volume
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except bowel fistula
    • Not suitable for child under 6 years; not recommended for child 6-12 years
    09.04.02 Nutrison®Concentrated 
    • More than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High calorie (2000 kcal/L), low volume, low potassium
    • First line in CF and renal patients
    09.04.02 Nutrison®Energy  
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High energy feed
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®Energy Multi Fibre 
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High energy feed with fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®MCT 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Pts with chyle leaks following upper GI surgery
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®Multi Fibre 

    First line

    • 1 kcal/mL and less than 5 g protein/100 mL
    • Standard 1 kcal/mL, With fibre
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Nutrison®Protein Plus 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Lower calorie, high protein feed. Fibre free
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula

     

    09.04.02 Nutrison®Protein Plus Multi Fibre 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Lower calorie, high protein feed. Added fibre
    05.02 Nystatin oral suspension
  • Not Sugar free
  • 12.03.02 Nystatin 100,000units/ml suspension 
  • Do not Prescribe as Sugar Free (SF)
  • A5.05.02 Oakmed Option Wound Manager  Wound drainage system consisting of a hydrocolloid adhesive wafer and a drainable drainage bag

    Type of wound product is suitable for
    Complex abdominal wounds, moderate to large fistula’s, orthopaedic wounds or
    fungating wounds with high levels of exudate, that are unmanaged with conventional dressings.

    Max Duration dressing remains on wound before changing
    Empty drainage bag as required. If no port for drainage, change as required.

    Frequency of dressing change
    As long as adhesive remains intact whilst being mindful of skin integrity

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product component sensitivity to hydrocolloid (Gelatine and Pectin)
    Low to moderate exuding wounds
    Do not use if a conventional dressing can manage the exudate levels

    Rationale for inclusion in formulary
    Various size selection with drainage ports and windows
    For highly exuding wounds that conventional dressings cannot manage the exudate levels


    01.09.01 Obeticholic acid  Ocaliva®
  • In line with NICE
  • 08.02.03 Obinutuzumab Gazyvaro® In line with NICE
    Hospital only- NHS England commissioned
    08.02.03 Ocrelizumab 

    In line with NICE

    11.08.02 Ocriplasmin Jetrea®
    12.02.03 Octenidine hydrochloride Octenisan® md Nasal gel
  • Classed as a medical device
  • Listed in drug tariff- 6ml tube
  • Added to formulary as alternative to Bactroban® nasal ointment in view of supply issues.
  • 13.01 Octenisan®  
  • For MRSA skin decolonisation , if chlorhexidine sensitivity is a problem
  • 13.11.02 Octenisan® antimicrobial wash lotion 
  • MRSA skin decolonisation, if chlorhexidine sensitivity is a problem
  • 01.09 Octreotide  Injection
    For specialist gastroenterologist initiation for intestinal secretions
    08.03.04.03 Octreotide Sandostatin® Amber Traffic Light Palliative Care use only
    Red Traffic Light Oncology
    Red Traffic Light Acromegaly
    08.03.04.03 Octreotide Sandostatin Lar® Amber Traffic Light Palliative Care use only
    Red Traffic Light Oncology
    Red Traffic Light Acromegaly
    06.04.01.01 Oestrogel® 
    07.02.01 Oestrogens, Topical Gynest®
    07.02.01 Oestrogens, Topical Estring®
    07.02.01 Oestrogens, Topical Ovestin®
    07.02.01 Oestrogens, Topical Vagifem®
    08.02.03 Ofatumumab Arzerra®
  • NHS England is responsible commissioner for its use in untreated chronic lymphocytic leukaemia (as per NICE TA 344)
  • 05.01.12 Ofloxacin 

    Green Traffic Light Only when used in line with Antimicrobial guidelines

    Amber Traffic Light When used outside Antimicrobial guidelines, on Specialist recommendation.

    11.03.01 Ofloxacin Eye drops 0.3% 
    01.07.03 Oily phenol injection BP 
    04.02.01 Olanzapine (oral) 
  • tablets
  • orodispersible tablets

  • Supported by ESCA, see link below.
  • 04.02.02 Olanzapine Embonate ZypAdhera® The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    08.01.05 Olaparib Lynparza ®
    • Hospital only- NHSE commissioned
    • In line with NICE and available from day 91 following publication of TA.
    12.01.03 Olive Oil Ear Drops 
    11.04.02 Olopatadine Opatanol®
  • 2nd line £££
  • 03.14 Omalizumab Xolair®
    • For specialist use only in line with NICE guidance below
    • NHS England is the responsible commissioner for use in Asthma
    • Clinical Commissioning Groups are the responsible commissioners for use in urticaria
    13.05.03 Omalizumab 
  • In line with NICE
  • 05.03.03.02 Ombitasvir-paritaprevir-ritonavir Viekirax® In line with NICE
    01.03.05 Omeprazole  Capsules 10mg, 20mg
    Capsules are more cost effective than tablets
    Most brands of capsules can be opened and beads swallowed without crushing, or can be mixed with food or drink
    01.03.05 Omeprazole dispersible Losec MUPS Orodispersible tablets 10mg, 20mg
    ££- Orodispersible tablets are very significantly more expensive than capsules.
    For use in swallowing difficulties or via nasogastric tubes when beads in the capsule are too large and lansoprazole orodispersible are not acceptable (e.g. children with fine bore NG tubes).
    01.03.05 Omeprazole IV  IV Infusion 40mg vial- Hospital use only
    A5.07.05 Omnistrip®  Adhesive wound closure strip
    Type of wound product is suitable for
    For atraumatic closure of minor wounds or surgical incisions
    Require a secondary dressing
    Duration dressing remains on wound before changing
    As necessary, up to 14 days
    Frequency of dressing change
    As necessary
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None
    Rationale for inclusion in formulary
    Cost effective
    Essential for closure of minor injuries
    04.06 Ondansetron 
  • tablets
  • melt tablets
  • suppositories
  • injection
  • SF syrup - swallowing difficulties only

    Amber Traffic Light  hyperemesis in pregnancy (off label)

    Amber Traffic Light  palliative care (off label)

    Red Traffic Light  Chemotherapy
  • 04.09.01 Opicapone Ongentys®
  • Second-line therapy to entacapone, in patients who fail to respond to, or are intolerant of, entacapone, in situations where apomorphine therapy has been considered.

  • Supported by an ESCA, see link below
  • 12.03.01 Orabase Protective Paste 
    12.03.01 Orahesive Powder 
    01.04 Oral Rehydration Salts   Powder
    Follow Scriptswitch advice for most cost-effective prescribing option
    09.02.01.02 Oral Rehydration Salts 
    04.05.01 Orlistat capsules 

    Orlistat 60mg capsules - Over the counter preparation suitable for self-care/purchase if appropriate

    05.03.04 Oseltamivir Tamiflu®

     

    PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza

    08.01.05 Osimertinib  In line with NICE
    09.04.02 Osmolite® 
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Pt requires 1 kcal/mL, vegetarian feed fish oil free (Nil fibre)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Osmolite®1.5 kcal 
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • High energy vegetarian fish oil free (Nil fibre)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.04.02 Osmolite®Plus 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Alternative standard feed, vegetarian fish oil free (1200 kcal/L) (Nil fibre)
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    09.05.02.02 Osvaren® 
  • Specialist Recommendation
  • 08.01.05 Oxaliplatin 
    06.04.03 Oxandrolone Tablets 2.5 mg 
    04.01.02 Oxazepam 
    04.08.01 Oxcarbazepine 
  • Tablets
  • Oral suspension

    MHRA Advice
    Care should be taken when switching between oral formulations.The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
  • 07.04.02 Oxybutynin immediate release tablets
  • 2.5mg and 5mg tablets only

  • 3mg tablets are non-formulary
  • 07.04.02 Oxybutynin Modified release tablets
    07.04.02 Oxybutynin Hydrochloride patch Kentera®
  • for patients who cannot tolerate oral agents
  • 13.12 Oxybutynin immediate release tablets 
  • For hyperhidrosis (off label use)
  • after trial of aluminium salts
  • 04.07.02 Oxycodone 
  • capsules
  • M/R tablets
  • SF solution

  • For patients who do not tolerate morphine
  • 04.07.02 Oxycodone injection 
    03.06 Oxygen  Green Traffic Light  Short term use in palliative care

    Amber Traffic Light  Long term use- requires specialist assessment


    05.01.03 Oxytetracycline 
    13.06.02 Oxytetracycline 
  • Topical treatments should be used first line.
  • Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.

    Please refer to Antimicrobial guidelines
  • 07.01.01 Oxytocin 
    08.01.05 Paclitaxel 
  • In line with NICE
  • 08.01.05 Paclitaxel - Albumin Bound Formulation Abraxane®
  • In line with NICE
  • 09.04 Paediasure®  
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • 1 kcal per ml low carbohydrate sip feed for children
    • Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg
    09.04 Paediasure® Plus 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • Lower Carbohydrate , 1.5kcal/ml sip feed, used in children with CHO intolerance
    • Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg
    09.04 Paediasure® Plus Fibre 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • Lower Carbohydrate , 1.5kcal/ml sip feed, used in children with CHO intolerance with added fibre
    • Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg. Not suitable for use in child under 1 year.
    09.04 Paediasure® Peptide 
    • Child: 1 kcal/ml and less than 4g protein
    • Peptide based sip feed used in pts with gut failure
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–10 years, body-weight 8–30 kg
    09.04 Paediatric Seravit® 
    • Vitamin and Mineral supplements
    • Used in children and low weight adults on very restricted diets who are not meeting vitamin and mineral requirements and in enteral feed patients.
    • For use in infants - unflavoured vitamin and mineral supplement given to infants and young children on low protein or low-fat diets who require vitamin and mineral supplementation. There are no other powdered preparations available that meet the requirements of infants on very limited diets with inherited metabolic disorders of metabolism. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient
    • Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets
    09.06.07 Paediatric Seravit® 
    • Used in children and low weight adults on very restricted diets who are not meeting vitamin and mineral requirements and in enteral feed patients.
    • For use in infants - unflavoured vitamin and mineral supplement given to infants and young children on low protein or low-fat diets who require vitamin and mineral supplementation. There are no other powdered preparations available that meet the requirements of infants on very limited diets with inherited metabolic disorders of metabolism. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets
    08.01.05 Palbociclib Ibrance®
  • In line with NICE
  • Hospital only - NHSE commissioned
  • 04.02.02 Paliperidone Trevicta® The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    04.02.02 Paliperidone Xeplion® The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    05.03.05 Palivizumab Synagis®
    04.06 Palonosetron Aloxi®
    01.09.04 Pancreatin Pancrex® V Powder

    Counsel patient on need for adequate hydration

    01.09.04 Pancreatin Creon® products
    Counsel patient on need for adequate hydration

    08.01.05 Panitumumab Vectibix®
    08.01.05 Panobinostat Farydak®Restricted Item
  • Hospital only- NHSE commissioned
  • In line with NICE and available from day 91 following publication of TA.
  • 04.07.01 Paracetamol 
    04.07.01 Paracetamol 
  • tablets
  • SF suspension
  • 500mg soluble tablets- high sodium content.Only for patients with swallowing difficulties.
  • 04.07.01 Paracetamol Perfalgan®
    04.07.01 Paracetamol and codeine Co-codamol ®15/500
  • £££
  • Limited evidence.
  • For elderly community who would not tolerate separate ingredients or to support a step down review.
  • 04.07.01 Paracetamol and codeine Co-codamol® 30/500
    • Use with caution in patients aged over 65
    • Contraindicated in children below the age of 12
    04.07.01 Paracetamol and codeine Co-codamol ®15/500
  • £££
  • Limited evidence.
  • High sodium content.
  • For elderly community who would not tolerate separate ingredients or to support a step down review.
  • 04.07.01 Paracetamol and codeine Co-codamol® 30/500
  • £££
  • High sodium content
  • Use in chronic pain only, and for patients with swallowing difficulties.
  • 04.08.02 Paraldehyde 
  • Rectal solution 50% in olive oil
  • 06.06.01 Parathyroid Hormone 
  • Injection
  • 05.04.05 Paromomycin  suspension
  • Unlicensed
  • 04.03.03 Paroxetine tablets 
    09.04.01 Pasta 

    Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 100g pasta = 10g protein.

    08.01.05 Pazopanib Votrient®
    14.04 Pediacel® 
    08.01.05 Pegaspargase Oncaspar®
  • Hospital only- NHSE Commissioned
  • In line with NICE and available from day 91 following publication of TA.
  • 09.01.06 Pegfilgrastim 
  • Hospital only.
  • 08.02.04 Peginterferon Alfa 
  • Hospital only
  • In line with NICE
  • 08.01.05 Pembrolizumab Keytruda®
  • NHS England is responsible commissioner in line with NICE (see links below)
  • 08.01.03 Pemetrexed Alimta®
    04.02.01 Penfluridol (Oral) 
    09.08.01 Penicillamine 
  • Wilson disease: Specialist Recommendation with ESCA (in development)
  • 10.01.03 Penicillamine  Supported by ESCA, see link below.
    11.03.01 Penicillin 500o units in 1 ml eye drops 
  • Unlicensed
  • Hospital use only- Ophthalmologists
  • 05.04.08 Pentamidine Isetionate Pantacarinat®
    01.02 Peppermint Oil  Capsule E/C 0.2ml
    01.02 Peppermint water  unlicensedunlicensed

    For specialist use only
    01.01.02 Peptac  Suspension
    09.04.02 Peptamen®  
    • 1 kcal/mL and less than 5 g protein/100 mL
    • Peptide-based formula
    • Where hydrolysate is required
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
    09.04 Peptamen® Junior 

     

    • Hydrolysate Formula
    • Ready to use, neutral pH, 1kcal/ml
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula, in child 1–10 years
    09.04 Peptamen® Junior 

     

    • Hydrolysate Formula
    • Powdered preparation only Used in children requiring hydrolysate, ability to concentrate or dilute to meet specific calorie density requirements
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula, in child 1–10 years
    09.04 Peptamen® Junior Advance 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml hydrolysed protein feed used in children over 8kg where whole protein is not tolerated. Increased MCT for use in liver failure.
    • Intractable malabsorption, short-bowel syndrome, bowel fistula, and proven inflammatory bowel disease in child 1–10 years
    09.04.02 Peptamen®AF 
  • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
  • Used in critical care settings
  • 09.04.02 Peptamen®HN 
    • Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Step down from Peptamen® AF
    • Intolerance to other feed
    • Hydrolysate 1300 kcal/L nutritionally complete in 1 litre
    • For patients with malabsorption where requirements (high protein/low volume) cannot be met with a standard 1Kcal/ml MCT peptide feed. Used in liver/hepatobiliary disease/conditions
    • Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula. Not suitable for child under 3 years
    04.08.01 Perampanel tablets 
  • Supported by an ESCA, see link below.

    MHRA Advice
    When prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability.

  • 02.06.03 Perhexiline tablets 
    04.02.01 Pericyazine (oral) 
    • £££
    • Supported by ESCA, see link below.
    02.05.05.01 Perindopril erbumine tablets 
    13.10.04 Permethrin 5% Lyclear® Dermal Cream

    Over the counter preparation suitable for self-care/purchase if appropriate

    04.02.01 Perphenazine (oral) 
    • £££
    • Supported by ESCA, see link below.
    08.01.05 Pertuzumab Perjeta® In line with NICE
    04.07.02 Pethidine injection 
    02.08.02 Phenindione tablets 
    04.08.01 Phenobarbital 
  • Tablets
  • Elixir

    MHRA Advice
    Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
  • 13.14.07 Phenol 2% w/w in compound zinc paste BP 
    02.05.04 Phenoxybenzamine Hydrochloride capsules  Check availibility
    05.01.01.01 Phenoxymethylpenicillin oral presentations
    02.07.02 Phenylephrine 
    11.05 Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride
    04.08.01 Phenytoin 
  • Capsules
  • Suspension

    MHRA Advice
    Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
  • 09.04 Phlexy-10® Exchange System 
    • Tablets maybe used in pregnancy, when suffering from morning sickness
    • Nutritional supplement for the dietary management of phenylketonuria.
    09.04 Phlexy-Vits® 
    • Vitamin and mineral supplement for teenagers and adults with phenylketonuria and other inborn errors of protein metabolism
    • The only suitable low volume (powder and tablets) comprehensive vitamin and mineral supplement for teenagers and adults that has been formulated for patients with phenylketonuria and other inborn errors of protein metabolism requiring very restrictive diets. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • For use as a vitamin and mineral component of restricted therapeutic diets in children over 11 years and adults with phenylketonuria and similar amino acid abnormalities.
    03.09.01 Pholcodine Linctus, BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    09.05.02.01 Phosphate supplements Phosphate-Sandoz®
    01.06.04 Phosphates (Rectal) Fletchers phosphate enema, fleet ready to use enema Enema
    09.06.06 Phytomenadione Konakion® MM
    09.06.06 Phytomenadione Konakion® MM Paediatric
    09.06.06 Phytomenadione 1mg  
    A5.06.01 PICO products  Disposable and portable system designed to kick start wound healing. Required
    components: One PICO device, 2 dressings per kit.
    Type of wound product is suitable for
    Acute, chronic, dehisced, partial thickness burns, flaps, grafts and traumatic wounds.
    Consider standard interactive dressings first.
    Duration dressing remains on wound before changing
    Twice a week dressing change, PICO device weekly change
    Frequency of dressing change
    Determined by exudate levels.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    It should not be used on:
    Confirmed and untreated osteomyelitis
    Malignancy in wound bed or wound margins
    Exposed blood vessels
    Organs
    Unexplored fistulae Necrotic wounds Anastomotic sites
    Emergency airway aspiration
    Pleural, mediastinal or chest tube drainage and surgical suction
    Rationale for inclusion in formulary
    These devices promote patient mobility at a cost effective price and is available on drug
    tariff which other comparable models are not.
    01.06.05 Picolax®  Oral powder
    11.06 Pilocarpine 1%,2% and 4% eye drops 
  • Specialist Ophthalmologist Recommendation
  • 12.03.05 pilocarpine Hydrochloride tablets Salagen®
  • Licensed for treatment of xerostomia following irradiation for head and neck cancer; dry mouth and dry eyes in Sjögren's syndrome.
  • Effective only in patients who have residual salivary gland function.
  • 11.06 Pilocarpine preservative free 
  • Hospital only
  • 13.05.03 Pimecrolimus  Elidel®
  • in line with NICE
  • 06.01.02.03 Pioglitazone 
    05.01.01.04 Piperacillin and Tazobactam 
    04.09.03 Piracetam 
  • Tablets
  • Oral solution
  • 04.02.03 Pirenzipine (unlicensed)  Hospital only
    03.11 Pirfenidone Esbriet®

    Hospital only - NHSE commissioned

    05.01.01.05 Pivmecillinam Hydrochloride 
    • In line with Antimicrobial Guidelines
    • Only on microbiology advice
    04.07.04.02 Pizotifen 
  • Tablets
  • Elixir
  • 09.04.01 Pizza bases 

    Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who do not tolerate very little natural protein. One regular pizza likely to provide 20g + protein.

    09.04 PKU Air 15 
    • A liquid amino acid which is lower in calories for children and adults with phenylketonuria
    09.04 PKU Air 20 
    • A supplement which is lower in calories for children and adults with phenylketonuria
    09.04 PKU Anamix first spoon 
    • A supplement without phenylalanine for children with phenylketonuria
    • One of 2 powdered weaning (thickened) amino acid supplement without phenylalanine for infants/young children with phenylketonuria. The consistency can be adjusted to suit the developmental age of the older baby/toddler. This is our preferable product because it has added long chain fatty acids.
    • Nutritional supplement for the dietary management of proven phenylketonuria in children from 6 months to 5 years.
    09.04 PKU Anamix® Infant 
    • A supplement without phenylalanine for infants with phenylketonuria
    • The only infant amino acid supplement without phenylalanine for infants with phenylketonuria
    • Nutritional supplement for the dietary management of proven phenylketonuria in children from birth to 3 years.
    09.04 PKU cooler 10® 
    • A supplement without phenylalanine for children and adults with phenylketonuria
    • An oral liquid amino acid supplement without phenylalanine formulated for children aged 3 to 6 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements. The 3 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of phenylketonuria in children over 3 years
    09.04 PKU cooler 15® 
    • A supplement without phenylalanine for children and adults with phenylketonuria
    • One of three oral liquid amino acid supplements without phenylalanine for children aged 7 to 12 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
    09.04 PKU cooler 20® 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • One of 3 liquid amino acid supplement without phenylalanine for teenagers and adults (>12 years of age) with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor and the potential outcome of poor compliance. The 3 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of phenylketonuria in children over 3 years.
    09.04 PKU express15® 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • The only powdered amino acid supplement without phenylalanine for 7 to 12-year olds with phenylketonuria. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
    • Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years.
    09.04 PKU express20® 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor. The 2 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years.
    09.04 PKU gel® 
    • A supplement without phenylalanine for children with phenylketonuria
    • One of 2 powdered weaning (thickened) amino acid supplement without phenylalanine for infants/young children with phenylketonuria. The consistency can be adjusted to suit the developmental age of the older baby/toddler. This was our product of choice 5 years ago. However, we have also older patients taking this protein substitute who refuse to change. Children with PKU are very neophobic about their protein substitutes and do not change easily. Without protein substitute it would cause low IQ and executive issues.
    • For use as part of the low-protein dietary management of phenylketonuria in children 1–10 years
    09.04 PKU Lophlex 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important we have a choice of more than 1 product for this age group as compliance is reported to be poor and the potential outcome of poor compliance is poor executive functioning. The 2 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.
    09.04 PKU Lophlex® LQ 10 
    • A supplement without phenylalanine for children and adults with phenylketonuria
    • One of three liquid amino acid supplement without phenylalanine formulated for children aged 3 to 6 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements. The 3 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women.
    09.04 PKU Lophlex® LQ 20 
    • A supplement without phenylalanine for teenagers and adults with phenylketonuria
    • One of 3 liquid amino acid supplements without phenylalanine for teenagers and adults (>12 years of age) with phenylketonuria that will met their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor. The 3 different products have a different degree of sweetness and range of flavours.
    • Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women.
    09.04 PKU Sphere 15 

    A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years

    09.04 PKU Sphere 20 

    A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adult struggling to take their amino acid product because of its taste. Suitable from aged 4 years

    09.04 PKU Start® 
    • For use in the dietary management of phenylketonuria.
    • Amino acid supplement. Without phenylalanine for infants with phenylketonuria.
    14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Synflorix®
    14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13®
    14.04 Pneumococcal polysaccharide vaccine (23-valent) Pneumovax ®
    13.07 Podophyllotoxin Condyline®
    13.07 Podophyllotoxin Warticon®
    13.07 Podophyllum 
    14.04 Poliomyelitis Vaccine Inactivated (Salk)  The polio vaccine is only given as part of combined products:
    ● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/
    Haemophilus influenzae type b (DTaP/IPV/Hib)
    ● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine (DTaP/
    IPV or dTaP/IPV)
    ● tetanus/diphtheria/inactivated polio vaccine (Td/IPV).
    09.04 Polycal® 
    • High-energy supplements: carbohydrate
    • Ready to use. Requires no specific instruction to prepare e.g. energy supplement/ used as pre and post bolus with patients with glycogen storage disease to prevent hypoglycaemia, also used in fatty acid oxidation disorders
    • There is no other liquid glucose supplement on ACBS prescription.
    • Also energy supplements/ used as pre-and post-bolus tube feeds with patients with glycogen storage disease to prevent hypoglycaemia. Also use as a quick access, liquid energy supplement in patients with fatty acid oxidation disorders. There is no other liquid glucose supplement on ACBS prescription. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.
    A5.07.01 Polyfield Nitrile Patient Pack  primary care and BCHC, other Trusts as per contract Sterile dressing pack
    Type of wound product is suitable for
    To be used on all wounds requiring aseptic dressing procedures
    Duration dressing remains on wound before changing
    Single use
    Frequency of dressing change
    Determined by wound type
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None listed
    Rationale for inclusion in formulary
    Available on drug tariff, cost effective and incorporates a measure guide which would
    be an additional cost with other packs
    A5.02.05 PolyMem  Foam dressing that contains a cleansing agent and glycerol

    Type of wound product is suitable for
    Low to moderately exuding wound including skin tears, and other traumatic wounds,
    superficial and partial thickness wounds, burns, donor and graft sites and radiotherapy induces reactions

    Duration dressing remains on wound before changing
    2-7 days

    Frequency of dressing change
    Up to 7 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Sensitivity to ingredients contained within the dressing
    Not for full thickness burns Not for ischaemic wounds Not for diabetic foot wounds
    Not in conjunction with solutions containing hypochlorite

    Rationale for inclusion in formulary
    Suitable for fragile and sensitive skin, Soft and comformable,
    Easy to redress awkward areas
    Wide range of sizes including digit shaped dressings
    14.04 Polysaccharide vaccine for injection Typhim Vi®, Typherix®
    14.04 Polysaccharide vaccine with hepatitis A vaccine 
    09.02.01.01 Polystyrene Sulphonate Resins 
    13.09 Polytar Plus® 
    • contains peanut oil

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.09 Polytar® 
    • contains peanut oil

    Over the counter preparation suitable for self-care/purchase if appropriate

    08.02.04 Pomalidomide Imnovid®
    • In line with NICE TA
    08.01.05 Ponatinib Iclusig® In line with NICE
    03.05.02 Poractant Alfa Curosurf® Hospital only
    05.02 Posaconazole 
    09.05.02.01 Potassium acid phosphate  
    09.02.01.01 Potassium Chloride efferevescent tablets Sando-K®
    09.02.01.01 Potassium Chloride MR tablets Slow-K®
    09.02.01.01 Potassium Chloride SF syrup Kay-Cee-L®
  • Specialist Recommendation
  • 07.04.03 Potassium Citrate 
    13.11.06 Potassium Permanganate tablets 
    13.11.04 Povidone-Iodine preparations 
    04.09.01 Pramipexole IR tablets 
    02.09 Prasugrel Efient®
    02.12 Pravastatin tablets 
    05.05.05 Praziquantel tablets
  • UNLICENSED, on specialist advice only
  • 01.05.02 Prednisolone  Tablets 5mg, EC 2.5mg, 5mg, Soluble 25mg
    Plain tablets are first line option.
    EC tablets are more expensive than plain tablets without any substantial evidence that they confer any GI benefits
    25mg tablets are more expensive per mg than 5mg tablets.
    Soluble tablets are significantly more expensive than normal tablets which can be crushed & dispersed (unlicensed).

    For short term use in acute exacerbation or 'flare-ups'of relevant conditions
    01.05.02 Prednisolone  Retention Enema (20mg/100ml single dose pack, Predsol®)
    Foam Enema ££- Predfoam® discontinued, generic replacement is very expensive
    Suppositories - (5mg, Predsol®)

    For short term use in acute exacerbation or 'flare-ups'of relevant conditions
    06.03.02 Prednisolone 
  • Plain tablets
  • 10.01.02.01 Prednisolone 
    10.01.02.01 Prednisolone  for use in children or patients with swallowing difficulties
    11.04.01 Prednisolone 0.5% eye drops  
  • Specialist Ophthalmologist Recommendation .
  • 11.04.01 Prednisolone 1% eye drops Pred Forte®
  • Specialist Ophthalmologist Recommendation.
  • For Anterior Uveitis in A&E-prednisolone acetate 1% as the drug of choice unless the patient has a preference for dexamethasone 0.1%
  • 11.04.01 Prednisolone preservative free eye drops 0.5% 
  • Specialist Ophthalmologist recommendation
  • Use in patients with severe Chronic Allergic Eye Disease who present to A&E with a flare up.
  • 03.12 Prednisolone tablets 
  • Plain tablets (not enteric coated)
  • 10.01.04 Prednisolone tablets 

    Second line gout treatment

    04.03.04 Pregabalin 
    • for generalised anxiety disorder
    • ££

    Schedule 3 Controlled Drug as of 01/04/2019

    04.07.03 Pregabalin 
    • 4th line after duloxetine
    • on advice of specialist if duloxetine is unsuitable
    • please be aware of the abuse potential associated with this class of agent
    • From 17th July 2017, clinicians can now return to normal practice when prescribing pregabalin and no longer need to specify a brand name when prescribing for neuropathic pain.

    Schedule 3 Controlled Drug as of 01/04/2019

    04.08.01 Pregabalin 
    • Capsules

      MHRA Advice
      For patients being treated for epilepsy, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors.

    Schedule 3 Controlled Drug as of 01/04/2019

    06.04.01.01 Premarin® 
    06.04.01.01 Premique® low dose 
    05.04.01 Primaquine 
  • Private prescription in Primary Care
  • 04.08.01 Primidone 
  • Tablets

    MHRA Advice
    Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
  • 04.09.03 Primidone 
    10.01.04 Probenecid 
    05.01.01.01 Procaine Penicillin G Injection  
    09.04 Pro-Cal® Shot 
    • Protein, fat, and carbohydrate
    • Used where energy and protein is required in small volume – only on recommendation of dietitian
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement.
    • Not suitable for child under 3 years.
    09.04 Pro-Cal® Singles 
    • Protein, fat, and carbohydrate
    • Used where energy and protein is required in small volume, where measured doses are required – only on recommendation of dietitian
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.
    08.01.05 Procarbazine 
    04.06 Prochlorperazine 
  • tablets
  • buccal tablets
  • syrup
  • injection
  • 04.02.03 Procyclidine 
    04.09.02 Procyclidine 
  • Tablets
  • SF syrup
  • 04.09.02 Procyclidine 
  • Injection
  • 13.10.05 Proflavine Cream, BPC   Hospital only
    06.04.01.02 Progesterone Crinone®
    06.04.01.02 Progesterone Cyclogest® Amber Traffic Light  Recurrent miscarriage (off label use)


    Red Traffic Light  Fertility (off label use)

    06.04.01.02 Progesterone (micronised) Utrogestan®
  • Supported by a RICaD
  • 05.04.01 Proguanil Hydrochloride 
  • Private prescription in Primary Care
  • 05.04.01 Proguanil Hydrochloride with Atovaquone 
  • Private prescription in Primary Care
  • 06.04.01.01 Progynova® 
    • Progynova® 1mg and 2mg tablets
    03.04.01 Promethazine 
    04.06 Promethazine Hydrochloride 
    04.01.01 Promethazine Hydrochloride 
    A5.03.04 Prontosan Wound Gel 30ml  A gel containing betaine, a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden.

    Type of wound product is suitable for
    Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns.

    Duration dressing remains on wound before changing
    Apply at each dressing change

    Frequency of dressing change
    As determined by the wound and exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None

    Rationale for inclusion in formulary
    Gel to cleanse and decontaminate wounds
    Antimicrobial
    Breaks down biofilms in chronic wounds
    A5.03.04 Prontosan Wound Irrigation Solution   Wound irrigation solution containing betaine a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden.

    Type of wound product is suitable for
    Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns.

    Duration dressing remains on wound before changing
    Apply at each dressing change

    Frequency of dressing change
    As determined by the wound and exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None

    Rationale for inclusion in formulary
    Solution to cleanse and decontaminate wounds
    Antimicrobial
    Breaks down biofilms in chronic wounds
    Can be used as an irrigation fluid with VAC Veraflow
    A5.12 Prontosan Wound Irrigation solution  See under antimicrobials

    02.03.02 Propafenone hydrochloride 
    13.12 Propantheline 
  • For hyperhidrosis (licensed indication)
  • Specialist recommendation
  • 02.04 Propranolol 
  • Tablets
  • Modified Release capsules
  • 04.07.04.02 Propranolol 
    04.09.03 Propranolol 
    13.14.01 Propylene glycol 20% w/w in aqueous cream 
    13.14.02 Propylene glycol 40% w/w in Dermovate® cream 
    06.02.02 Propylthiouracil 
    A5.15 Proshield plus ®  Skin protectant
    Type of wound product is suitable for
    To treat injured skin associated with incontinence where a dressing seal cannot be achieved
    Frequency of use
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Do not apply to pressure ulcers or leg ulcers
    Not to be used as a first line barrier cream
    Not to be used to protect peri wound
    Not to be used as an emollient
    Rationale for inclusion in formulary
    For treatment of incontinence lesions where a standard dressing seal cannot be achieved
    A5.15 ProShield®  Skin cleanser for use in patients with chronic diarrhoea or incontinence of urine.
    Type of wound product is suitable for
    To cleanse intact or injured skin from contamination of urine or faeces
    Frequency of use
    Apply at each episode of hygiene
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    External use only
    Avoid contact with eyes
    Known allergic sensitivity to any of the components
    Keep out of reach of children
    Rationale for inclusion in formulary
    For skin cleansing related to incontinence.
    Only skin cleanser available on drug tarrif
    09.04 Prosource® Jelly 
    • High-energy supplements: protein
    • Liver/hepatobiliary disease/conditions.
    • Other patients groups, based on clinical assessment.
    • Pts requiring increased protein in a low volume
    • Hypoproteinaemia. Not recommended for child under 3 years
    09.04 Prosource® Liquid 
    • Protein and carbohydrate
    • Pts requiring low volume, low cal, low CHO protein supplement (10g/30ml) for oral and tube feeders. Useful in allergy to milk and soya proteins. For high protein requirements.
    • Liver/hepatobiliary disease/conditions.
    • Biochemically proven hypoproteinaemia.
    • Not recommended for child under 3 years.
    09.04 ProSource® Plus 
    • Protein and carbohydrate
    • Pts requiring low volume, low cal, low CHO protein supplement (15g/30ml) for oral and tube feeders.
    • Useful in allergy to milk and soya proteins.
    • Liver/hepatobiliary disease/conditions.
    • Hypoproteinaemia.
    • Not recommended for child under 3 years
    09.04 ProSource® TF 
    • Protein and carbohydrate
    • Pts requiring low volume, low cal, low CHO protein supplement (11g/30ml) specifically formulated for tube feeders. Useful in allergy to milk and soya proteins. Low osmolality.
    • Liver/hepatobiliary disease/conditions.
    02.08.03 Protamine Sulphate 
    02.11 Prothrombin complex injection 
    09.04 Protifar® 
    • High-energy supplements: protein
    • High protein modular powder, to be added to other food, drink and feeds in a range of conditions
    • Nutritional supplement for use in biochemically proven hypoproteinaemia.
    06.05.01 Protirelin TRH
    09.04 ProZero® 
    • Low protein milk replacer in children and adults with inborn errors of protein metabolism on low protein diets
    • A protein-free milk in children and adults with inborn errors of protein metabolism on low protein diets. It contains equal calories per 100 ml to cow’s milk. It is particularly suitable for MSUD patients. Available in 1 litre /250 ml cartons. The dose and frequency of administration will be determined by the specialist dietitian
    • A protein-free nutritional supplement for the dietary management of inborn errors of metabolism in children over 6 months and adults.
    01.06.07 Prucalopride Resolor ®

    Available for use in men and women for chronic constipation.

    03.10 Pseudoephedrine Hydrochloride 

    Over the counter preparation suitable for self-care/purchase if appropriate 

    05.01.09 Pyrazinamide 

    Pyrazinamide liquid 500mg in 5ml (unlicensed)

    10.02.01 Pyridostigmine Bromide 
    09.06.02 Pyridoxine Hydrochloride 
    05.04.01 Pyrimethamine Darprim®
    04.02.01 Quetiapine Modified-release preparations 
  • Supported by ESCA, see link below.
  • Rationale for prescribing rather than first line antipsychotics to be provided with ESCA.


    APC preferred brands
    Biquelle XL, Sondate XL, Zaluron XL
    Choose most cost-effective option.
  • 04.02.01 Quetiapine tablets 
  • Supported by ESCA, see link below.
  • 06.07.01 Quinagolide 
    05.04.01 Quinine dihydrochloride  
  • Injection
  • 05.04.01 Quinine sulphate 
  • Tablets
  • 10.02.02 Quinine sulphate  Short term use only- MHRA guidance
    14.05 Rabies immunoglobulin 
    • Use in line with protocol
    16.02 Radium-223 Xofigo®
  • Hospital only- NHSE commissioned
  • In line with NICE and available from day 91 following publication of TA.
  • 06.04.01.01 Raloxifene Hydrochloride 

    In line with NICE

    • Generic 
    • Evirex® £££
    • Evista® £££
    • Ostiral® £££
    • Razylan® £££
    05.03.01 Raltegravir Isentress ®
    08.01.03 Raltitrexed Tomudex®
    02.05.05.01 Ramipril capsules 
    11.08.02 Ranibizumab Lucentis®
  • Use in line with NICE
  • 01.03.01 Ranitidine  Prescribe standard release tablets only; modified release (MR) preparations are non-formulary
    01.03.01 Ranitidine Effervescent tablet For use in patients with swallowing difficulties or via nasogastric tubes only
    01.03.01 Ranitidine IV  Injection 50mg/2ml
    For specialist use only
    02.06.03 Ranolazine Ranexa® Supported by RICaD, see link below.
    04.09.01 Rasagiline  Azilect®
    • Tablets
    10.01.04 Rasburicase Fastertec®
    • Hospital only
    13.14.07 Reflectant (Dundee) sunscreens  coffee, coral pink, beige
    08.01.05 Regorafenib Stivarga®
  • In line with NICE
  • NHS E commissioned
  • 01.01 Remote Control Panasonic® Control the TV and costs £20 to replace

    Restricted Item MR tabs restricted for use in xyz
    09.04 Renapro® 
    • Specialised formulas for specific clinical conditions
    • For patients with high protein needs, low volume, low phosphate requirements.
    • Used in renal patients.
    • Used in liver/hepatobiliary diseases/conditions.
    09.04 Renapro® shot 
    • Hospital use only. For patients with high protein needs, low phosphate requirements.
    • Used for renal patients.
    • Used in liver/hepatobiliary diseases/conditions
    • Dietitians to review and consider Renapro powder prior to discharge.
    09.04 Renastart® 
    • Specialised formulas for specific clinical conditions
    • Used in infants and children with renal disease when low Potassium and Low phosphate feed is required, can be given orally or as a tube feed
    • Dietary management of renal failure in child from birth to 10 years.
    09.04 Renastart® 
    • Used in infants and children with renal disease when low Potassium and Low phosphate feed is required, can be given orally or as a tube feed
    • Dietary management of renal failure in child from birth to 10 years.
    A5.06.01 Renasys products  The use of sub atmospheric pressure to promote or assist wound healing or to remove fluids from a site. Required components: Pump, Dressings foam or gauze, tubing and canister.

    Type of wound product is suitable for
    Acute, chronic and traumatic wounds. Can be used as a adjunct to surgery and for
    salvage procedures such as wound dehiscence. Benefits are that it removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment.
    Consider standard interactive dressings first.
    Duration dressing remains on wound before changing
    Every three days
    Frequency of dressing change
    Determined by exudate levels. Different canister sizes available
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    It should not be used on: Grossly infected or bleeding wounds
    Malignancy
    Exposed blood vessels
    Organs
    Unexplored fistulae
    Extensive necrotic wounds
    Caution with foam, document the number inserted, ensure all pieces are retrieved.

    Rationale for inclusion in formulary
    It removes excess fluid that may contain bacterial pathogens, reduces soft tissue
    oedema, promotes granulation and provides a moist wound healing environment. Both companies products are included due to different contracting arrangements. Can be used on large open wounds to increase speed of wound healing
    09.06.07 Renavit® 
    • For renal patients as per APC formulary
    • Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis.
    • Dietary management of water-soluble vitamine deficiency in adults with renal failure on dialysis
    09.04 Renilon® 7.5 
    • More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
    • Low potassium, low phosphate sip feed
    • Dietetic advice
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    • Not suitable for child under 3 years; use with caution in child 3–5 years.
    06.01.02.03 Repaglinide 
    14.04 Repevax® 
    03.14 Reslizumab Cinqaero®
    • For specialist use only in line with NICE
    • NHS England is the responsible commissioner for use in Asthma
    09.04 Resource® Junior 
    • Child: More than 1 kcal/mL and less than 4 g protein/100 mL
    • First Choice Alternative to Fortini, for patients who have taste fatigue - long term use
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable for use in child under 3 years
    09.04 Resource® Optifibre 
    • High-fibre supplements
    • A fibre source added to oral and tube feeds
    • This is added to low protein tube feeds for patients with propionic acidaemia, methyl malonic acidaemia to provide a source of fibre. Children with these conditions become easily constipated leading to metabolic instability and hospital admissions so an additional source extra to fibre content of existing enteral feeds is essential. this product cannot be purchased from the supermarket and is essential. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except dysphagia
    • Not suitable for child under 5 years
    09.09 Resource® ThickenUp Clear 
    • Recommended by SALTs for patients with dysphagia requiring thickened fluids Gum based products are generally preferred as they thicken to a more stable end point (unlike starch based products, they do not continue thickening over time) and provide a smoother texture, which improves acceptability and palatability for patients.
    09.04.02 Resource®Energy 
    • 1.5 kcal/mL and 5g (or more) protein/100 mL
    • Paediatrics and specialists adults use only
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
    02.10.02 Reteplase 
  • Hospital only
  • 14.04 Revaxis® 
    05.03.05 Ribavirin 
  • Capsules
  • Tablets
  • Inhalation
  • 08.01.05 Ribociclib Kisqali®
  • In line with NICE
  • Hospital only - NHSE commissioned
  • 09.06.02 Riboflavin 
  • Specialist Recommendation
  • Inherited metabolic disease
  • 05.01.09 Rifabutin 
    05.01.09 Rifampicin infusion
    05.01.09 Rifampicin oral presentations
    13.06.02 Rifampicin 
  • Specialist initiation
  • 05.01.09 Rifampicin and Isoniazid Rifinah® 300
    05.01.09 Rifampicin and Isoniazid Rifinah® 150
    05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®
    05.01.09 Rifampicin with ethambutol, isoniazid and pyrazinamide Voractiv®
    05.01.07 Rifaximin 
  • In line with NICE
  • Supported by RICaD, see link below.
  • 05.03.01 Rilpivirine hydrochloride Edurant®
    04.09.03 Riluzole Rilutek®
  • Supported by an ESCA, see link below.
  • 06.06.02 Risedronate  
    • The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
    04.02.02 Risperidone Risperdal Consta® The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
    04.02.01 Risperidone (oral) 
  • tablets
  • liquid

  • Supported by ESCA, see link below.
  • 05.03.01 Ritonavir Norvir®
    08.02.03 Rituximab 
  • NHSE is the responsible commissioner.In line with NICE
  • 10.01.03 Rituximab (rheumatology) MabThera® Hospital only
    02.08.02 Rivaroxaban Restricted Item APC preferred agent: this recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.


    Amber Traffic Light  Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Rivaroxaban in AF

    Amber Traffic Light  For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD.
    RICaD: Rivaroxaban in DVT /PE


    Amber Traffic Light  For preventing adverse outcomes after acute management of ACS (TA335) use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD.
    RICaD: Rivaroxaban post ACS



    Red Traffic Light  Use following Hip and Knee surgery- full course of treatment supplied on discharge.
    04.11 Rivastigmine 
  • capsules
  • patches

    The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer.
    HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
  • 04.07.04.01 Rizatriptan  Green Traffic Light  Tablets
    Green Traffic Light  Orodispersible tablets SF- reserve for patients who are vomiting due to migraine

    Black Traffic Light  Wafer/oral lyophilisates SF £££
    03.03.03 Roflumilast Daxas®

    In line with NICE
    Specialist initiation- transfer of prescribing supported by RICaD

    RICaD: Roflumilast for treating COPD

    09.01.04 Romiplostim Nplate®
    04.09.01 Ropinirole M/R tablets 


    04.09.01 Ropinirole tablets 
    • For use in Restless Legs - Supported by an ESCA, see link below.
    02.12 Rosuvastatin tablets 
    14.04 Rotavirus vaccine Rotarix®
    04.09.01 Rotigotine patches 
    04.08.01 Rufinamide 
  • Tablets
  • Supported by an ESCA, see link below.

    MHRA advises that when prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability.
  • 08.01.05 Ruloxitinib Jakavi®
  • Hospital only- NHS England is responsible commissioner
  • In line with NICE and available from day 91 following publication of TA (see links below)
  • 09.04 S.O.S® 
    • High-energy supplements: carbohydrate
    • Individual dose sachets, to be made as needed –pre measured dose to be made up by parents.
    • Essential for use in an emergency regimen in inborn errors of metabolism / module in tube feed for low amino acid or fat diets / energy supplement.
    • Also essential core ingredient in emergency feeds for inborn errors of metabolism / or used as an Individual carbohydrate module in tube feeds for low amino acid or fat diets / or as an energy supplement. Particularly important to use with non-English speaking families and vulnerable families as it is supplied in pre-measured sachets. Research as shown that it is safer to use than conventional glucose polymer powders. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • For use as an emergency regimen in the dietary management of inborn errors of metabolism in adults and children from birth.
    02.05.05 Sacubitril valsartan Entresto ®
  • In line with NICE
  • transfer to Primary care at 3 months following initiation by Heart Failure specialist supported by a RICaD. Click here to access RICaD
  • 03.01.01.01 Salbutamol 
  • Inhaler
  • oral preparations
  • Nebules
  • 07.01.03 Salbutamol 
    03.01.01.01 Salbutamol IV 
    13.07 Salicylic Acid Salatac®

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.14.06 Salicylic acid 10% w/w in emulsifying ointment 
    13.07 Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol®

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.14.06 Salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream 
    13.14.06 Salicylic acid 2% w/w in emulsifying ointment 
    13.14.06 Salicylic acid 20% w/w in emulsifying ointment 
    13.14.02 Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate® cream 
    13.07 Salicylic Acid Ointment Verrugon®

    Over the counter preparation suitable for self-care/purchase if appropriate

    12.03.05 Saliveze® Oral spray  Approved for
  • ACBS conditions i.e. patients suffering from xerostomia (dry mouth) as a result of having or having undergone radiotherapy or sicca syndrome.
  • Palliative Care
  • Dental practitioners


  • 12.03.05 Salivix® pastilles  Approved for
  • ACBS conditions i.e. patients suffering from xerostomia (dry mouth) as a result of having or having undergone radiotherapy or sicca syndrome.
  • Palliative Care
  • Dental practitioners


  • only useful in patients who have residual salivary gland function.
  • 03.01.01.01 Salmeterol 
  • Prescribe by brand to ensure patients receive the device they are used to.
  • Check licensed indication (differences among brands).
  • Be aware of differences in excipients among the different brands.
  • 09.05.01.01 Sandocal-1000® 
    06.04.01.01 Sandrena® gel 
    09.04.01 Sapropterin Dihydrochloride  Kuvan®
    05.03.01 Saquinavir Invirase®
    08.02.04 Sarilumab Kevzara®
  • In line with NICE
  • Commissioned by CCGs.
  • 09.04.01 Savoury meals and mixes 

    Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein-. 1 ordinary meal is likely to provide ≥25g protein.

    09.04 Scandishake® Mix 
    • Protein, fat, and carbohydrate
    • Second choice for patients with very high energy requirement eg cystic fibrosis
    • In adults with cystic fibrosis, nutritional advice and interventions should be aimed at maintaining a BMI of 22kg/m2 in women and 23kg/m2 in men, as these are associated with better lung function (Nutritional management of CF – Consensus document – 2016)
    • Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.
    01.07.02 Scheriproct® suppositories  Scheriproct ointment and suppositories
    A5.11 Seal-Tight Wound care protector  Waterproof protector, non slip latex free
    Type of wound product is suitable for
    Used to keep leg and foot dressings dry, can be fully submerged in water
    Rationale for inclusion in formulary
    Multiple sizing for leg including extra large limb
    No adjustments required
    13.05.02 Sebco® 
    13.05.03 Secukinumab 
  • Use in line with NICE
  • 04.09.01 Selegiline Hydrochloride 
    • Tablets
    • Oral lyophilisate reserved for patients with swallowing difficulties in Parkinson's disease
    09.05.05 Selenium capsules/tablets Selenase®
  • Specialist Recommendation
  • 13.09 Selenium Sulphide Selsun®

    Over the counter preparation suitable for self-care/purchase if appropriate

    06.01.02.03 Semaglutide Ozempic®

    Caution - retinopathy. Do not use in patients with pre-proliferative/proliferative retinopathy (R2/R3 grade) or maculopathy (M1) or who are undergoing or awaiting eye laser or intravitreal treatments. Ensure all patients are up-to-date with their retinopathy screening programme prior to initiation of semaglutide, and that they attend their annual screening whilst on treatment.

    01.06.02 Senna  Tablets 7.5mg; Syrup 7.5mg/5ml
    - Syrup is currently more cost effective than tablets
    - Time to effect approximately 8 to 12 hours
    04.03.03 Sertraline tablets 
    09.05.02.02 Sevelamer  
  • Specialist Recommendation
  • No ESCA
  • Common Practice
  • 02.05.01 Sildenafil Revatio® NHS England commissioned
    07.04.05 Sildenafil tablets GENERIC 
  • no restrictions on quantity to be supplied to ensure adequate trial of treatment
  • SLS criteria no longer apply


    For use in digital ulceration, see chapter 10
  • 10.04 Sildenafil tablets GENERIC 
  • Use in digital ulceration is commissioned by NHS England
  • All prescribing retained in Secondary Care
  • Off label use
  • A5.16 Silver nitrate   NOT 1ST LINE TREATMENT
    ONLY TO BE USED IN A CLINIC SETTING OR BY A CLINICAL SPECIALIST
    Type of wound product is suitable for
    For treatment of chronic overgranulation, non acute or weeping.
    Duration product remains on wound before changing
    Apply moistened caustic pencil tip for 1-2 mins, whilst protecting the surrounding skin with soft paraffin.
    Frequency of use
    Maximum treatment: 3 applications
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Keep away from the eyes
    Not suitable for use on the face, ano-genital region or large areas
    Not for untreated bacterial, fungal or viral skin lesions
    Can cause chemical burns
    Rationale for inclusion in formulary
    Treatment of overgranulation
    13.07 Silver Nitrate 95% with Potassium Nitrate 5% AVOCA®

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.07 Silver Nitrate applicators ( 40% ,75% and 95%) 

    Over the counter preparation suitable for self-care/purchase if appropriate

    13.07 Silver Nitrate caustic applicator 
    13.10.01.01 Silver Sulfadiazine Flamazine®
  • For infected burns
  • A5.17 silver sulfadiazine 1% Flamazine® Type of wound product is suitable for
    Partial thickness & full thickness burn injuries. Sloughy burn wounds or areas of graft loss
    Duration preparation remains on wound before changing
    24-48 hours
    Frequency of use
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Not to use in pregnancy or breast feeding
    Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose
    6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy
    Rationale for inclusion in formulary
    Prevent and treat bacterial infections in burns, skin graft donor sites.
    A5.17 Silver sulfadiazine 1.0g & Cerium nitrate 2.2g Flammercerium® Type of wound product is suitable for
    Partial thickness & full thickness burn injuries.
    Duration preparation remains on wound before changing
    24-48 hours
    Frequency of use
    Daily- occasionally alternate day
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Allergy to any ingredients.
    Not to use in pregnancy or breast feeding, infants or babies under the age of 2 years.
    Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose
    6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy
    Rationale for inclusion in formulary
    Prevent and treat bacterial infections in burns
    01.01.01 Simeticone  

    Green   Drops
                      For use in infantile colic

    Red For Endoscopy use

    09.04 Similac® Alimentum 
    • Specialised formulas: Infant and child: Hydrolysate formula
    • Casein hydrolysate with MCT. Use in infants (from birth – 6 mths) ) who have cow’s milk intolerance / allergy and also malabsorption. Tube or oral feed. Similac has fat as 50% MCT and more complex CHO
    • Cows’ milk protein allergy and other conditions where an extensively hydrolysed formula is indicated.
    03.09.02 Simple Linctus, BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    03.09.02 Simple Linctus, Paediatric BP 

    Over the counter preparation suitable for self-care/purchase if appropriate

    02.12 Simvastatin tablets 
    08.02.02 Sirolimus Rapamune® Red Traffic Light  Post transplant- new patients
    Amber Traffic Light  Post transplant-patients initiated pre April 2013
    06.01.02.03 Sitagliptin Januvia® In line with NICE
    09.04 Slo drinks milkshakes 
    • 1.5 kcal/ml and 5g (or more) protein/100ml
    • First line For dysphagia pts only
    • Not suitable for CKD 4-5, renal pts.
    • Not suitable for lactose intolerance
    • Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
    • To be made up with whole milk.
    • Contains 24g protein per serving as served.
    09.09 SLO Drinks® 
    • Used in a complex specific patient group advised by a SALT specialist
    • Nutritional supplement for patient hydration in the dietary management of dysphagia. Not suitable for children under 3 years.
    09.04 SMA LF® Lactose Free Formula (previous name SMA® LF) 
    • Specialised formulas: Infant and child: Residual lactose formula
    • Can be purchased over the counter.
    • Only prescribable for patients who currently do not pay for formula feeds (eg healthy start scheme)
    • For infants with lactose intolerance
    • Proven lactose intolerance
    09.04.02 SMA® PRO Gold Prem 2 

    Child under 12 years

    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • Post discharge formula for pre term infants <34 weeks to aid growth
    • Powder feed
    • Partially hydrolysed
    • For catch-up growth in preterm infants and small for gestational age babies on discharge from hospital until 6 months corrected age. It may be used as the sole source of nutrition until complementary feeding commences.
    09.04.02 SMA® PRO High Energy  

    Child under 12 years

    • Less than 1 kcal/mL and less than 4g protein/100 mL
    • High energy feed for faltering growth
    • Single use only in acute setting – risk of increased waste.
    • Once open must be used within 24 hours
    • Disease-related malnutrition, malabsorption, and growth failure in infancy.
    10.01.03 Sodium Aurothiomalate Myocrisin® Supported by ESCA, see link below.
    07.04.03 Sodium Bicarbonate 
    12.01.03 Sodium Bicarbonate 5% ear drops 
    09.02.01.03 Sodium Bicarbonate capsules 
  • Specialist Recommendation
  • 03.01.05 Sodium Chloride 
    09.02.01.02 Sodium Chloride  


    Green Traffic Light  Sodium chloride M/R Tablets


    Red Traffic Light  Sodium chloride 5mmol solution


    Amber Traffic Light  Sodium chloride 1mmol/mL oral solution. Amber Specialist recommendation

    11.08.01 Sodium Chloride Minims® Saline
  • Hospital only. Diluent for impregnated dye strips
  • 03.07 Sodium chloride 0.9% 
    07.04.04 Sodium Chloride 0.9%  Catheter Patency Solutions
    13.11.01 Sodium Chloride 0.9% irrigation sachets 
    11.08.01 Sodium Chloride 0.9% Solutions 
  • Hospital only- Theatre use
  • 11.08.01 Sodium Chloride 5% eye ointment 
  • Specialist Ophthalmologist Recommendation
  • 11.08.01 Sodium Chloride 5% PF drops Moorfields
  • Specialist Ophthalmologist Recommendation
  • 12.02.02 Sodium Chloride Nose drops 10ml 
    07.04.04 Sodium Citrate  Hospital only
    01.06.04 Sodium Citrate (Rectal)  Micro-enema
    Microlette®, Relaxit® and Micralax®
    06.06.02 Sodium Clodronate 
  • For the management of osteolytic lesions, bone pain and hypercalcaemia associated with multiple myeloma or breast cancer.
  • Supported by an ESCA, see link below.
  • 11.04.02 Sodium Cromoglicate 2% eye drops 
    11.04.02 Sodium Cromoglicate 2% eye drops  preservative free
  • Specialist Ophthalmologist recommendation as Catacrom
  • 09.01.01.01 Sodium Feredetate SF Elixir Sytron®
    09.05.03 Sodium Fluoride Mouthwash, BP 
  • Dental prescribing only
  • 09.05.03 Sodium Fluoride Toothpaste 0.619% (2800ppm), DPF 
    • Dental prescribing only
    09.05.03 Sodium Fluoride Toothpaste 1.1% (5000ppm), DPF 
    • Dental prescribing only
    11.08.01 Sodium Hyaluronate 0.15% Multi Hyabak®
  • Specialist Ophthalmologist Recommendation
  • 11.08.01 Sodium Hyaluronate 0.2% eye drops PF Evolve HA ®
    • Specialist Ophthalmologist Recommendation 

    Approved onto formulary January 2019

    11.08.01 Sodium Hyaluronate 0.2% PF Multi Hylo-Forte®
  • Specialist Ophthalmologist Recommendation
  • 11.08.01 Sodium Hyaluronate 0.4% SDU  Clinitas®
  • Specialist Ophthalmologist Recommendation
  • Each preservative-free unit is resealable and may be used for up to 12 hours.
  • 02.05.01 Sodium nitroprusside 

    Injection (Secondary Care only)

    02.13 Sodium Tetradecyl Sulphate Fibro-Vein®
    04.08.01 Sodium Valproate 
    • E/C tablets
    • M/R tablets
    • Crushable tablets
    • SF liquid
    • M/R granules see Episenta®
      MHRA Advice
      Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.

    Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme.  See MHRA guidance

    04.08.01 Sodium Valproate Episenta®
    • Paediatrician initiation.
    • For patients with epilepsy aged up to and including 16 years of age unable to swallow tablets and who require a modified release formulation in whom other formulations are more expensive or not appropriate.
      MHRA Advice
      Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.

    Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme.  See MHRA guidance

    05.03.03.02 Sofosbuvir-velpatasvir-voxilaprevir 

    Hospital only - NHSE commissioned

    In line with NICE

    A5.01.02 Softpore - self adhesive  Type of wound product is suitable for
    Low to moderately exuding wounds, superficial wounds (closed), light amounts of
    exudate.
    Use alone without other products, also can be used as a protective dressing for sutured
    post operative wounds. Can be used as a protective dressing for newly epithelialised wounds. Can be used for minor traumatic wounds

    Duration dressing remains on wound before changing
    Maximum 7 days, dependent on exudate levels

    Frequency of dressing change
    If daily change is required; review dressing type

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known product or component sensitivity

    Rationale for inclusion in formulary
    Sutured/Post-surgical wound for protection . Most cost effective option.
    Can be used as a protective dressing for newly epithelialized wounds. Can be used for minor traumatic wounds
    07.04.02 Solifenacin Vesicare®
  • place in therapy is after agents that have effectiveness at lower costs
  • 06.05.01 Somatropin 
    08.01.05 Sorafenib Nexavar®
    A5.02.06 Sorbsan range  Calcium alginate dressing

    Type of wound product is suitable for
    Use in moderate to highly exuding wounds with a sloughy or granulating wound bed. Also helps with haemostasis in wounds with minor bleeding or where blood is present in the exudate.
    Available in flat and rope dressing
    Primary dressing only. Secondary dressing will be required.

    Duration dressing remains on wound before changing
    Can be left in place for approximately 4 days

    Frequency of dressing change
    1-4 days dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Do not use in individuals with a known sensitivity to any of the components of the dressing
    Do no use on dry or lightly exuding wounds as adherence is an issue
    Extreme caution if used for tumours with friable tissue

    Rationale for inclusion in formulary
    Sorbsan can facilitate debridement, absorb exudate and is a haemostat
    Cost effective
    Biodegradable
    02.04 Sotalol  Anti Arrhythmic
    07.03.03 Spermicidal Contraceptives Gygel®2%
    05.04.07 Spiramycin 
  • Unlicensed
  • 02.02.03 Spironolactone tablets 
    09.04.01 Spreads 

    Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 portion ordinary spread likely to provide 2-5g protein.

    01.04 St Mark’s powder   Unlicensed
    Specialist use only
    01.04 St Mark’s recipe  For fluid and electrolyte replacement following diarrhoea
    03.01.05 Standard range peak flow meter 
    05.03.01 Stavudine Zerit®
    A5.05.01 Sterile Gauze swabs 7.5cmx7.5cm ONLY  7.5cm x 7.5cm only
    Type of wound product is suitable for
    Cleansing wounds via aseptic technique
    Duration dressing remains on wound before changing
    N/A
    Frequency of dressing change
    N/A
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be applied to a wound as a dressing
    Necessity for wound cleansing
    Cost effective
    Included in Sterile wound packs or used to supplement sterile packs
    04.08.01 Stiripentol Diacomit® Severe myoclonic epilepsy in infancy (Dravet syndrome)
    APC supports use in Adults: for continuation of therapy started in childhood. (Note Off Label use in adults)
    02.10.02 Streptokinase 
  • Hospital only
  • 05.01.09 Streptomycin Sulphate 
    01.03.03 Sucralfate Antepsin® Tablet 1g, Suspension 500mg/5ml
    For specialist use only
    09.05.02.02 Sucroferric oxyhydroxide Velphoro®

    2nd or 3rd line agent

    Specialist use only

    A5.15 Sudocrem ®  Barrier cream
    Type of wound product is suitable for
    Intact skin, not to be applied to a wound.
    To protect the skin from moisture, irritation and chafing. To protect the peri wound when utilising free range larvae
    Frequency of use
    Application at every episode of hygiene. Apply a thin layer sparingly. Remove with olive oil.
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Not to be used in conjunction with containment products for incontinence due to the inclusion of lanolin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients
    Rationale for inclusion in formulary
    Dermatology approved
    13.02.02 Sudocrem® 
    • avoid use with continence pads

    Over the counter preparation suitable for self-care/purchase if appropriate

    05.01.08 Sulfadiazine 
    01.05.01 Sulfasalazine  Plain tablets are more cost effective than enteric coated tablets.
    10.01.03 Sulfasalazine  Supported by ESCA, see link below.
    10.01.01 Sulindac 
  • For polyhydramnios (women only)
  • 04.02.01 Sulpiride (oral) 
  • Supported by ESCA, see link below.
  • 04.07.04.01 Sumatriptan 
  • Tablets (prescribe as generic)
  • Nasal spray £££
  • injection £££
  • 08.01.05 Sunitinib Sutent®
    13.08.01 Sunsense® Ultra  Non-formulary if not for ACBS approved indication
    A5.02.03 Suprasorb X  Biocellulose gel sheet dressing
    Type of wound product is suitable for
    Light to moderately, non infected exuding wounds
    Duration dressing remains on wound before changing
    1-7 days
    Frequency of dressing change
    1-7 days, dependent on exudate levels
    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to any components of the dressing
    Rationale for inclusion in formulary
    Light to moderate exudate.
    A5.03.04 Suprasorb X + PHMB   Biocellulose gel sheet dressing with PHMB antimicrobial properties

    Type of wound product is suitable for
    Light to moderately, critically colonised or infected exuding wounds
    Can be used on all wound types at all stages of wound healing
    Can be cut or folded to wound shape size

    Duration dressing remains on wound before changing
    1-3 days

    Frequency of dressing change
    1-3 days, dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Known sensitivity to PHMB or any components of the dressing
    Heavily exuding wounds

    Rationale for inclusion in formulary
    Light to moderate exudate in clinically infected wounds.
    Suitable for all wounds at all stages of wound healing
    Doesn’t affect healthy cells, suitable for long term use when necessary
    Specialist recommendation
    04.13 Tacrolimus 

    Specialist use only for neurological conditions

    08.02.02 Tacrolimus 

    Prescribe by brand name only to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)

    • Prograf ®: immediate- release capsule, twice daily dosage

      Red Traffic Light  Post transplant- new patients
      Amber Traffic Light  Post transplant-patients initiated pre April 2013
    08.02.02 Tacrolimus  

    Prescribe by brand name only and do not switch  to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)

    • Advagraf ®: prolonged release capsule, once daily dosage

      Red Traffic Light  Post transplant- new patients
      Amber Traffic Light  Post transplant-patients initiated pre April 2013
    13.05.03 Tacrolimus  Protopic®
  • in line with NICE
  • 0.03% & 0.1% ointment
  • 13.14.07 Tacrolimus 0.1% w/w in OrabaseTM 
    13.14.07 Tacrolimus 0.3% w/w in OrabaseTM 
    07.04.05 Tadalafil tablets 10mg, 20mg ONLY 
    • Erectile Dysfunction Only 
    • on demand preparation only
    • SLS criteria still apply
    • quantities in line with HSC guidance
      (max 4 tablets per month)
    • Black for Lower Urinary tract symptoms in Benign Prostatic Hyperplasia
    11.06 Tafluprost (Preservative Free) 15micrograms/ml 
  • Specialist Ophthalmologist Recommendation
  • 2nd line PF option
  • 08.01.05 Talimogene laherparepvec Restricted Item  Imlygic®
  • Hospital only- NHS E commissioned
  • In line with NICE and available from day 91 following publication of TA (see link below)
  • 08.03.04.01 Tamoxifen 
    07.04.01 Tamsulosin M/R capsules 
    04.07.02 Tapentadol Palexia®
    13.05.02 Tars - bath preparations Psoriderm emulsion®
    02.08.01 TauroLock TauroLock HEP 500 ®
    A5.02.05 Tegaderm Foam Adhesive  Type of wound product is suitable for
    Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers
    Can be used as a primary or secondary dressing
    Film border increases adherence

    Duration dressing remains on wound before changing
    Can stay in place up to 3-7 days

    Frequency of dressing change
    Dependent on exudate levels

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    Care with fragile skin

    Rationale for inclusion in formulary
    Can be used for low to moderate exudate levels
    Different sizes and shapes available
    Conformability around difficult areas such as heels and elbows
    Can be used on sacral and buttock wounds where incontinence is an issue due to film backing and border.
    05.01.07 Teicoplanin injection
    05.03.03 Telaprevir Incivo®
    05.03.03.01 Telbivudine Sebivo®
  • NOT RECOMMENDED
  • A5.01.02 Telfa  Thin absorbent cotton pad with non adherent film

    Type of wound product is suitable for
    Dry or lightly exuding wounds

    Duration dressing remains on wound before changing
    1-7 days

    Frequency of dressing change
    As exudate levels determines

    Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
    None

    Rationale for inclusion in formulary
    Cost effective. Non adherent dressing for dry or lightly exuding wounds
    04.01.01 Temazepam  From Monday 1 June 2015 prescriptions for temazepam will be required to meet full prescription requirements for Schedule 3 controlled drugs (CDs).
    04.01.01 Temazepam  From Monday 1 June 2015 prescriptions for temazepam will be required to meet full prescription requirements for Schedule 3 controlled drugs (CDs).
    05.01.01.02 Temocillin Negaban®
    08.01.05 Temozolomide Temodal®
    08.01.05 Temsirolimus Torisel®
    02.10.02 Tenecteplase 
  • Hospital only
  • 05.03.01 Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla®
    05.03.01 Tenofovir and Emtricitabine Truvada®
    05.03.01 Tenofovir Disproxil Viread®
    09.04 Tentrini® 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • Polymeric feed, used in children 20-45kg as tube feed, no added fibre
    • Also essential low protein tube feeds for teenagers with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) due to its protein profile. It provides a natural protein source. It is used when IMD teenagers cannot tolerate fibre. To change to an alternative enteral feed with teenagers with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 7–12 years, body-weight 21–45 kg
    09.04 Tentrini® 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • Polymeric feed, used in children 20-45kg as tube feed, no added fibre
    • Also essential low protein tube feeds for teenagers with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) due to its protein profile. It provides a natural protein source. It is used when IMD teenagers cannot tolerate fibre. To change to an alternative enteral feed with teenagers with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 7–12 years, body-weight 21–45 kg
    09.04 Tentrini® 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • Polymeric feed, used in children 20-45kg as tube feed, no added fibre
    • Also essential low protein tube feeds for teenagers with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) due to its protein profile. It provides a natural protein source. It is used when IMD teenagers cannot tolerate fibre. To change to an alternative enteral feed with teenagers with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 7–12 years, body-weight 21–45 kg
    09.04 Tentrini® Energy 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml tube feed for children 20-45kg
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure, in child 7–12 years, body-weight 21–45 kg
    09.04 Tentrini® Energy Multi Fibre 
    • Child: 1.5 kcal/mL and more than 4 g protein/100 mL
    • 1.5kcal/ml tube feed for children 20-45kg with added fibre
    • Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula and proven inflammatory bowel disease, in child 7–12 years, body-weight 21–45 kg
    09.04 Tentrini® Multi Fibre 
    • Child: 1 kcal/ml and less than 4g protein/100ml
    • Polymeric feed, used in children 20-45kg as tube feed, added fibre
    • Also essential in low protein tube feeds for teenagers with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) due to its protein profile. It provides a natural protein source. It is used when IMD teenagers cannot tolerate fibre. To change to an alternative enteral feed with teenagers with metabolic disorders would potentially require hospital admission to ensure stabilisation with new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
    • Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except bowel fistula, and growth failure in child 7–12 years body-weight 21–45 kg

     

    05.02 Terbinafine tablets
    13.10.02 Terbinafine 1% cream 
  • First line for dermatophyte skin infection

  • 07.01.03 Terbutaline 
    03.01.01.01 Terbutaline Inhaler 
    03.01.01.01 Terbutaline Nebulised 
    08.02.04 Teriflunomide Aubagio®
  • In line with NICE
  • 06.06.01 Teriparatide Forsteo®
  • In line with NICE
  • 06.04.02 Testosterone gel 
    • Testim (Discontinued)
    • Testavan 
    • Testogel
    • Tostran
    • use in women with low libido approved by APC (unlicensed). Specialist to initiate and issue first supply.
    06.04.02 Testosterone implants 
    06.04.02 Testosterone injection Sustanon 250®
    06.04.02 Testosterone undecanoate injection 
    06.04.02 Testosterone undecanoate oral Restandol Testocaps®
  • For paediatric directorate only
  • For induction of puberty
  • 14.05.02 Tetanus immunoglobulin 
    04.09.03 Tetrabenazine 
  • Tablets
  • 15.02 Tetracaine (Amethocaine) Ametop®
  • First line at Birmingham Children's Hospital
  • 06.05.01 Tetracosactide Synacthen®, Synacthen Depot®
    05.01.03 Tetracycline 
  • For H. pylori eradication
  • 13.05.03 Thalidomide 
  • NHS England commissioned drug
  • 08.02.04 Thalidomide capsules 
  • In line with NICE
  • 03.01.03 Theophylline Uniphyllin® Continus
    09.06.02 Thiamine 
    09.06.02 Thiamine Pabrinex®
    • Secondary care use only
    09.09 Thixo-D® 
    • Intolerance to locust bean gum in children under 1.
    • For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
    06.04.01.01